ATE517992T1 - Funktionelle und hyperfunktionelle sirna - Google Patents

Funktionelle und hyperfunktionelle sirna

Info

Publication number
ATE517992T1
ATE517992T1 AT03786798T AT03786798T ATE517992T1 AT E517992 T1 ATE517992 T1 AT E517992T1 AT 03786798 T AT03786798 T AT 03786798T AT 03786798 T AT03786798 T AT 03786798T AT E517992 T1 ATE517992 T1 AT E517992T1
Authority
AT
Austria
Prior art keywords
functional
hyperfunctional sirna
gene silencing
silencing
sirna
Prior art date
Application number
AT03786798T
Other languages
English (en)
Inventor
Anastasia Khvorova
Angela Reynolds
Devin Leake
William Marshall
Stephen Scaringe
Original Assignee
Dharmacon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dharmacon Inc filed Critical Dharmacon Inc
Application granted granted Critical
Publication of ATE517992T1 publication Critical patent/ATE517992T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/12—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of one atom of oxygen (internal monooxygenases or internal mixed function oxidases)(1.13.12)
    • C12Y113/12007—Photinus-luciferin 4-monooxygenase (ATP-hydrolysing) (1.13.12.7), i.e. firefly-luciferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1048—SELEX
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y502/00—Cis-trans-isomerases (5.2)
    • C12Y502/01—Cis-trans-Isomerases (5.2.1)
    • C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Analytical Chemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
AT03786798T 2002-11-14 2003-11-14 Funktionelle und hyperfunktionelle sirna ATE517992T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42613702P 2002-11-14 2002-11-14
US50205003P 2003-09-10 2003-09-10
PCT/US2003/036787 WO2004045543A2 (en) 2002-11-14 2003-11-14 Functional and hyperfunctional sirna

Publications (1)

Publication Number Publication Date
ATE517992T1 true ATE517992T1 (de) 2011-08-15

Family

ID=32329096

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03786798T ATE517992T1 (de) 2002-11-14 2003-11-14 Funktionelle und hyperfunktionelle sirna

Country Status (9)

Country Link
US (52) US8090542B2 (de)
EP (7) EP2213738B1 (de)
JP (2) JP2006507841A (de)
AT (1) ATE517992T1 (de)
AU (1) AU2003295600A1 (de)
DK (1) DK2284266T3 (de)
ES (1) ES2440284T3 (de)
PT (1) PT2284266E (de)
WO (1) WO2004045543A2 (de)

Families Citing this family (1469)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US20050053976A1 (en) * 1996-06-06 2005-03-10 Baker Brenda F. Chimeric oligomeric compounds and their use in gene modulation
CA2329252A1 (en) * 1998-05-21 1999-11-25 Isis Pharmaceuticals Inc. Compositions and methods for topical delivery of oligonucleotides
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US7098192B2 (en) * 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
EP1176195B1 (de) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Verfahren zur kontrolle der aktivität von immunologisch funktionellem molekül
US20040157327A1 (en) * 1999-10-22 2004-08-12 Wyeth Pablo, a polypeptide that interacts with BCL-XL, and uses related thereto
DE10100586C1 (de) 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
PT1309726E (pt) 2000-03-30 2010-03-08 Whitehead Biomedical Inst Mediadores de interferência por rna específicos de sequência de rna
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
KR100909681B1 (ko) 2000-12-01 2009-07-29 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US7423142B2 (en) 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7767802B2 (en) * 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
WO2002092616A1 (en) * 2001-05-11 2002-11-21 Orasense, Ltd. Antisense permeation enhancers
US20070173473A1 (en) * 2001-05-18 2007-07-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of proprotein convertase subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA)
US20050164968A1 (en) * 2001-05-18 2005-07-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of ADAM33 gene expression using short interfering nucleic acid (siNA)
WO2008030239A1 (en) * 2006-09-05 2008-03-13 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF HISTONE DEACETYLASE (HDAC) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20050196767A1 (en) * 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
US20050119212A1 (en) * 2001-05-18 2005-06-02 Sirna Therapeutics, Inc. RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA)
US20050019915A1 (en) 2001-06-21 2005-01-27 Bennett C. Frank Antisense modulation of superoxide dismutase 1, soluble expression
US20030144221A1 (en) * 2001-07-17 2003-07-31 Isis Pharmaceuticals Inc. Antisense modulation of BCL2-associated X protein expression
US7425545B2 (en) * 2001-07-25 2008-09-16 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
US20050043256A1 (en) * 2001-07-30 2005-02-24 Isis Pharmaceuticals, Inc. Antisense modulation of stearoyl-CoA desaturase expression
AU2002330724A1 (en) * 2001-08-16 2003-03-10 Bar Ilan University Diagnosis, prevention and treatment of cancer
DE10154163A1 (de) 2001-11-03 2003-05-22 Advanced Med Tech Vorrichtung zum Aufrichten und Stabilisieren der Wirbelsäule
US20060009409A1 (en) * 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
WO2003064625A2 (en) * 2002-02-01 2003-08-07 Sequitur, Inc. Oligonucleotide compositions with enhanced efficiency
EP1572902B1 (de) * 2002-02-01 2014-06-11 Life Technologies Corporation HOCHWIRKSAME siRNAS ZUR REDUZIERUNG DER EXPRESSION VON ZIELGENEN
US7405292B2 (en) * 2002-02-19 2008-07-29 The Children's Hospital Of Philadelphia Cellular genes regulated by HIV-1 infection and methods of use thereof
US7662952B2 (en) * 2002-02-20 2010-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acid (siNA)
US8067575B2 (en) * 2002-02-20 2011-11-29 Merck, Sharp & Dohme Corp. RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
CA2482904A1 (en) * 2002-04-18 2003-10-23 Lynkeus Biotech Gmbh Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification
US7199107B2 (en) 2002-05-23 2007-04-03 Isis Pharmaceuticals, Inc. Antisense modulation of kinesin-like 1 expression
US20040248094A1 (en) * 2002-06-12 2004-12-09 Ford Lance P. Methods and compositions relating to labeled RNA molecules that reduce gene expression
US7582058B1 (en) * 2002-06-26 2009-09-01 Nuvasive, Inc. Surgical access system and related methods
US6793678B2 (en) 2002-06-27 2004-09-21 Depuy Acromed, Inc. Prosthetic intervertebral motion disc having dampening
DE60330010D1 (de) 2002-07-19 2009-12-24 Interventional Spine Inc Vorrichtung zur wirbelsäulenfixierung
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
AU2003261231A1 (en) * 2002-07-26 2004-02-16 Chiron Corporation Modified small interfering rna molecules and methods of use
US20080274989A1 (en) * 2002-08-05 2008-11-06 University Of Iowa Research Foundation Rna Interference Suppression of Neurodegenerative Diseases and Methods of Use Thereof
WO2004014933A1 (en) 2002-08-07 2004-02-19 University Of Massachusetts Compositions for rna interference and methods of use thereof
US20040029275A1 (en) * 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
EP1532249A2 (de) * 2002-08-21 2005-05-25 The University of British Columbia Inhibitorische rns sonden gegen krebs-assozierte proteine
KR101476067B1 (ko) 2002-09-06 2014-12-23 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
EP1549767A4 (de) 2002-09-26 2006-06-07 Amgen Inc Modulation der expression von forkhead-box o1a
US20060160759A1 (en) * 2002-09-28 2006-07-20 Jianzhu Chen Influenza therapeutic
US20050259483A1 (en) * 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Genes and polypeptides relating to prostate cancers
US7892793B2 (en) * 2002-11-04 2011-02-22 University Of Massachusetts Allele-specific RNA interference
US9827263B2 (en) 2002-11-05 2017-11-28 Ionis Pharmaceuticals, Inc. 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations
AU2003295472A1 (en) * 2002-11-13 2004-06-03 Metabolex, Inc. A pancreatic islet transcription factor and uses thereof
US20060009410A1 (en) * 2002-11-13 2006-01-12 Crooke Rosanne M Effects of apolipoprotein B inhibition on gene expression profiles in animals
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US9879266B2 (en) 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7977471B2 (en) * 2002-11-14 2011-07-12 Dharmacon, Inc. siRNA targeting TNFα
US20100113307A1 (en) * 2002-11-14 2010-05-06 Dharmacon, Inc. siRNA targeting vascular endothelial growth factor (VEGF)
US7635770B2 (en) * 2002-11-14 2009-12-22 Dharmacon, Inc. siRNA targeting protein kinase N-3 (PKN-3)
US7592442B2 (en) * 2002-11-14 2009-09-22 Dharmacon, Inc. siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
US8090542B2 (en) * 2002-11-14 2012-01-03 Dharmacon Inc. Functional and hyperfunctional siRNA
US10011836B2 (en) 2002-11-14 2018-07-03 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7691998B2 (en) * 2002-11-14 2010-04-06 Dharmacon, Inc. siRNA targeting nucleoporin 62kDa (Nup62)
US7781575B2 (en) 2002-11-14 2010-08-24 Dharmacon, Inc. siRNA targeting tumor protein 53 (p53)
US9839649B2 (en) 2002-11-14 2017-12-12 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US7619081B2 (en) * 2002-11-14 2009-11-17 Dharmacon, Inc. siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
US7951935B2 (en) 2002-11-14 2011-05-31 Dharmacon, Inc. siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
US9719094B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting SEC61G
US20090227780A1 (en) * 2002-11-14 2009-09-10 Dharmacon, Inc. siRNA targeting connexin 43
US9771586B2 (en) 2002-11-14 2017-09-26 Thermo Fisher Scientific Inc. RNAi targeting ZNF205
US8198427B1 (en) 2002-11-14 2012-06-12 Dharmacon, Inc. SiRNA targeting catenin, beta-1 (CTNNB1)
US7612196B2 (en) * 2002-11-14 2009-11-03 Dharmacon, Inc. siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
US9719092B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting CNTD2
US20080268457A1 (en) * 2002-11-14 2008-10-30 Dharmacon, Inc. siRNA targeting forkhead box P3 (FOXP3)
WO2004048566A1 (ja) * 2002-11-22 2004-06-10 Bio-Think Tank Co., Ltd. Ｒｎａ干渉の標的塩基配列検索方法、ｒｎａ干渉を生じさせるポリヌクレオチドの塩基配列設計方法、２本鎖ポリヌクレオチドの作製方法、遺伝子の発現抑制方法、塩基配列処理装置、塩基配列処理方法をコンピュータに実行させるプログラム、記録媒体、および、塩基配列処理システム
US7618948B2 (en) 2002-11-26 2009-11-17 Medtronic, Inc. Devices, systems and methods for improving and/or cognitive function through brain delivery of siRNA
US20060257851A1 (en) * 2002-11-26 2006-11-16 Itzhak Bentwich Bioinformatically detectable group of novel viral regulatory genes and uses thereof
US7829694B2 (en) 2002-11-26 2010-11-09 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US7605249B2 (en) 2002-11-26 2009-10-20 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
JP3792655B2 (ja) * 2003-01-20 2006-07-05 日本電気株式会社 新規な癌遺伝子、該癌遺伝子由来の組換えタンパク質、およびそれらの用途
US7732591B2 (en) * 2003-11-25 2010-06-08 Medtronic, Inc. Compositions, devices and methods for treatment of huntington's disease through intracranial delivery of sirna
US7994149B2 (en) 2003-02-03 2011-08-09 Medtronic, Inc. Method for treatment of Huntington's disease through intracranial delivery of sirna
US8084432B2 (en) 2003-02-13 2011-12-27 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of pouchitis
US8796235B2 (en) * 2003-02-21 2014-08-05 University Of South Florida Methods for attenuating dengue virus infection
KR20050098954A (ko) * 2003-03-05 2005-10-12 세네스코 테크놀로지스 인코포레이티드 이아이에프-5에이1의 발현을 억제하기 위한 안티센스올리고뉴클레오타이드 또는 에스아이알엔에이의 이용
JP2006521111A (ja) * 2003-03-12 2006-09-21 バスジーン セラピューティクス， インコーポレイテッド 血管形成及び腫瘍増殖阻害用ポリペプチド化合物及びその応用
US20040185559A1 (en) * 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
AU2003225410A1 (en) 2003-03-21 2004-10-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
WO2004100977A1 (en) * 2003-03-25 2004-11-25 The Board Of Trustees Of The University Of Illinois Inhibition of tumor cell proliferation by foxm1b inhibitors
EP1469070A1 (de) * 2003-04-15 2004-10-20 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Livinspezifische SiRNAs zur Behandlung von therapie-resistente Tumoren
US7994305B2 (en) * 2003-04-18 2011-08-09 The Trustees Of The University Of Pennsylvania Compositions and methods for siRNA inhibition of angiopoietin 1 and 2 and their receptor Tie2
KR20060063788A (ko) * 2003-05-30 2006-06-12 니뽄 신야쿠 가부시키가이샤 올리고 핵산 담지 복합체, 이 복합체를 함유하는 의약조성물
KR20060013426A (ko) * 2003-05-30 2006-02-09 니뽄 신야쿠 가부시키가이샤 Ｂｃｌ-2의 발현을 억제하는 올리고 이중쇄 ＲＮＡ와그것을 함유하는 의약 조성물
US7459547B2 (en) 2003-06-02 2008-12-02 University Of Massachusetts Methods and compositions for controlling efficacy of RNA silencing
US7750144B2 (en) 2003-06-02 2010-07-06 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of RNA silencing
ATE485394T1 (de) * 2003-06-02 2010-11-15 Univ Massachusetts Verfahren und zusammensetzungen zur verbesserung der wirksamkeit und spezifität von fnai
US7595306B2 (en) * 2003-06-09 2009-09-29 Alnylam Pharmaceuticals Inc Method of treating neurodegenerative disease
CA2542232A1 (en) * 2003-06-09 2005-01-20 Alnylam Pharmaceuticals, Inc. Method for treating neurodegenerative disease by inhibiting alpha-synuclein
US8575327B2 (en) 2003-06-12 2013-11-05 Alnylam Pharmaceuticals, Inc. Conserved HBV and HCV sequences useful for gene silencing
WO2005046573A2 (en) * 2003-06-27 2005-05-26 Diadexus, Inc. Pro104 ANTIBODY COMPOSITIONS AND METHODS OF USE
WO2005020888A2 (en) * 2003-07-02 2005-03-10 Saint Louis University Compositions and methods of treating and diagnosing hepatoma
FR2857013B1 (fr) * 2003-07-02 2005-09-30 Commissariat Energie Atomique Petits arn interferents specifiques des sous-unites alpha, alpha prime et beta de la proteine kinase ck2 et leurs applications
JP2007524397A (ja) * 2003-07-03 2007-08-30 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア Ｓｙｋキナーゼ発現の阻害
JP2007502284A (ja) * 2003-08-13 2007-02-08 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ ｓｉＲＮＡによるＴＧＦベータＩＩ型受容体発現のサイレンシング
US7888497B2 (en) * 2003-08-13 2011-02-15 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
WO2005017154A1 (ja) * 2003-08-18 2005-02-24 Japan Health Sciences Foundation 改良されたｓｉＲＮＡ分子およびこれを用いた遺伝子発現の抑制法
US7825235B2 (en) * 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
US8501705B2 (en) * 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
EP2261331A1 (de) * 2003-09-11 2010-12-15 Hubit Genomix, Inc. Verfahren und Kit zur Detektion proliferativer, Sklerose verursachender Erkrankungen, Vorbeugungsmittel und/oder Heilmittel für proliferative, Sklerose verursachende Erkrankungen und Verfahren und Kit zur Identifizierung einer wirksamen Substanz zur Vorbeugung und/oder Behandlung proliferativer, Sklerose verursachender Erkrankungen
ES2485848T3 (es) * 2003-09-12 2014-08-14 University Of Massachusetts ARN de interferencia para el tratamiento de trastornos relacionados con la ganancia de función
US8680063B2 (en) 2003-09-12 2014-03-25 University Of Massachusetts RNA interference for the treatment of gain-of-function disorders
NZ545134A (en) 2003-09-18 2009-06-26 Lilly Co Eli Modulation of eIF4E expression
WO2005037303A1 (en) * 2003-09-22 2005-04-28 Board Of Trustees Of The University Of Illinois Methods and compositions of ig20 and denn-sv splice variants
JP2007506425A (ja) * 2003-09-24 2007-03-22 オンコセラピー・サイエンス株式会社 肝細胞癌を診断する方法
AR041407A1 (es) * 2003-09-26 2005-05-18 Nestor Alberto Kerner Oligonucleotidos antiandrogenos utilizables en el tratamiento de patologias dermatologicas relacionadas con el metabolismo de los androgenos, sus composiciones farmaceuticas y sus usos y metodos de tratamiento
US8258105B2 (en) 2003-10-07 2012-09-04 Isis Pharmaceuticals, Inc. Antisense oligonucleotides optimized for kidney targeting
US8138159B2 (en) * 2003-10-09 2012-03-20 Takara Bio Inc. Composition for inhibiting function of human Flt3
US20080227733A1 (en) * 2003-10-30 2008-09-18 Immune Disease Institute, Inc. Method for Treating and Preventing Ischemia-Reperfusion Injury Using Rna Interfering Agent
US20050191653A1 (en) * 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
US20070238676A1 (en) 2003-12-04 2007-10-11 Mohapatra Shyam S Polynucleotides for Reducing Respiratory Syncytial Virus Gene Expression
SE0303397D0 (sv) * 2003-12-17 2003-12-17 Index Pharmaceuticals Ab Compounds and method for RNA interference
US20060134787A1 (en) 2004-12-22 2006-06-22 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of single and double blunt-ended siRNA
JP2007520474A (ja) * 2004-01-12 2007-07-26 ジーンセンス テクノロジーズ インコーポレーテッド リボヌクレオチドレダクターゼｒ２に向けられたアンチセンスオリゴヌクレオチドおよび癌の処置のための併用療法におけるこの使用
EP1778858A4 (de) * 2004-01-15 2009-08-19 Univ Washington Unter verwendung von drosophila an pharmazeutika durchgeführtes screening mit hohem durchsatz
WO2005067971A1 (ja) * 2004-01-16 2005-07-28 Takeda Pharmaceutical Company Limited 動脈硬化の予防・治療用医薬
US20050164271A1 (en) * 2004-01-20 2005-07-28 Sanjay Bhanot Modulation of glucocorticoid receptor expression
US7468431B2 (en) * 2004-01-22 2008-12-23 Isis Pharmaceuticals, Inc. Modulation of eIF4E-BP2 expression
US8778900B2 (en) * 2004-01-22 2014-07-15 Isis Pharmaceuticals, Inc. Modulation of eIF4E-BP1 expression
WO2005090606A2 (en) * 2004-01-23 2005-09-29 Dharmacon, Inc. Identification of toxic nucleotide sequences
WO2005079397A2 (en) * 2004-02-13 2005-09-01 Rockefeller University Anti-microrna oligonucleotide molecules
US8491914B2 (en) * 2004-02-13 2013-07-23 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for delivery of interference RNA
GB0404209D0 (en) * 2004-02-25 2004-03-31 Uws Ventures Ltd Materials and methods for treatment of allergic disease
JP2007527240A (ja) * 2004-03-01 2007-09-27 マサチューセッツ インスティテュート オブ テクノロジー アレルギー性鼻炎および喘息のためのＲＮＡｉベースの治療
DE102004010547A1 (de) * 2004-03-03 2005-11-17 Beiersdorf Ag Oligoribonukleotide zur Behandlung von irritativen und/oder entzündlichen Hauterscheinungen durch RNA-Interferenz
WO2005089224A2 (en) * 2004-03-12 2005-09-29 Alnylam Pharmaceuticals, Inc. iRNA AGENTS TARGETING VEGF
US8084599B2 (en) 2004-03-15 2011-12-27 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
MXPA06010667A (es) * 2004-03-19 2007-07-04 Penn State Res Found Metodos combinatorios y composiciones para el tratamiento de melanoma.
TW200600785A (en) * 2004-03-23 2006-01-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancer
JP2005312428A (ja) * 2004-03-31 2005-11-10 Keio Gijuku Ｓｋｐ−２発現抑制を利用した癌の治療
KR101147147B1 (ko) 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
US8088902B2 (en) * 2004-04-05 2012-01-03 The Rockefeller University DNA virus microRNA and methods for inhibiting same
US7416842B2 (en) * 2004-04-05 2008-08-26 The Rockefeller University DNA virus microRNA
JP2007531794A (ja) 2004-04-05 2007-11-08 アルニラム ファーマスーティカルズ インコーポレイテッド オリゴヌクレオチドの合成および精製に使用する方法および反応試薬
US20050244869A1 (en) * 2004-04-05 2005-11-03 Brown-Driver Vickie L Modulation of transthyretin expression
US8193332B2 (en) 2004-04-09 2012-06-05 Genecare Research Institute Co., Ltd. Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes
US7365058B2 (en) * 2004-04-13 2008-04-29 The Rockefeller University MicroRNA and methods for inhibiting same
WO2005117938A2 (en) * 2004-04-13 2005-12-15 Regents Of The University Of Minnesota Methods of treating ocular conditions
US20050261233A1 (en) * 2004-04-21 2005-11-24 Sanjay Bhanot Modulation of glucose-6-phosphatase translocase expression
CA2562673A1 (en) * 2004-04-22 2005-11-03 Yissum Research Development Company Of The Hebrew University Of Jerusal Em Universal target sequences for sirna gene silencing
EP1768998A2 (de) 2004-04-27 2007-04-04 Alnylam Pharmaceuticals Inc. Einzelstrang- und doppelstrang-oligonukleotide mit 2-arylpropyl-anteil
MXPA06012162A (es) * 2004-04-27 2007-03-30 Galapagos Nv Metodos, agentes y ensayos de seleccion de compuestos para inducir diferenciacion de celulas de mamifero no diferenciadas, en osteoblastos.
EP3034510A1 (de) 2004-04-30 2016-06-22 Alnylam Pharmaceuticals Inc. Oligonukleotide mit c5-modifiziertem pyrimidin
US20050287558A1 (en) 2004-05-05 2005-12-29 Crooke Rosanne M SNPs of apolipoprotein B and modulation of their expression
US7605250B2 (en) * 2004-05-12 2009-10-20 Dharmacon, Inc. siRNA targeting cAMP-specific phosphodiesterase 4D
EP2322650A1 (de) * 2004-05-14 2011-05-18 Rosetta Genomics Ltd Mikro-RNAs und deren Verwendung
WO2005111213A1 (ja) * 2004-05-18 2005-11-24 Kurume University Ｍｙｃ標的遺伝子mimitin
US7563885B1 (en) * 2004-05-24 2009-07-21 Isis Pharmaceuticals, Inc. Modulation of Tudor-SN expression
US8101350B1 (en) * 2004-05-24 2012-01-24 Isis Pharmaceuticals, Inc. Modulation of exportin 5 expression
US20100152280A1 (en) * 2004-05-24 2010-06-17 Isis Pharmaceuticals, Inc. Modulation of sid-1 expression
US7795419B2 (en) * 2004-05-26 2010-09-14 Rosetta Genomics Ltd. Viral and viral associated miRNAs and uses thereof
US7575863B2 (en) 2004-05-28 2009-08-18 Applied Biosystems, Llc Methods, compositions, and kits comprising linker probes for quantifying polynucleotides
US20060015264A1 (en) * 2004-06-02 2006-01-19 Mcshea Andrew Interfering stem-loop sequences and method for identifying
US8394947B2 (en) * 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
CA2569419A1 (en) * 2004-06-03 2005-12-22 Isis Pharmaceuticals, Inc. Double strand compositions comprising differentially modified strands for use in gene modulation
EP1602926A1 (de) 2004-06-04 2005-12-07 University of Geneva Neue Mittel und Verfahren zur Behandlung von Gehörverlust oder Tinnitus
US7740861B2 (en) * 2004-06-16 2010-06-22 University Of Massachusetts Drug delivery product and methods
US20060156421A1 (en) * 2004-06-18 2006-07-13 Cagan Ross L High throughput screening methods for anti-metastatic compounds
JP4852539B2 (ja) * 2004-06-22 2012-01-11 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 腫瘍細胞増殖をＦＯＸＭ１ｓｉＲＮＡによって阻害する方法
US20060051815A1 (en) * 2004-06-25 2006-03-09 The J. David Gladstone Institutes Methods of treating smooth muscle cell disorders
SI2206781T1 (sl) 2004-06-28 2016-05-31 The University Of Western Australia Protismiselni oligonukleotidi za induciranje preskakovanja eksona in postopki njihove uporabe
EP1789553B1 (de) 2004-06-30 2014-03-26 Alnylam Pharmaceuticals Inc. Oligonukleotide mit einer nicht-phosphat-rückgratbindung
US20060004398A1 (en) * 2004-07-02 2006-01-05 Binder Lawrence J Jr Sequential dilator system
JP2006031308A (ja) * 2004-07-15 2006-02-02 Mitsubishi Space Software Kk 核酸配列設計装置、核酸配列設計方法、核酸配列設計プログラム、機能阻害効果算出装置、機能阻害効果算出方法、機能阻害効果算出プログラム、機能阻害影響度算出装置、機能阻害影響度算出方法および機能阻害影響度算出プログラム。
WO2006093526A2 (en) 2004-07-21 2006-09-08 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a modified or non-natural nucleobase
EP1778310A2 (de) * 2004-07-21 2007-05-02 Medtronic, Inc. Medizinprodukte und verfahren zur verringerung von lokalisierter fibrose
WO2006017556A1 (en) * 2004-08-02 2006-02-16 University Of Iowa Research Foundation Methods of inhibiting cox-2
AU2005330637B2 (en) 2004-08-04 2012-09-20 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase
US20060223147A1 (en) * 2004-08-05 2006-10-05 Kyowa Hakko Kogyo Co., Ltd., Process for producing glycoprotein composition
JP4468989B2 (ja) 2004-08-16 2010-05-26 クアーク・ファーマスーティカルス、インコーポレイテッド Ｒｔｐ８０１阻害剤の治療への使用
CA2577036A1 (en) * 2004-08-18 2006-02-23 Genesense Technologies Inc. Small interfering rna molecules against ribonucleotide reductase and uses thereof
US20110313024A1 (en) * 2004-08-20 2011-12-22 Leonid Beigelman RNA INTERFERENCE MEDIATED INHIBITION OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
CN105251024A (zh) * 2004-08-23 2016-01-20 西伦蒂斯私人股份公司 眼病的治疗
CN100410373C (zh) * 2004-08-24 2008-08-13 暨南大学 抑制bcl-2基因表达的siRNA双链
CN1324136C (zh) * 2004-08-24 2007-07-04 暨南大学 抑制bc1－2基因表达的siRNA双链及其应用
CN100395335C (zh) * 2004-08-24 2008-06-18 暨南大学 抑制bcl-2基因表达的siRNA双链
MX2007002423A (es) * 2004-08-31 2007-08-07 Sylentis Sau Metodos y composiciones para inhibir la expresion del receptor p2x7.
ES2375995T3 (es) 2004-09-17 2012-03-08 University Of Massachusetts Composiciones y sus usos para deficiencias de enzima lisosomal.
GB0420977D0 (en) * 2004-09-21 2004-10-20 Keymed Medicals & Ind Equip An instrument for use in a medical simulator
JP2008514925A (ja) * 2004-09-23 2008-05-08 バスジーン セラピューティクス， インコーポレイテッド 腫瘍を検出し且つ治療するための組成物及び方法
CN101133074B (zh) 2004-09-24 2012-05-30 阿尔尼拉姆医药品有限公司 APOB的RNAi调节及其用途
EP1799269B1 (de) * 2004-09-28 2016-09-07 Quark Pharmaceuticals, Inc. Oligoribonukleotide und anwendungsverfahren dafür zur behandlung von alopezie, akuter niereninsuffizienz und anderen erkrankungen
CN101291948B (zh) * 2004-09-28 2012-05-30 夸克医药公司 寡核糖核苷酸以及其用于治疗脱发、肾衰竭和其它疾病的方法
CA2580189C (en) * 2004-09-29 2013-05-21 Children's Memorial Hospital Sirna-mediated gene silencing of alpha synuclein
US8765704B1 (en) 2008-02-28 2014-07-01 Novartis Ag Modified small interfering RNA molecules and methods of use
ES2441791T3 (es) * 2004-10-01 2014-02-06 Novartis Vaccines And Diagnostics, Inc. Moléculas de ARN de interferencia pequeñas modificadas y métodos de uso
US7825229B2 (en) * 2005-03-25 2010-11-02 Rosetta Genomics Ltd. Lung cancer-related nucleic acids
US20090186353A1 (en) * 2004-10-04 2009-07-23 Rosetta Genomics Ltd. Cancer-related nucleic acids
CA2582464A1 (en) * 2004-10-13 2006-04-27 Sanjay Bhanot Antisense modulation of ptp1b expression
US8080420B2 (en) 2004-10-22 2011-12-20 University Of Central Florida Research Foundation, Inc. Methods and products for biasing cellular development
US7790878B2 (en) * 2004-10-22 2010-09-07 Alnylam Pharmaceuticals, Inc. RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
US20060110440A1 (en) * 2004-10-22 2006-05-25 Kiminobu Sugaya Method and system for biasing cellular development
US20060115453A1 (en) * 2004-11-12 2006-06-01 Yaffe Michael B Methods and compositions for treating cellular proliferative diseases
US8440610B2 (en) 2004-11-12 2013-05-14 Massachusetts Institute Of Technology Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells
US20060134189A1 (en) * 2004-11-17 2006-06-22 Protiva Biotherapeutics, Inc siRNA silencing of apolipoprotein B
JP4809240B2 (ja) * 2004-11-19 2011-11-09 株式会社ジーンケア研究所 癌細胞特異的細胞増殖抑制剤
US7923207B2 (en) 2004-11-22 2011-04-12 Dharmacon, Inc. Apparatus and system having dry gene silencing pools
US7923206B2 (en) 2004-11-22 2011-04-12 Dharmacon, Inc. Method of determining a cellular response to a biological agent
US7935811B2 (en) 2004-11-22 2011-05-03 Dharmacon, Inc. Apparatus and system having dry gene silencing compositions
US8003780B2 (en) * 2004-11-24 2011-08-23 Neomics Co., Ltd. AIMP2-DX2 gene and SiRNA targeting AIMP2-DX2
US9944713B2 (en) 2004-11-24 2018-04-17 Medicinal Bioconvergence Research Center Antibody specific to the AIMP2-DX2
AU2005323303A1 (en) * 2004-11-24 2006-07-13 Alnylam Pharmaceuticals, Inc. RNAi modulation of the Bcr-Abl fusion gene and uses thereof
WO2006063164A2 (en) * 2004-12-08 2006-06-15 Wisconsin Alumni Research Foundation Compositions and methods for treating neuroendocrine tumors
WO2006062369A1 (en) 2004-12-08 2006-06-15 Bioneer Corporation Method of inhibiting expression of target mrna using sirna consisting of nucleotide sequence complementary to said target mrna
AU2005313883B2 (en) * 2004-12-09 2011-03-31 Alnylam Pharmaceuticals, Inc. Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering RNAs
US20100260675A1 (en) * 2004-12-09 2010-10-14 Chong Huang Oxytocin Receptor Antagonists and Their Use for the Treatment of Pulmonary Related Diseases
ATE544774T1 (de) * 2004-12-14 2012-02-15 Alnylam Pharmaceuticals Inc Rnai-modulation von mll-af4 und verwendungen dafür
US7332591B2 (en) * 2004-12-21 2008-02-19 The University Of Iowa Research Foundation Bardet-Biedl susceptibility gene and uses thereof
EP2316942B1 (de) * 2004-12-22 2021-04-21 Alnylam Pharmaceuticals, Inc. Zum gen-silencing geeignete konservierte hbv- und hcv-sequenzen
TWI401316B (zh) * 2004-12-23 2013-07-11 Alcon Inc 用於治療青光眼之血清澱粉樣蛋白Ａ的ＲＮＡｉ抑制作用
US20060166920A1 (en) * 2005-12-27 2006-07-27 Regents Of The University Of Michigan Oligonucleotide based therapeutics
US7507809B2 (en) * 2005-01-07 2009-03-24 Alnylam Pharmaceuticals, Inc. RNAi modulation of RSV and therapeutic uses thereof
DE102005003788A1 (de) 2005-01-19 2006-07-20 Eberhard-Karls-Universität Tübingen Universitätsklinikum siRNA-Moleküle zur Behandlung von Blutgefäßen
US20060217324A1 (en) * 2005-01-24 2006-09-28 Juergen Soutschek RNAi modulation of the Nogo-L or Nogo-R gene and uses thereof
US7879992B2 (en) * 2005-01-31 2011-02-01 Isis Pharmaceuticals, Inc. Modification of MyD88 splicing using modified oligonucleotides
TW200639253A (en) * 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular targets
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
AU2006216514C1 (en) 2005-02-25 2012-09-27 Isis Pharmaceuticals, Inc. Compositions and their uses directed to IL-4R alpha
ATE443138T1 (de) * 2005-03-02 2009-10-15 Nat Inst Immunology Hemmung der expression von spag9 mit sirnas
US20070185044A1 (en) * 2005-03-08 2007-08-09 Dobie Kenneth W Modulation of ace2 expression
KR20080018858A (ko) 2005-03-11 2008-02-28 알콘, 인코퍼레이티드 녹내장 치료용 플리즐 관련 단백질―１의 ＲＮＡⅰ－중재저해
GB0505081D0 (en) * 2005-03-14 2005-04-20 Genomica Sau Downregulation of interleukin-12 expression by means of rnai technology
EP1877556B1 (de) * 2005-03-25 2011-09-14 Medtronic, Inc. Verwendung von anti-tnf oder anti-il1-rnai zur unterdrückung der wirkung entzündungsfördernder cytokine zur lokalen schmerzbehandlung
JP4131271B2 (ja) * 2005-03-30 2008-08-13 ソニー株式会社 情報処理装置および方法、並びにプログラム
JP2008537551A (ja) * 2005-03-31 2008-09-18 カランド ファーマシューティカルズ， インコーポレイテッド リボヌクレオチドレダクターゼサブユニット２の阻害剤およびその使用
EP1871351A4 (de) * 2005-04-08 2011-07-20 Isis Pharmaceuticals Inc Zusammensetzungen und ihre verwendungen gegen acetyl-coa-carboxylasen
US20070213293A1 (en) * 2005-04-08 2007-09-13 Nastech Pharmaceutical Company Inc. Rnai therapeutic for respiratory virus infection
AU2006235489A1 (en) 2005-04-12 2006-10-19 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
US20090117539A1 (en) * 2005-04-12 2009-05-07 Larry Gilbertson DNA sequences for gene suppression
EP2098593B1 (de) * 2005-04-15 2011-12-28 National University Corporation Tottori University Gen zur Regulierung der hTERT-Expression
WO2006113743A2 (en) * 2005-04-18 2006-10-26 Massachusetts Institute Of Technology Compositions and methods for rna interference with sialidase expression and uses thereof
US20060253068A1 (en) * 2005-04-20 2006-11-09 Van Bilsen Paul Use of biocompatible in-situ matrices for delivery of therapeutic cells to the heart
EP1714970A1 (de) * 2005-04-22 2006-10-25 Universität des Saarlandes Anwendung von Inhibitoren von Enzymen der RNAse-A Genfamilie zur Stabilisierung von Oligonukleotiden mit RNA interferierender Aktivität
CA2605701C (en) 2005-04-29 2015-12-08 Rockefeller University Human micrornas and methods for inhibiting same
US20060257912A1 (en) * 2005-05-06 2006-11-16 Medtronic, Inc. Methods and sequences to suppress primate huntington gene expression
US7902352B2 (en) * 2005-05-06 2011-03-08 Medtronic, Inc. Isolated nucleic acid duplex for reducing huntington gene expression
KR20060119412A (ko) * 2005-05-20 2006-11-24 아주대학교산학협력단 ＩＬ-6 발현 억제를 위한 ｓｉＲＮＡ 및 이를 함유하는조성물
WO2006127913A2 (en) * 2005-05-24 2006-11-30 Isis Pharmaceuticals, Inc. Modulation of lmw-ptpase expression
EP1728514A1 (de) * 2005-06-03 2006-12-06 Immunotech S.A. Verwendungen von Oligonukleotiden welche mesenchymale Stammzellen Proliferation verursachen
AU2006254891B2 (en) 2005-06-06 2011-04-14 Gen-Probe Incorporated Compositions, methods and kits for determining the presence of Chlamydophila pneumoniae in a test sample
US20100266574A1 (en) * 2005-06-10 2010-10-21 Orna Mor Oligoribonucleotides and Methods of Use Thereof for Treatment of Fibrotic Conditions and Other Diseases
EP1734118A1 (de) * 2005-06-15 2006-12-20 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Genom-weites RNAi-Screening zur Identifizierung von Genen die das JAK/STAT Pathway modulieren
FI20050640A0 (fi) * 2005-06-16 2005-06-16 Faron Pharmaceuticals Oy Yhdisteitä amiinioksidaasista riippuvien sairauksien tai häiriöiden hoitoon tai estoon
US8361977B2 (en) * 2005-06-23 2013-01-29 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of SMN2 splicing
US7737265B2 (en) * 2005-06-27 2010-06-15 Alnylam Pharmaceuticals, Inc. RNAi modulation of HIF-1 and therapeutic uses thereof
US9133517B2 (en) 2005-06-28 2015-09-15 Medtronics, Inc. Methods and sequences to preferentially suppress expression of mutated huntingtin
US20080280843A1 (en) * 2006-05-24 2008-11-13 Van Bilsen Paul Methods and kits for linking polymorphic sequences to expanded repeat mutations
AU2006272808C1 (en) * 2005-07-21 2010-10-21 Alnylam Pharmaceuticals, Inc. RNAi modulation of the Rho-A gene and uses thereof
US20090155241A1 (en) * 2005-07-22 2009-06-18 Japanese Foundation For Cancer Research Prophylactic/therapeutic agent for cancer
US8053183B2 (en) 2005-07-27 2011-11-08 Oncotherapy Science, Inc. Method of diagnosing esophageal cancer
US20070026436A1 (en) * 2005-07-28 2007-02-01 University Of Massachusetts Glucose transport-related genes, polypeptides, and methods of use thereof
WO2007022470A2 (en) * 2005-08-18 2007-02-22 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating neurological disease
ATE532878T1 (de) * 2005-08-24 2011-11-15 Life Technologies Corp Verfahren zur quantifizierung von sirnas, mirnas und polymorphen mirnas
US20070054873A1 (en) * 2005-08-26 2007-03-08 Protiva Biotherapeutics, Inc. Glucocorticoid modulation of nucleic acid-mediated immune stimulation
PT2270181E (pt) * 2005-09-16 2016-01-26 Devgen Nv Arncd como agente de controlo de insetos
EP1941040A1 (de) * 2005-09-19 2008-07-09 Johnson & Johnson Pharmaceutical Research & Development L.L.C. Modulation der expression des glucocorticoidrezeptors
US20080311552A1 (en) * 2005-09-20 2008-12-18 London Health Sciences Centre Research, Inc. Use of Sirnas in Organ Storage/Reperfusion Solutions
US20120164730A1 (en) * 2005-10-11 2012-06-28 Ben-Gurion University Of The Negev Research And Development Authority Ltd. Compositions for silencing the expression of vdac1 and uses thereof
EP2392646A1 (de) * 2005-10-14 2011-12-07 MUSC Foundation For Research Development Targeting von PAX2 zur Induktion der DEFB1-vermittelten Tumorimmunität und Krebstherapie
GB0521351D0 (en) * 2005-10-20 2005-11-30 Genomica Sau Modulation of TRPV expression levels
US8258109B2 (en) * 2005-10-20 2012-09-04 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of LMNA expression
WO2007049624A1 (ja) * 2005-10-24 2007-05-03 Takeda Pharmaceutical Company Limited 癌の予防・治療剤
GB0521716D0 (en) * 2005-10-25 2005-11-30 Genomica Sau Modulation of 11beta-hydroxysteriod dehydrogenase 1 expression for the treatment of ocular diseases
WO2007051077A2 (en) * 2005-10-28 2007-05-03 The Regents Of The University Of California Methods and compounds for lymphoma cell detection and isolation
US7723314B1 (en) * 2005-10-28 2010-05-25 Transderm, Inc. Methods and compositions for treating pachyonychia congenita
CN101365801B (zh) 2005-10-28 2013-03-27 阿尔尼拉姆医药品有限公司 抑制亨廷顿基因表达的组合物和方法
US20080090775A1 (en) * 2005-10-31 2008-04-17 Chong Huang Antagonist of TEB4 and Methods of Use
CN101346393B (zh) 2005-11-02 2015-07-22 普洛体维生物治疗公司 修饰的siRNA分子及其应用
JP4929288B2 (ja) * 2005-11-04 2012-05-09 アルナイラム ファーマシューティカルズ， インコーポレイテッド Ｎａｖ１．８遺伝子の発現を抑制するための組成物および方法
CA2626690A1 (en) * 2005-11-09 2007-05-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of factor v leiden mutant gene
US8066730B2 (en) * 2005-11-14 2011-11-29 Scapa Flow, Llc Medical dilator system or dilator device
US8067558B2 (en) 2005-12-19 2011-11-29 New York University Constitutively active fragments of eukaryotic heat shock RNA
US7919603B2 (en) * 2005-12-19 2011-04-05 New York University Heat shock RNA
US20070270366A1 (en) * 2005-12-20 2007-11-22 Karras James G Double stranded nucleic acid molecules targeted to il-4 receptor alpha
US8258287B2 (en) * 2005-12-21 2012-09-04 Centre de Cooperation Internationale en Recherche Agronomique pour le Developpment (CIRAD) Interfering RNAs targeting the morbillivirus nucleoprotein gene
EP2221378B1 (de) * 2005-12-22 2013-04-17 OPKO Pharmaceuticals, LLC Zusammensetzungen und Verfahren zur Regulierung eines Komplementsystems
AR057252A1 (es) 2005-12-27 2007-11-21 Alcon Mfg Ltd Inhibicion de rho quinasa mediada por arni para el tratamiento de trastornos oculares
US8673873B1 (en) 2005-12-28 2014-03-18 Alcon Research, Ltd. RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders
TW200731980A (en) 2005-12-29 2007-09-01 Alcon Mfg Ltd RNAi-mediated inhibition of HIF1A for treatment of ocular angiogenesis
US7444453B2 (en) * 2006-01-03 2008-10-28 International Business Machines Corporation Address translation device
EP1984400B1 (de) 2006-01-05 2012-11-28 Immune Disease Institute, Inc. Regulatoren von nfat
MX2008009220A (es) * 2006-01-17 2008-10-10 Biolex Therapeutics Inc Composiciones y metodos para la humanizacion y optimizacion de n-glicanos en plantas.
US20090060921A1 (en) * 2006-01-17 2009-03-05 Biolex Therapeutics, Inc. Glycan-optimized anti-cd20 antibodies
WO2007084954A2 (en) * 2006-01-19 2007-07-26 The Board Of Trustees Of The University Of Illinois Selective inhibition of ig20 splice variants to treat cancers
US7825099B2 (en) * 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
DOP2007000015A (es) 2006-01-20 2007-08-31 Quark Biotech Inc Usos terapéuticos de inhibidores de rtp801
JP5425474B2 (ja) * 2006-01-26 2014-02-26 アイシス ファーマシューティカルズ， インコーポレーテッド ハンチンチン対する、組成物及びその使用
US8229398B2 (en) * 2006-01-30 2012-07-24 Qualcomm Incorporated GSM authentication in a CDMA network
US20090221435A1 (en) * 2006-02-08 2009-09-03 Dharmacon, Inc. Microarray for detecting and quantifying microrna
CN101384721A (zh) * 2006-02-13 2009-03-11 孟山都技术有限公司 选择和稳定dsRNA构建体
JP4961549B2 (ja) * 2006-02-16 2012-06-27 国立大学法人愛媛大学 アンドロゲン受容体遺伝子に特異的なｓｉＲＮＡ
US7910566B2 (en) * 2006-03-09 2011-03-22 Quark Pharmaceuticals Inc. Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
FI20060246A0 (fi) * 2006-03-16 2006-03-16 Jukka Westermarck Uusi kasvua stimuloiva proteiini ja sen käyttö
EP1993611A4 (de) * 2006-03-16 2013-05-22 Alnylam Pharmaceuticals Inc Rnai-modulation von tgf-beta und ihre therapeutische verwendung
CA2644621A1 (en) * 2006-03-24 2007-10-04 Novartis Ag Dsrna compositions and methods for treating hpv infection
JP5704741B2 (ja) 2006-03-31 2015-04-22 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｅｇ５遺伝子発現の抑制のための組成物および方法
WO2007120883A2 (en) * 2006-04-12 2007-10-25 Isis Pharmaceuticals, Inc. Compositions and their uses directed to hepcidin
WO2007121156A2 (en) * 2006-04-13 2007-10-25 Alcon Research, Ltd Rnai-mediated inhibition of histamine receptor h1-related conditions
TW200808360A (en) * 2006-04-13 2008-02-16 Alcon Mfg Ltd RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
WO2007123391A1 (en) * 2006-04-20 2007-11-01 Academisch Ziekenhuis Leiden Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
WO2007124130A2 (en) * 2006-04-21 2007-11-01 Interventional Spine, Inc. Method and apparatus for spinal fixation
JP4812874B2 (ja) 2006-04-28 2011-11-09 アルナイラム ファーマシューティカルズ， インコーポレイテッド Ｊｃウイルス遺伝子の発現を抑制するための組成物および方法
CA3044969A1 (en) * 2006-05-05 2007-12-21 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating gene expression
US8158598B2 (en) * 2006-05-05 2012-04-17 Isis Pharmaceuticals, Inc. Compositions and their uses directed to PTPR alpha
TWI322690B (en) * 2006-05-11 2010-04-01 Flysun Dev Co Ltd Short interference ribonucleic acids for treating allergic dieases
EP2194128B1 (de) 2006-05-11 2012-08-01 Alnylam Pharmaceuticals Inc. Zusammensetzungen und Verfahren zur Hemmung der PCSK9-Genexpression
US20090130212A1 (en) * 2006-05-15 2009-05-21 Physical Pharmaceutica, Llc Composition and improved method for preparation of small particles
US8243715B2 (en) * 2006-05-15 2012-08-14 Oracle Israel Ltd. Delivering sip-based call services to circuit-switched terminals
JP2009537153A (ja) * 2006-05-19 2009-10-29 アルニラム ファーマシューティカルズ， インコーポレイテッド ＡｈａのＲＮＡｉ調節およびその治療上の使用
BRPI0711950A2 (pt) * 2006-05-19 2011-12-13 Scripps Research Inst tratamento para o dobramento inadequado da proteìna
AU2012201409B2 (en) * 2006-05-19 2014-06-12 Arrowhead Research Corporation RNAi-Mediated inhibition of tumor necrosis factor alpha-related conditions
US8198252B2 (en) * 2006-05-19 2012-06-12 Board Of Regents, The University Of Texas System SIRNA inhibition of PI3K P85, P110, and AKT2 and methods of use
EP1857548A1 (de) * 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Mittel und Verfahren zur Induktion von Exon-skipping
KR20120093306A (ko) * 2006-05-19 2012-08-22 알콘 리서치, 리미티드 종양 괴사 인자 α-관련 증상의 ＲＮＡｉ-매개 억제
AU2007253677B2 (en) * 2006-05-22 2011-02-10 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of IKK-B gene
US9273356B2 (en) 2006-05-24 2016-03-01 Medtronic, Inc. Methods and kits for linking polymorphic sequences to expanded repeat mutations
US8430813B2 (en) 2006-05-26 2013-04-30 Depuy Spine, Inc. Illuminated surgical access system including a surgical access device and integrated light emitter
US8598333B2 (en) * 2006-05-26 2013-12-03 Alnylam Pharmaceuticals, Inc. SiRNA silencing of genes expressed in cancer
WO2007143584A2 (en) * 2006-06-02 2007-12-13 Alcon Research, Ltd. RNAi-MEDIATED INHIBITION OF STROMAL CELL-DERIVED FACTOR 1-RELATED TARGETS FOR TREATMENT OF NEOVASCULARIZATION-RELATED CONDITIONS
WO2007141796A2 (en) * 2006-06-09 2007-12-13 Quark Pharmaceuticals, Inc. Therapeutic uses of inhibitors of rtp801l
US7915399B2 (en) * 2006-06-09 2011-03-29 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
CN101495630B (zh) * 2006-06-09 2012-12-26 株式会社益力多本社 与人癌细胞的永生化相关的基因及其应用
US20080152654A1 (en) * 2006-06-12 2008-06-26 Exegenics, Inc., D/B/A Opko Health, Inc. COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOGENESIS
KR100794705B1 (ko) * 2006-06-13 2008-01-14 (주)바이오니아 선택적 스플라이싱을 고려한 ｓｉＲＮＡ를 이용하여 표적ｍＲＮＡ의 발현을 억제하는 방법
GB0612342D0 (en) 2006-06-21 2006-08-02 Glaxosmithkline Biolog Sa Method
WO2008005769A2 (en) * 2006-06-30 2008-01-10 Immusol, Incorporated Methods of inhibiting hcv replication
US8124752B2 (en) * 2006-07-10 2012-02-28 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the MYC gene
JP4756271B2 (ja) * 2006-07-18 2011-08-24 独立行政法人産業技術総合研究所 ガン細胞の老化、アポトーシス誘導剤
EP1884569A1 (de) 2006-07-31 2008-02-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Sensibilisierung von Krebszellen für eine Therapie unter der Verwendung von siNA gerichtet gegen Gene aus der 1p und 19q chromosomalen Region
US8138160B2 (en) 2006-08-03 2012-03-20 Warsaw Orthopedic, Inc. Reagents, methods and systems to suppress pro-inflammatory cytokines
US8003620B2 (en) * 2006-08-04 2011-08-23 Isis Pharmaceuticals, Inc. Compositions and their uses directed to diacylglycerol acyltransferase 1
US8101585B2 (en) * 2006-08-04 2012-01-24 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of JNK proteins
EP4082551A1 (de) 2006-08-08 2022-11-02 Rheinische Friedrich-Wilhelms-Universität Bonn Struktur und verwendung von 5'-phosphat-oligonukleotiden
JP6047270B2 (ja) 2006-08-11 2016-12-21 バイオマリン テクノロジーズ ベー．フェー． Ｄｎａリピートの不安定性に関連した遺伝的障害を治療するための方法及び手段
US20080039415A1 (en) * 2006-08-11 2008-02-14 Gregory Robert Stewart Retrograde transport of sirna and therapeutic uses to treat neurologic disorders
EP2077326A4 (de) * 2006-09-04 2010-11-10 Kyowa Hakko Kirin Co Ltd Neuartige nukleinsäure
US7872118B2 (en) * 2006-09-08 2011-01-18 Opko Ophthalmics, Llc siRNA and methods of manufacture
US7737266B2 (en) 2006-09-18 2010-06-15 Board Of Regents, The University Of Texas System RNAi modulation of SCAP and therapeutics uses thereof
US20100144830A1 (en) * 2006-09-19 2010-06-10 Masahiko Kuroda Cancer cell identification marker and cancer cell proliferation inhibitor
US20090209478A1 (en) * 2006-09-21 2009-08-20 Tomoko Nakayama Compositions and methods for inhibiting expression of the hamp gene
AR055648A1 (es) * 2006-09-21 2007-08-29 Gen Med Sa Un oligonucleotido de rna de doble cadena una composicion farmaceutica o cosmetica que lo comprende y uso del mismo enla preparacion de un medicamento para el tratamiento de enfermedades relacionadas con el metabolismo de androgenos
WO2008036841A2 (en) 2006-09-22 2008-03-27 Dharmacon, Inc. Tripartite oligonucleotide complexes and methods for gene silencing by rna interference
EP2076600A1 (de) * 2006-10-18 2009-07-08 Nastech Pharmaceutical Company Inc. Nukleinsäuremoleküle mit nicks oder gaps und verwendungen davon
US8299040B2 (en) * 2006-10-18 2012-10-30 Board Of Regents, The University Of Texas System Methods for treating cancer targeting transglutaminase
JP2010507387A (ja) * 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のｓｉＲＮＡおよびその使用方法
US9375440B2 (en) * 2006-11-03 2016-06-28 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
US8324367B2 (en) 2006-11-03 2012-12-04 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
EP2087112A1 (de) * 2006-11-09 2009-08-12 UnibioScreen S.A. Alpha-1- oder alpha-3-untereinheit von na+, k+-atpase als ziel bei der behandlung proliferativer erkrankungen
US8304399B2 (en) * 2006-11-09 2012-11-06 The Board Of Regents Of The University Of Texas System Hedgehog signaling pathway proteins and uses thereof
EP2087114B1 (de) * 2006-11-13 2013-05-29 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Verfahren zur behandlung von krebs mittels gegen cd24 gerichteten sirna-molekülen
USD631962S1 (en) 2006-11-14 2011-02-01 Scapa Flow, Llc Medical dilator
US8034921B2 (en) * 2006-11-21 2011-10-11 Alnylam Pharmaceuticals, Inc. IRNA agents targeting CCR5 expressing cells and uses thereof
US7819842B2 (en) 2006-11-21 2010-10-26 Medtronic, Inc. Chronically implantable guide tube for repeated intermittent delivery of materials or fluids to targeted tissue sites
US7988668B2 (en) * 2006-11-21 2011-08-02 Medtronic, Inc. Microsyringe for pre-packaged delivery of pharmaceuticals
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
EP2453016A1 (de) * 2006-11-27 2012-05-16 Isis Pharmaceuticals, Inc. Verfahren zur Behandlung von Hypercholesterinämie
US20080171719A1 (en) * 2006-11-28 2008-07-17 Alcon Manufacturing, Ltd. RNAi-MEDIATED INHIBITION OF AQUAPORIN 1 FOR TREATMENT OF IOP-RELATED CONDITIONS
US8105382B2 (en) 2006-12-07 2012-01-31 Interventional Spine, Inc. Intervertebral implant
US8979931B2 (en) 2006-12-08 2015-03-17 DePuy Synthes Products, LLC Nucleus replacement device and method
JPWO2008084319A1 (ja) * 2006-12-18 2010-04-30 協和発酵キリン株式会社 新規核酸
CA2672979A1 (en) * 2006-12-22 2008-07-03 F. Hoffmann-La Roche Ag Selection method
US8476243B2 (en) 2006-12-29 2013-07-02 Transderm, Inc. Methods and compositions for treating keratin hyperproliferative disorders
US7754698B2 (en) * 2007-01-09 2010-07-13 Isis Pharmaceuticals, Inc. Modulation of FR-alpha expression
EP2114416B1 (de) 2007-01-16 2015-08-05 The University Of Queensland Verfahren zur auslösung einer immunantwort
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
WO2008094860A2 (en) 2007-01-30 2008-08-07 Allergan, Inc. Treating ocular diseases using peroxisome proliferator-activated receptor delta antagonists
MX2009008104A (es) 2007-02-02 2009-08-07 Amgen Inc Hepcidina, antagonistas de hepcidina y metodos de uso.
US20080188433A1 (en) * 2007-02-07 2008-08-07 Academia Sinica Methods of diagnosis of spinal muscular atrophy and treatments thereof
US20090163431A1 (en) * 2007-02-14 2009-06-25 Ontherex Llc Compositions and methods for modulation of pdx-1
US7872119B2 (en) * 2007-02-26 2011-01-18 Quark Pharmaceuticals, Inc. Inhibitors of RTP801 and their use in disease treatment
US20100292301A1 (en) * 2007-02-28 2010-11-18 Elena Feinstein Novel sirna structures
EP2121924A1 (de) * 2007-03-02 2009-11-25 MDRNA, Inc. Nukleinsäureverbindungen zur hemmung der vegf-familien-genexpression und anwendungen davon
JP2010519910A (ja) * 2007-03-02 2010-06-10 エムディーアールエヌエー，インコーポレイテッド Ｂｃｌ２遺伝子の発現を抑制するための核酸化合物およびその使用
WO2008109373A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting erbb gene expression and uses thereof
US20080299659A1 (en) * 2007-03-02 2008-12-04 Nastech Pharmaceutical Company Inc. Nucleic acid compounds for inhibiting apob gene expression and uses thereof
WO2008109381A2 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting hif1a gene expression and uses thereof
US20090018099A1 (en) * 2007-03-02 2009-01-15 Hitto Kaufmann Protein production
CA2679244A1 (en) * 2007-03-02 2009-03-05 Mdrna, Inc. Nucleic acid compounds for inhibiting myc gene expression and uses thereof
WO2008109518A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting wnt gene expression and uses thereof
US20100105134A1 (en) * 2007-03-02 2010-04-29 Mdrna, Inc. Nucleic acid compounds for inhibiting gene expression and uses thereof
US20100112687A1 (en) * 2007-03-02 2010-05-06 Mdrna, Inc. Nucleic acid compounds for inhibiting erbb family gene expression and uses thereof
EP2121925A2 (de) * 2007-03-02 2009-11-25 MDRNA, Inc. Nukleinsäureverbindungen zur hemmung der ras-genexpression und anwendungen davon
SI2126093T1 (sl) * 2007-03-02 2013-01-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Izboljšanje priprave proteinov
WO2008109362A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting vegf gene expression and uses thereof
JP2010519905A (ja) * 2007-03-02 2010-06-10 エムディーアールエヌエー，インコーポレイテッド Ａｋｔ遺伝子の発現を抑制するための核酸化合物およびその使用
US20100292302A1 (en) * 2007-03-08 2010-11-18 Mak Tak W Induction of apoptosis and inhibition of cell proliferation through modulation of carnitine palmitoyltransferase 1c activity
US8232085B2 (en) * 2007-03-14 2012-07-31 Bionsil S.R.L. Isoform of bruton's tyrosine kinase (BTK) protein
JP5103621B2 (ja) * 2007-03-20 2012-12-19 国立大学法人愛媛大学 ＡＤＡＴ１遺伝子に特異的なｓｉＲＮＡ
US7812002B2 (en) * 2007-03-21 2010-10-12 Quark Pharmaceuticals, Inc. Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
RU2559536C2 (ru) 2007-03-24 2015-08-10 Джензим Корпорейшн Введение антисмысловых олигонуклеотидов, комплементарных человеческому аполипопротеину в
PE20090064A1 (es) * 2007-03-26 2009-03-02 Novartis Ag Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
AP3018A (en) * 2007-03-29 2014-10-31 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expressionof a gene from the ebola
GB0707069D0 (en) * 2007-04-12 2007-05-23 Medical Res Council Methods and uses
WO2008124927A1 (en) * 2007-04-13 2008-10-23 Vincent Research & Consulting Inc. Sirna against thymidylate synthase and uses thereof in cancer treatment regimens
WO2008143774A2 (en) * 2007-05-01 2008-11-27 University Of Massachusetts Methods and compositions for locating snp heterozygosity for allele specific diagnosis and therapy
WO2008132234A2 (en) * 2007-05-01 2008-11-06 Santaris Pharma A/S Rna antagonist compounds for the modulation of beta-catenin
DK2573176T3 (en) * 2007-05-04 2016-08-01 Index Pharmaceuticals Ab Tumor growth retardant compounds and methods of use thereof
US20100286238A1 (en) * 2007-05-15 2010-11-11 Rivory Laurent Pierre Suppression of viruses involved in respiratory infection or disease
DE202007007322U1 (de) * 2007-05-23 2008-10-02 Baumgart, Rainer, Prof. Dr.med., Dipl.-Ing. Instrumentensatz zur minimal invasiven Vorbereitung einer Knochennagelung
WO2008147839A1 (en) 2007-05-23 2008-12-04 Dharmacon, Inc. Micro-rna scaffolds and non-naturally occurring micro-rnas
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
WO2008148304A1 (en) * 2007-05-31 2008-12-11 Xiamen University Rna interference target for treating aids
DK2152897T3 (en) * 2007-06-05 2015-04-27 Biocistronix Ab Methods and materials related to hårpigmentering and cancer
US20090054366A1 (en) * 2007-06-15 2009-02-26 Reliance Life Sciences Pvt. Ltd. RNAi MEDIATED KNOCKDOWN OF NUMA FOR CANCER THERAPY
AU2012203780B2 (en) * 2007-06-15 2014-06-26 Arrowhead Pharmaceuticals, Inc. RNAi inhibition of alpha-ENaC expression
US20100273854A1 (en) * 2007-06-15 2010-10-28 Hagar Kalinski Compositions and methods for inhibiting nadph oxidase expression
AR066984A1 (es) * 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
US8900307B2 (en) 2007-06-26 2014-12-02 DePuy Synthes Products, LLC Highly lordosed fusion cage
US20110206673A1 (en) * 2007-06-27 2011-08-25 Liu Dongxu Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof
HRP20140522T1 (hr) 2007-06-27 2014-08-15 Quark Pharmaceuticals, Inc. Pripravci i metode za inhibiranje izražaja proapoptotiäśkih gena
US8043343B2 (en) 2007-06-28 2011-10-25 Zimmer Spine, Inc. Stabilization system and method
JP5298014B2 (ja) 2007-07-03 2013-09-25 杏林製薬株式会社 インフルエンザ治療
JP5558346B2 (ja) 2007-07-05 2014-07-23 ノバルティス アーゲー ウイルス感染を処置するためのｄｓＲＮＡ
JP5706157B2 (ja) * 2007-07-12 2015-04-22 プロセンサ テクノロジーズ ビー．ブイ．Ｐｒｏｓｅｎｓａ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｂ．Ｖ． 化合物を種々の選択臓器又は組織に標的化するための分子
WO2009008725A2 (en) * 2007-07-12 2009-01-15 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs, tissues or tumor cells
EP2017340A1 (de) * 2007-07-16 2009-01-21 Qiagen GmbH Positive Kontrollen für expressionsmodulierende Experimente
US20090035225A1 (en) * 2007-08-03 2009-02-05 Alcon Research, Ltd. RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF GLAUCOMA
UY31267A1 (es) 2007-08-03 2009-01-05 Alcon Res Ltd Inhibición del pasaje de senalización del tnfa relacionada con arni para el tratamiento de la angiogénesis ocular
US8435510B2 (en) * 2007-08-08 2013-05-07 Sutter West Bay Hospitals Platelet derived growth factor receptor supports cytomegalovirus infectivity
WO2009035804A2 (en) * 2007-08-10 2009-03-19 Oncomune, Llc Gene silencing of the brother of the regulator of imprinted sites (boris)
EP2185702A4 (de) * 2007-08-21 2011-05-04 Scott And White Memorial Hospital And Scott Sherwood And Brindley Foundation Verfahren und zusammensetzungen posttranskriptionelle genausschaltung
US20110160280A1 (en) * 2007-08-24 2011-06-30 Oncotherapy Science, Inc. Cancer-related genes, cdca5, epha7, stk31 and wdhd1
DK2193140T3 (en) * 2007-08-27 2017-01-23 Iglobe Health Inst Llc COMPOSITIONS OF ASYMMETRIC INTERFERRING RNA AND ITS APPLICATIONS
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
CA2704737A1 (en) * 2007-09-18 2009-09-03 Intradigm Corporation Compositions comprising k-ras sirna and methods of use
EP2548962B1 (de) 2007-09-19 2016-01-13 Applied Biosystems, LLC Sirna-sequenz-unabhängige Modifikationsformate zur Verringerung von das Ziel verfehlenden phänotypischen Effekten bei RNAI und stabilisierte Formen davon
US20090088789A1 (en) 2007-09-28 2009-04-02 O'neil Michael J Balloon With Shape Control For Spinal Procedures
MX2010003606A (es) * 2007-10-01 2010-07-02 Isis Pharmaceuticals Inc Modulacion antisentido de la expresion del receptor del factor de crecimiento fibroblastico 4.
WO2009044392A2 (en) * 2007-10-03 2009-04-09 Quark Pharmaceuticals, Inc. Novel sirna structures
AU2008308426A1 (en) 2007-10-05 2009-04-09 Synthes Gmbh Dilation system and method of using the same
WO2009047362A2 (en) * 2007-10-12 2009-04-16 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Method for opening tight junctions
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
DK2203173T3 (en) 2007-10-26 2016-02-29 Academisch Ziekenhuis Leiden Materials and methods for prevention of muscle diseases
EP2222283A2 (de) * 2007-10-29 2010-09-01 University of Massachusetts Zur freisetzung von nukleinsäuren (sirna) mit hefe-zellwandproteinen verkapselte mehrlagige nanopatikel
US8097712B2 (en) 2007-11-07 2012-01-17 Beelogics Inc. Compositions for conferring tolerance to viral disease in social insects, and the use thereof
CN101984759A (zh) * 2007-11-09 2011-03-09 Isis药物公司 因子9表达的调节
US9029337B2 (en) 2007-11-09 2015-05-12 Isis Pharmaceuticals, Inc. Modulation of factor 7 expression
EP2617828B1 (de) 2007-12-10 2014-09-24 Alnylam Pharmaceuticals Inc. Zusammensetzungen und Verfahren zur Hemmung der Faktor VII-Genexpression
US20100204305A1 (en) * 2007-12-11 2010-08-12 Lorus Therapeutics Inc. Small interfering rna molecules against ribonucleotide reductase and uses thereof
US20110105584A1 (en) * 2007-12-12 2011-05-05 Elena Feinstein Rtp80il sirna compounds and methods of use thereof
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof
AU2008334948B2 (en) 2007-12-13 2014-11-20 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of RSV infection
US20090176729A1 (en) * 2007-12-14 2009-07-09 Alnylam Pharmaceuticals, Inc. Method of treating neurodegenerative disease
EP2628486A3 (de) 2007-12-14 2013-10-30 Amgen, Inc. Verfahren zur Behandlung von Knochenbrüchen mit Anti-Sclerostin-Antikörpern
KR100949791B1 (ko) * 2007-12-18 2010-03-30 이동기 오프-타겟 효과를 최소화하고 ＲＮＡｉ 기구를 포화시키지않는 신규한 ｓｉＲＮＡ 구조 및 그 용도
CA2709635A1 (en) * 2007-12-20 2009-07-02 Angiochem Inc. Polypeptide-nucleic acid conjugates and uses thereof
EP2077335A1 (de) * 2007-12-22 2009-07-08 Universitätsklinikum Schleswig-Holstein EXO1-Promoter-Polymorphismus im Zusammenhang mit außergewöhnlich hoher Lebenserwartung beim Menschen
KR100942807B1 (ko) * 2007-12-26 2010-02-18 재단법인서울대학교산학협력재단 폐암의 예방 또는 치료용 유전자 치료제 및 약제 조성물
EP2238251B1 (de) * 2007-12-27 2015-02-11 Protiva Biotherapeutics Inc. Silencing der polo-like-kinase-expression unter verwendung von interferenz-rna
EP2075333A1 (de) * 2007-12-28 2009-07-01 Qiagen GmbH Positive Kontrollen für expressionsmodulierende Experimente
EP2242854A4 (de) * 2008-01-15 2012-08-15 Quark Pharmaceuticals Inc Sirna-verbindungen und verfahren zur verwendung davon
EP2471493A1 (de) 2008-01-17 2012-07-04 Synthes GmbH Ein expansibles Zwischenwirbelimplantat und Herstellungsverfahren
EP2246422A4 (de) * 2008-01-24 2012-07-25 Nat Inst Of Advanced Ind Scien Polynukleotid oder analogon davon und verfahren zur genexpressionsregulierung mit dem polynukleotid oder dem analogon davon
WO2009096612A1 (en) * 2008-01-30 2009-08-06 Korea Institute Of Science And Technology Regulation of neutrotransmittter release through anion channels
WO2009134487A2 (en) * 2008-01-31 2009-11-05 Alnylam Pharmaceuticals, Inc. Optimized methods for delivery of dsrna targeting the pcsk9 gene
EP2249874A1 (de) * 2008-02-08 2010-11-17 ProSensa Holding BV Verfahren und mittel zur behandlung von mit dna-repeat-instabilität assoziierten erkrankungen
US8188060B2 (en) 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
US10131904B2 (en) 2008-02-11 2018-11-20 Rxi Pharmaceuticals Corporation Modified RNAi polynucleotides and uses thereof
US8288525B2 (en) * 2008-02-12 2012-10-16 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of CD45 gene
WO2009103067A2 (en) * 2008-02-14 2009-08-20 The Children's Hospital Of Philadelphia Compositions and methods to treat asthma
KR100870314B1 (ko) * 2008-02-19 2008-11-25 고려대학교 산학협력단 암 치료용 핵산 의약 조성물
DE112009000372A5 (de) * 2008-02-20 2011-01-27 Technische Universität Dresden Verwendung von Substanzen zur Sensibilisierung von Tumorzellen gegen Bestrahlung und/oder Chemotherapie
MX2010009611A (es) 2008-03-05 2010-12-15 Alnylam Pharmaceuticals Inc Composiciones y metodos para inhibir la expresion de genes eg5 y vegf.
KR101123130B1 (ko) * 2008-03-17 2012-03-30 연세대학교 산학협력단 Ｐｔｋ７ 단백질의 기능 저해를 통한 세포의 이동, 침윤 또는 혈관신생 억제제
CN102026670A (zh) * 2008-03-20 2011-04-20 夸克医药公司 用于抑制RTP801的新型siRNA化合物
EP2105145A1 (de) * 2008-03-27 2009-09-30 ETH Zürich Verfahren zur muskelspezifischen Abgabe lipidkonjugierter Oligonukleotide
KR20100131509A (ko) * 2008-03-31 2010-12-15 내셔날 인스티튜트 오브 어드밴스드 인더스트리얼 사이언스 앤드 테크놀로지 Ｒｎａ 간섭 효과가 높은 2본쇄 지질 수식 ｒｎａ
WO2009122639A1 (ja) * 2008-03-31 2009-10-08 Sugimoto Yoshikazu Ａｂｃトランスポーター蛋白質発現抑制剤
US7902166B2 (en) * 2008-04-03 2011-03-08 The Board Of Regents Of The University Of Oklahoma Compositions comprising inhibitors of RNA binding proteins and methods of producing and using same
US8936941B2 (en) 2008-04-03 2015-01-20 The Board Of Regents Of The University Of Oklahoma Compositions useful for cancer detection and treatment, a cancer stem cell model, and methods of production and use thereof
TWI348916B (en) * 2008-04-03 2011-09-21 Univ Nat Taiwan A novel treatment tool for cancer: rna interference of bcas2
US8198255B2 (en) * 2008-05-16 2012-06-12 The Board Of Regents Of The University Of Oklahoma SiRNA-mediated inhibition of doublecortin and Ca2+/calmodulin-dependent kinase-like-1
US7956044B1 (en) 2008-04-03 2011-06-07 The Board Of Regents Of The University Of Oklahoma Compositions comprising inhibitors of RNA binding proteins and methods of producing and using same
CN102037123A (zh) * 2008-04-04 2011-04-27 卡兰多制药股份有限公司 Epas1抑制剂的组合物和用途
JP5441997B2 (ja) 2008-04-05 2014-03-12 ジンテス ゲゼルシャフト ミット ベシュレンクテル ハフツング 拡張可能な椎骨間インプラント
EP2268812A1 (de) * 2008-04-09 2011-01-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Stim1-inhibitoren zur behandlung kardiovaskulärer erkrankungen
WO2009144704A2 (en) * 2008-04-15 2009-12-03 Quark Pharmaceuticals, Inc. siRNA COMPOUNDS FOR INHIBITING NRF2
AU2009236219B8 (en) * 2008-04-15 2015-06-25 Arbutus Biopharma Corporation Silencing of CSN5 gene expression using interfering RNA
WO2009129465A2 (en) 2008-04-17 2009-10-22 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of xbp-1 gene
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
JP5860698B2 (ja) * 2008-04-18 2016-02-16 アンジオケム，インコーポレーテッド パクリタキセル、パクリタキセル類似体またはパクリタキセルコンジュゲートの医薬組成物ならびに関連する調製方法および使用方法
CN102014859B (zh) 2008-04-22 2015-05-20 法国国家科学研究中心 抑制黑素生成的新组合物及其应用
US8324366B2 (en) 2008-04-29 2012-12-04 Alnylam Pharmaceuticals, Inc. Compositions and methods for delivering RNAI using lipoproteins
EP2119783A1 (de) * 2008-05-14 2009-11-18 Prosensa Technologies B.V. Verfahren für effizientes Exon (44)-Skipping bei Duchenne-Muskeldystrophie und entsprechende Mittel
US9663585B2 (en) 2008-05-16 2017-05-30 The Board Of Regents Of The University Of Oklahoma Anti-DCLK1 monoclonal antibodies and methods of production and use thereof
EP2291544B1 (de) 2008-05-16 2017-10-25 The Children's Hospital of Philadelphia Genetische veränderungen auf chromosomen 21q, 6q und 15q sowie verfahren zur verwendung davon bei der diagnose und behandlung von typ-i-diabetes
EP2297323A1 (de) 2008-05-21 2011-03-23 Hartmann, Gunther 5 -triphosphat-oligonukleotid mit stumpfem ende und verwendugen davon
WO2009143391A2 (en) * 2008-05-22 2009-11-26 Isis Pharmaceuticals, Inc Methods for modulation expression of creb
WO2009143390A2 (en) 2008-05-22 2009-11-26 Isis Pharmaceuticals, Inc. Methods for modulating expression of rbp4
ES2361099B1 (es) 2008-05-26 2012-05-08 Rudolf Morgenstern Lopez "prótesis intervertebral"
WO2009148137A1 (ja) * 2008-06-04 2009-12-10 協和発酵キリン株式会社 肥満細胞の脱顆粒を制御する核酸
WO2009147246A1 (en) * 2008-06-06 2009-12-10 Medizinische Universität Graz Compounds reducing or inhibiting the expression of pkd1 for diagnosis and therapy of brain tumors
US8431692B2 (en) * 2008-06-06 2013-04-30 Quark Pharmaceuticals, Inc. Compositions and methods for treatment of ear disorders
CN102099467A (zh) * 2008-06-06 2011-06-15 株式会社遗传科技 人骨桥蛋白siRNA
CA2643886A1 (en) * 2008-06-13 2009-12-13 Oregon Health & Science University Selection of personalized cancer therapy regimens using interfering rna functional screening
US20110053226A1 (en) * 2008-06-13 2011-03-03 Riboxx Gmbh Method for enzymatic synthesis of chemically modified rna
TWI455944B (zh) * 2008-07-01 2014-10-11 Daiichi Sankyo Co Ltd 雙股多核苷酸
US20110172293A1 (en) * 2008-07-08 2011-07-14 Fish Jason E Methods and Compositions for Modulating Angiogenesis
KR20110044983A (ko) 2008-07-10 2011-05-03 아카데미쉬 지에켄후이스 비즈 드 유니버시테이트 반 암스테르담 보체 길항제 및 그 용도
WO2010006111A2 (en) * 2008-07-10 2010-01-14 Merck & Co., Inc. Methods of using compositions comprising mir-192 and/or mir-215 for the treatment of cancer
EP2313506A1 (de) * 2008-07-11 2011-04-27 Medizinische Universität Innsbruck Antagonisten von nr2f6 zur verstärkung der immunantwort
US20110184046A1 (en) * 2008-07-11 2011-07-28 Dinah Wen-Yee Sah Compositions And Methods For Inhibiting Expression Of GSK-3 Genes
WO2010008562A2 (en) 2008-07-16 2010-01-21 Recombinetics Methods and materials for producing transgenic animals
US8815818B2 (en) 2008-07-18 2014-08-26 Rxi Pharmaceuticals Corporation Phagocytic cell delivery of RNAI
EP2316491B1 (de) * 2008-07-18 2016-10-12 National University Corporation Nagoya University Zellproliferationshemmer
CN101632833B (zh) * 2008-07-25 2013-11-06 上海市计划生育科学研究所 一种前列腺癌相关的基因及其用途
JP2011529686A (ja) 2008-07-29 2011-12-15 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム ポリグルタミンタンパク質発現の選択的阻害
US20110237646A1 (en) * 2008-08-07 2011-09-29 Isis Pharmaceuticals, Inc. Modulation of transthyretin expression for the treatment of cns related disorders
WO2010019270A1 (en) 2008-08-14 2010-02-18 Isis Pharmaceuticals, Inc. Modulation of prion expression
US8946172B2 (en) * 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
DK2331141T3 (en) * 2008-08-25 2016-04-04 Excaliard Pharmaceuticals Inc Antisense oligonucleotides WHO IS TARGETING connective tissue, AND USES THEREOF
US20130324478A1 (en) * 2008-09-08 2013-12-05 Laurence Faure Pharmacodiagnosis Test Targeting Oncology and Neurodegeneration
ES2799507T3 (es) 2008-09-10 2020-12-18 Univ Rutgers Obtención de imágenes de moléculas de ARNm individuales, usando múltiples sondas marcadas con un solo marcador
DK2334794T3 (en) 2008-09-15 2017-02-20 Children's Medical Center Corp MODULATION OF BCL11A FOR TREATMENT OF HEMOGLOBINOPATHIES
JP2010068723A (ja) * 2008-09-16 2010-04-02 Tokyo Medical & Dental Univ アレルギー疾患の治療のための核酸医薬
US8796443B2 (en) 2008-09-22 2014-08-05 Rxi Pharmaceuticals Corporation Reduced size self-delivering RNAi compounds
EP2334793B1 (de) 2008-09-25 2016-04-06 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur hemmung der expression des serumamyloid-a-gens
WO2010042547A1 (en) 2008-10-06 2010-04-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of an rna from west nile virus
EP2344204A4 (de) * 2008-10-07 2012-07-04 Harvard College Telomerasehemmer und anwendungsverfahren dafür
HRP20171969T1 (hr) 2008-10-15 2018-04-06 Ionis Pharmaceuticals, Inc. Modulacija ekspresije faktora 11
EP2355833A4 (de) * 2008-10-15 2012-12-26 Promising Future Llc Auf fas/fasl oder andere todesrezeptoren zielende verfahren und zusammensetzungen zum abtöten von tumorzellen
EP2346906A4 (de) 2008-10-15 2013-04-24 Angiochem Inc Konjugate aus glp-1-agonisten und ihre verwendung
JP5705118B2 (ja) 2008-10-15 2015-04-22 アンジオケム インコーポレーテッド 薬物送達のためのエトポシドおよびドキソルビシン複合体
SG10201809460SA (en) * 2008-10-20 2018-11-29 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of transthyretin
AU2015249072C1 (en) * 2008-10-20 2022-10-27 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of transthyretin
EP2350277A1 (de) * 2008-10-23 2011-08-03 Alnylam Pharmaceuticals, Inc. Verfahren und zusammensetzungen zur vorbeugung oder behandlung einer rsv-infektion unter verwendung modifizierter duplex-rna-moleküle
EP2762567B1 (de) 2008-10-24 2016-07-13 Sarepta Therapeutics, Inc. Mehrere Exon-Skipping-Zusammensetzungen für DMD
US8962581B2 (en) * 2008-10-30 2015-02-24 The Translational Genomics Research Institute Methods and kits to identify invasive glioblastoma
US9095592B2 (en) * 2008-11-07 2015-08-04 The Research Foundation For The State University Of New York Bruton's tyrosine kinase as anti-cancer drug target
US20100267803A1 (en) * 2008-11-07 2010-10-21 The Research Foundation Of State University Of New York Regulators Of Fat Metabolism As Anti-Cancer Targets
EP2365804B1 (de) * 2008-11-13 2015-05-06 Modgene, Llc Reduktion der amyloid-beta-belastung in nicht aus dem gehirn stammendem gewebe
WO2010059226A2 (en) 2008-11-19 2010-05-27 Rxi Pharmaceuticals Corporation Inhibition of map4k4 through rnai
EP2373308A2 (de) 2008-11-21 2011-10-12 Isis Pharmaceuticals, Inc. Kombinationstherapie zur behandlung von krebs
WO2010064851A2 (ko) * 2008-12-02 2010-06-10 울산대학교 산학협력단 종간 교차활성을 지닌 ｍＴＯＲ을 표적으로 하는 ｓｉＲＮＡ, 이를 포함하는 재조합벡터 및 이를 함유하는 약학조성물
US9394333B2 (en) 2008-12-02 2016-07-19 Wave Life Sciences Japan Method for the synthesis of phosphorus atom modified nucleic acids
CN108042560A (zh) * 2008-12-04 2018-05-18 库尔纳公司 通过抑制针对沉默调节蛋白1的天然反义转录物来治疗沉默调节蛋白1相关的疾病
AU2009322279A1 (en) 2008-12-04 2011-07-14 Opko Pharmaceuticals, Llc Compositions and methods for selective inhibition of pro-angiogenic VEGF isoforms
KR101866152B1 (ko) 2008-12-04 2018-06-08 큐알엔에이, 인크. 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
JP5759379B2 (ja) 2008-12-05 2015-08-05 アンジオケム インコーポレーテッド ニューロテンシンまたはニューロテンシンアナログおよびその使用
US20110144687A1 (en) * 2009-12-10 2011-06-16 Kleiner Jeffrey Lateral Based Retractor System
CA2746514C (en) 2008-12-10 2018-11-27 Alnylam Pharmaceuticals, Inc. Gnaq targeted dsrna compositions and methods for inhibiting expression
BRPI0923005A2 (pt) * 2008-12-17 2015-08-04 Commw Scient Ind Res Org Metodos para modulacao dos exo de aves
CN102325534B (zh) 2008-12-18 2016-02-17 戴瑟纳制药公司 延长的dicer酶底物和特异性抑制基因表达的方法
US11408003B2 (en) 2008-12-18 2022-08-09 Dicerna Pharmaceuticals, Inc. Extended dicer substrate agents and methods for the specific inhibition of gene expression
US20100249214A1 (en) 2009-02-11 2010-09-30 Dicerna Pharmaceuticals Multiplex dicer substrate rna interference molecules having joining sequences
JP2012512642A (ja) * 2008-12-18 2012-06-07 サントル・ナショナル・ドゥ・ラ・レシェルシュ・サイエンティフィーク−セ・エン・エール・エス− Ｔｒａｉｌ誘導アポトーシスに関する遺伝子の同定方法およびその治療適用
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
US20120035242A1 (en) * 2009-01-08 2012-02-09 Shionogi & Co., Ltd. Pharmaceutical composition for treating obesity or diabetes
US9127273B2 (en) * 2009-01-13 2015-09-08 The Board Of Regents Of The University Of Texas System UNC-45A splice variants based cancer diagnostics and therapeutics
WO2010093263A1 (en) * 2009-02-03 2010-08-19 Solilrna Biosciences Limited Compositions and methods for the treatment and prevention of neoplastic disorders
AU2010211133A1 (en) * 2009-02-03 2011-07-21 F. Hoffmann-La Roche Ag Compositions and methods for inhibiting expression of PTP1B genes
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
WO2010091396A2 (en) * 2009-02-09 2010-08-12 Archemix Corp. Aptamers to von willerbrand factor and their use as thrombotic, hematologic and cardiovascular disease therapeutics
KR101682735B1 (ko) * 2009-02-12 2016-12-06 큐알엔에이, 인크. 뇌 유래된 신경영양성 인자 (ｂｄｎｆ)에 대한 자연 안티센스 전사체의 저해에 의한 뇌 유래된 신경영양성 인자 (ｂｄｎｆ) 관련된 질환의 치료
WO2010091878A2 (en) * 2009-02-13 2010-08-19 Silence Therapeutics Ag Means for inhibiting the expression of opa1
CN102333869A (zh) * 2009-02-24 2012-01-25 里博克斯艾克斯有限公司 小干扰rna的改进设计
GB2468477A (en) * 2009-03-02 2010-09-15 Mina Therapeutics Ltd Double stranded RNA molecule comprising siRNA and miRNA precursors
EP2403946A4 (de) * 2009-03-04 2012-11-14 Behandlung von sirtuin 1 (sirt1)-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen sirt 1
US9181525B2 (en) 2009-03-06 2015-11-10 Mie University Method for enhancing a function of a T cell
NZ594995A (en) * 2009-03-12 2013-06-28 Alnylam Pharmaceuticals Inc LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HUMAN KINESIN FAMILY MEMBER 11 (Eg5) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) GENES
WO2010107838A1 (en) 2009-03-16 2010-09-23 Isis Pharmaceuticals, Inc. Targeting apolipoprotein b for the reduction of apolipoprotein c-iii
MX2011009751A (es) * 2009-03-16 2011-09-29 Opko Curna Llc Tratamiento de enfermedades relacionadas con factor nuclear (eritroide derivado 2) tipo 2 (nrf2) por inhibicion del transcrito antisentido natural a nrf2.
EA201171144A1 (ru) * 2009-03-19 2012-04-30 Мерк Шарп Энд Домэ Корп. ОПОСРЕДОВАННОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНА ГОМОЛОГА 1 BTB И CNC, ОСНОВНОГО ФАКТОРА ТРАНСКРИПЦИИ С ЛЕЙЦИНОВОЙ МОЛНИЕЙ 1 (Bach1) С ИСПОЛЬЗОВАНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
WO2010107958A1 (en) * 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20100239632A1 (en) 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
US8444983B2 (en) 2009-03-23 2013-05-21 Quark Pharmaceuticals, Inc. Composition of anti-ENDO180 antibodies and methods of use for the treatment of cancer and fibrotic diseases
JP2012521760A (ja) * 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたアポトーシスシグナル調節キナーゼ１（ＡＳＫ１）遺伝子発現のＲＮＡ干渉媒介性阻害
US20120022143A1 (en) * 2009-03-27 2012-01-26 Merck Sharp & Dohme Corp RNA Interference Mediated Inhibition of the Thymic Stromal Lymphopoietin (TSLP) Gene Expression Using Short Interfering Nucliec Acid (siNA)
WO2010111468A2 (en) * 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
US9526620B2 (en) 2009-03-30 2016-12-27 DePuy Synthes Products, Inc. Zero profile spinal fusion cage
KR101579638B1 (ko) * 2009-03-31 2015-12-22 데루타-후라이 화마 가부시키가이샤 티미딜산 합성효소에 대한 ＲＮＡｉ 분자 및 그의 용도
EP2414520A2 (de) 2009-03-31 2012-02-08 Altair Therapeutics, Inc. Verfahren zur modulation einer immunantwort auf eine virusinfektion
WO2010115202A2 (en) * 2009-04-03 2010-10-07 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of kras by blunt ended double-stranded rna
CN102575254B (zh) 2009-04-03 2015-03-04 戴瑟纳制药公司 利用不对称双链rna特异性抑制kras的方法和组合物
ES2468890T3 (es) * 2009-04-07 2014-06-17 Biedermann Technologies Gmbh & Co. Kg Herramienta utilizable con un anclaje para hueso, en particular para la cirugía vertebral
EP2421562B1 (de) 2009-04-20 2019-03-13 Angiochem Inc. Behandlung von ovarialkarzinom mit einem an ein angiopep-2-analogon konjugierten antitumorwirkstoff
ES2593836T3 (es) 2009-04-24 2016-12-13 Biomarin Technologies B.V. Oligonucleótido que comprende una inosina para tratar la DMD
US8349808B2 (en) * 2009-05-05 2013-01-08 Medical Diagnostic Laboratories, Llc Identification of a novel repressor on IFN-lambda promoter and siRNA against ZEB1 and BLIMP-1 to increase IFN-lambda gene activity
JP2012525826A (ja) 2009-05-05 2012-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｈｏ／ｃｅｒｔ細胞系
CN102459596B (zh) * 2009-05-06 2016-09-07 库尔纳公司 通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
KR101224828B1 (ko) 2009-05-14 2013-01-22 (주)바이오니아 ｓｉＲＮＡ 접합체 및 그 제조방법
GB0908467D0 (en) * 2009-05-15 2009-06-24 Univ Gent Use of the gtpase rab27b as biomarker to stratify patients with estrogen-receptor-positive breast cancer and to monitor their disease progression
CA2762524A1 (en) * 2009-05-18 2011-01-13 Ensysce Biosciences, Inc. Carbon nanotubes complexed with multiple bioactive agents and methods related thereto
EP2432882B1 (de) * 2009-05-22 2019-12-25 CuRNA, Inc. Behandlung von erkrankungen im zusammenhang mit dem transkriptionsfaktor e3 (tfe3) und dem insulinrezeptorsubstrat 2 (irs2) mittels hemmung des natürlichen antisense-transkripts gegen tfe3
US9034838B2 (en) * 2009-05-25 2015-05-19 Universita Degli Studi Di Roma “La Sapienza” miR-31 in duchenne muscular dystrophy therapy
WO2010136988A2 (en) * 2009-05-27 2010-12-02 Convergin Israel Ltd. Providing session-based services to event-based networks
GB2471065A (en) * 2009-06-10 2010-12-22 Univ Sheffield Modulator of claspin for treatment of cell proliferative disorder
KR20120050429A (ko) * 2009-06-15 2012-05-18 알닐람 파마슈티칼스 인코포레이티드 Ｐｃｓｋ9 유전자를 표적으로 하는 지질 제형된 ｄｓｒｎａ
US9051567B2 (en) 2009-06-15 2015-06-09 Tekmira Pharmaceuticals Corporation Methods for increasing efficacy of lipid formulated siRNA
PT3449926T (pt) 2009-06-17 2019-11-12 Cold Spring Harbor Laboratory Composições e métodos de modulação de excisões de smn2 em um sujeito
US8921330B2 (en) * 2009-06-26 2014-12-30 Curna, Inc. Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
JP5766188B2 (ja) 2009-07-01 2015-08-19 プロチバ バイオセラピューティクス インコーポレイティッド 固形腫瘍に治療剤を送達するための脂質製剤
RU2012103240A (ru) 2009-07-02 2013-08-10 Ангиокем Инк. Мультимерные пептидные конъюгаты и их применение
MX342945B (es) 2009-07-06 2016-10-18 Ontorii Inc * Profármacos de ácido nucleico novedosos y métodos de uso de los mismos.
US9849146B2 (en) 2009-07-20 2017-12-26 Rutgers, The State University Of New Jersey Inhibition of nonsense mediated mRNA decay by drugs that prevent hypusination of eukaryotic initiation factor 5A
US8603814B2 (en) * 2009-07-20 2013-12-10 Rutgers The State University Of New Jersey Method of inhibiting nonsense-mediated mRNA decay
WO2011011700A2 (en) * 2009-07-24 2011-01-27 Curna, Inc. Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
US20120156180A1 (en) * 2009-08-10 2012-06-21 The Board Of Trustees Of The University Of Illinois Compositions and methods for the treatment of krabbe and other neurodegenerative diseases
JP6189594B2 (ja) * 2009-08-11 2017-08-30 クルナ・インコーポレーテッド アディポネクチン（ａｄｉｐｏｑ）に対する天然アンチセンス転写物の抑制によるアディポネクチン（ａｄｉｐｏｑ）関連疾患の治療
US8840889B2 (en) 2009-08-13 2014-09-23 The Johns Hopkins University Methods of modulating immune function
AP2015008874A0 (en) 2009-08-14 2015-11-30 Alnylam Pharmaceuticals Inc Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
US8598327B2 (en) * 2009-08-18 2013-12-03 Baxter International Inc. Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
CN102482670B (zh) * 2009-08-21 2018-06-15 库尔纳公司 通过抑制‘hsp70-相互作用蛋白的c末端’(chip)的天然反义转录物而治疗chip相关疾病
US9114197B1 (en) 2014-06-11 2015-08-25 Silver Bullett Therapeutics, Inc. Coatings for the controllable release of antimicrobial metal ions
US10265435B2 (en) 2009-08-27 2019-04-23 Silver Bullet Therapeutics, Inc. Bone implant and systems and coatings for the controllable release of antimicrobial metal ions
US8221396B2 (en) 2009-08-27 2012-07-17 Silver Bullet Therapeutics, Inc. Bone implants for the treatment of infection
US9821094B2 (en) 2014-06-11 2017-11-21 Silver Bullet Therapeutics, Inc. Coatings for the controllable release of antimicrobial metal ions
US8927004B1 (en) 2014-06-11 2015-01-06 Silver Bullet Therapeutics, Inc. Bioabsorbable substrates and systems that controllably release antimicrobial metal ions
US20120171213A1 (en) * 2009-09-10 2012-07-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of treating tumors
NZ599032A (en) 2009-09-11 2014-09-26 Isis Pharmaceuticals Inc Modulation of huntingtin expression
CN102639115A (zh) 2009-09-15 2012-08-15 阿尔尼拉姆医药品有限公司 脂质配制的组合物及抑制eg5和vegf基因的表达的方法
US9187746B2 (en) 2009-09-22 2015-11-17 Alnylam Pharmaceuticals, Inc. Dual targeting siRNA agents
CA2775092A1 (en) * 2009-09-23 2011-03-31 Protiva Biotherapeutics, Inc. Compositions and methods for silencing genes expressed in cancer
CN102028947B (zh) * 2009-09-29 2014-02-05 苏州瑞博生物技术有限公司 Fam3b基因的抑制剂和组合物及抑制方法以及脂肪肝的疗法和抑制剂的制药用途
CN102869775A (zh) 2009-09-30 2013-01-09 哈佛大学校长及研究员协会 通过调节自噬抑制基因产物调节自噬的方法
US8394778B1 (en) 2009-10-08 2013-03-12 Immune Disease Institute, Inc. Regulators of NFAT and/or store-operated calcium entry
US8962584B2 (en) 2009-10-14 2015-02-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Compositions for controlling Varroa mites in bees
US20110104154A1 (en) * 2009-10-30 2011-05-05 Alcon Research, Ltd. Single nucleotide polymorphisms and genes associated with age-related macular degeneration
WO2011056883A1 (en) 2009-11-03 2011-05-12 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of transthyretin (ttr)
JP2013509874A (ja) * 2009-11-04 2013-03-21 エラスムス ユニバーシティ メディカル センター ロッテルダム 新脈管形成を調節する為の新規化合物及びこれらの化合物を使用する処置方法
US9799416B2 (en) * 2009-11-06 2017-10-24 Terrapower, Llc Methods and systems for migrating fuel assemblies in a nuclear fission reactor
CN101708328A (zh) * 2009-11-06 2010-05-19 上海市免疫学研究所 Cyr61蛋白在制药中的应用
WO2011057171A1 (en) 2009-11-08 2011-05-12 Quark Pharmaceuticals, Inc. METHODS FOR DELIVERY OF siRNA TO THE SPINAL CORD AND THERAPIES ARISING THEREFROM
SMT201800579T1 (it) 2009-11-12 2019-01-11 Univ Western Australia Molecole antisenso e metodi per trattare patologie
EP2322927A1 (de) * 2009-11-16 2011-05-18 Deutsches Krebsforschungszentrum Verbindungen zum Hemmen der CD95-Signalisierung bei der Behandlung von Pankreaskrebs
CA2776568A1 (en) 2009-11-26 2011-06-03 Quark Pharmaceuticals, Inc. Sirna compounds comprising terminal substitutions
KR101168726B1 (ko) * 2009-11-30 2012-07-30 한국생명공학연구원 암 치료용 약학 조성물
WO2011072082A2 (en) 2009-12-09 2011-06-16 Nitto Denko Corporation Modulation of hsp47 expression
US9393129B2 (en) 2009-12-10 2016-07-19 DePuy Synthes Products, Inc. Bellows-like expandable interbody fusion cage
CA2784783C (en) * 2009-12-18 2021-07-20 Novartis Ag Organic compositions to treat hsf1-related diseases
AU2014280918B2 (en) * 2009-12-18 2016-11-17 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat HSF1-related diseases
GB0922332D0 (en) 2009-12-22 2010-02-03 Isis Innovation Method of treatment and screening method
JP6031356B2 (ja) * 2009-12-23 2016-11-24 カッパーアールエヌエー，インコーポレイテッド Ｕｃｐ２に対する天然アンチセンス転写産物の阻害による脱共役タンパク質２（ｕｃｐ２）関連疾患の治療
KR101891352B1 (ko) * 2009-12-23 2018-08-24 큐알엔에이, 인크. 간세포 성장 인자(ｈｇｆ)에 대한 천연 안티센스 전사체의 억제에 의한 ｈｇｆ 관련 질환의 치료
WO2011078672A1 (en) 2009-12-24 2011-06-30 Prosensa Technologies B.V. Molecule for treating an inflammatory disorder
WO2011084193A1 (en) 2010-01-07 2011-07-14 Quark Pharmaceuticals, Inc. Oligonucleotide compounds comprising non-nucleotide overhangs
EP2521556B1 (de) 2010-01-08 2018-05-30 Ionis Pharmaceuticals, Inc. Modulation einer angiopoietin-3-ähnlichen expression
JP6027893B2 (ja) * 2010-01-11 2016-11-16 カッパーアールエヌエー，インコーポレイテッド 性ホルモン結合グロブリン（ｓｈｂｇ）に対する天然アンチセンス転写物の阻害による性ホルモン結合グロブリン（ｓｈｂｇ）関連疾患の治療
EP2524038A4 (de) * 2010-01-12 2013-11-20 Isis Pharmaceuticals Inc Modulation der transformierung einer wachstumsfaktor-beta-1-expression
WO2011091396A1 (en) * 2010-01-25 2011-07-28 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of mylip/idol gene
WO2011097644A2 (en) 2010-02-08 2011-08-11 Isis Pharmaceuticals, Inc. Selective reduction of allelic variants
EP3561060A1 (de) 2010-02-08 2019-10-30 Ionis Pharmaceuticals, Inc. Selektive reduktion von allelvarianten
EP2539356A4 (de) * 2010-02-26 2014-03-05 Isis Pharmaceuticals Inc Modulation der smad3-expression
PL2545182T4 (pl) 2010-03-08 2017-11-30 Monsanto Technology Llc Cząsteczki polinukeotydu do regulacji genów w roślinach
IL265674B2 (en) 2010-03-24 2024-05-01 Phio Pharm Corp Rana disorder in cutaneous and fibrotic symptoms
RU2615143C2 (ru) 2010-03-24 2017-04-04 Адвирна Самодоставляющие PHKi соединения уменьшенного размера
US9095504B2 (en) * 2010-03-24 2015-08-04 Rxi Pharmaceuticals Corporation RNA interference in ocular indications
US8853182B2 (en) * 2010-03-26 2014-10-07 The University Of Tokyo Cell growth inhibitor and screening method thereof
WO2011118778A1 (ja) 2010-03-26 2011-09-29 国立大学法人東京大学 細胞増殖抑制剤及びそのスクリーニング方法
US20130281510A1 (en) 2010-03-29 2013-10-24 Kumamoto University siRNA Therapy for Transthyretin (TTR) Related Ocular Amyloidosis
AU2011237630B2 (en) 2010-04-06 2016-01-21 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of CD274/PD-L1 gene
AU2015268740B2 (en) * 2010-04-06 2017-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of cd274/pd-l1 gene
CA2797051C (en) 2010-04-23 2021-01-12 Novartis Ag Organic compositions to treat beta-enac-related diseases
ES2625689T3 (es) 2010-04-29 2017-07-20 Ionis Pharmaceuticals, Inc. Modulación de la expresión de transtiretina
RU2693462C2 (ru) * 2010-05-03 2019-07-03 Курна, Инк. Лечение заболеваний, связанных с сиртуином (sirt), путем ингибирования природного антисмыслового транскрипта к сиртуину (sirt)
WO2011140365A1 (en) * 2010-05-05 2011-11-10 Auburn University Targeted particles comprising landscape phage fusion proteins and heterologous nucleic acid
AU2011255203B2 (en) * 2010-05-21 2016-01-21 Peptimed, Inc. Reagents and methods for treating cancer
AU2011261434B2 (en) * 2010-06-02 2015-11-26 Alnylam Pharmaceuticals, Inc. Compositions and methods directed to treating liver fibrosis
KR102008708B1 (ko) * 2010-06-23 2019-08-08 큐알엔에이, 인크. 전압 작동 나트륨 통로, 알파 소단위(scna)에 대한 자연 안티센스 전사체의 저해에 의한 전압 작동 나트륨 통로, 알파 소단위(scna) 관련된 질환의 치료
US9282979B2 (en) 2010-06-24 2016-03-15 DePuy Synthes Products, Inc. Instruments and methods for non-parallel disc space preparation
US8979860B2 (en) 2010-06-24 2015-03-17 DePuy Synthes Products. LLC Enhanced cage insertion device
EP2588034B1 (de) 2010-06-29 2018-01-03 Synthes GmbH Auslenkendes zwischenwirbelimplantat
FR2962041B1 (fr) * 2010-07-01 2012-07-27 Genethon Inhibiteurs de la calpaine 3 pour le traitement de dystrophies musculaires et de cardiomyopathies
WO2012006241A2 (en) * 2010-07-06 2012-01-12 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of androgen receptor by double-stranded rna
US20130225659A1 (en) 2010-07-19 2013-08-29 Isis Pharmaceuticals, Inc. Modulation of nuclear-retained rna
CN103068981A (zh) 2010-07-28 2013-04-24 爱尔康研究有限公司 靶向VEGFA的siRNA及用于体内治疗的方法
US8455304B2 (en) 2010-07-30 2013-06-04 Atmel Corporation Routable array metal integrated circuit package fabricated using partial etching process
WO2012023288A1 (en) * 2010-08-20 2012-02-23 Oncotherapy Science, Inc. Fam161a as a target gene for cancer therapy and diagnosis
WO2012027467A1 (en) * 2010-08-26 2012-03-01 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2426203B1 (de) 2010-09-02 2016-07-13 Université de Mons Zur Behandlung von fazioskapulohumeraler Muskeldystrophie nützliche Wirkstoffe
CN103221428B (zh) 2010-09-09 2016-02-10 辉瑞公司 4-1bb结合分子
US20140141015A1 (en) * 2010-09-20 2014-05-22 Douglas Lake QSOX1 as an Anti-Neoplastic Drug Target
US8217163B2 (en) * 2010-09-20 2012-07-10 Biomics Biotechnologies Co., Ltd. Application of highly conserved domain sequences from viral genome as template to design therapeutic slirnas
US8946186B2 (en) * 2010-09-20 2015-02-03 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University QSOX1 as an anti-neoplastic drug target
JP5860038B2 (ja) * 2010-09-22 2016-02-16 国立大学法人北海道大学 抗メタボリックシンドローム効果を持つ核酸
DK2620428T3 (da) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
EP2621502A4 (de) * 2010-09-30 2014-08-13 Nitto Denko Corp Modulation der timp1- und timp2-expression
WO2012043633A1 (ja) * 2010-09-30 2012-04-05 独立行政法人国立精神・神経医療研究センター 優性変異遺伝子発現抑制剤
US20120083035A1 (en) 2010-09-30 2012-04-05 Dharmacon, Inc. Modified Cell Lines for Increasing Lentiviral Titers
WO2012048316A2 (en) * 2010-10-08 2012-04-12 Immune Disease Institute, Inc. Regulators of nfat and/or store-operated calcium entry
US9402732B2 (en) 2010-10-11 2016-08-02 DePuy Synthes Products, Inc. Expandable interspinous process spacer implant
WO2012053741A2 (ko) 2010-10-22 2012-04-26 성균관대학교산학협력단 Rna 간섭을 유도하는 핵산 분자 및 그 용도
CN103201385A (zh) 2010-10-27 2013-07-10 德福根有限公司 下调昆虫害虫中的基因表达
WO2012056441A1 (en) * 2010-10-28 2012-05-03 Nanodoc Ltd. Compositions and methods for specific cleavage of exogenous rna in a cell
WO2012058693A2 (en) * 2010-10-29 2012-05-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibition of pcsk9 genes
WO2012064758A2 (en) 2010-11-08 2012-05-18 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
WO2012064402A1 (en) 2010-11-12 2012-05-18 Silver Bullet Therapeutics, Inc. Bone implant and systems that controllably releases silver
US9920317B2 (en) 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
AU2011325956B2 (en) 2010-11-12 2016-07-14 The General Hospital Corporation Polycomb-associated non-coding RNAs
WO2012068405A2 (en) 2010-11-17 2012-05-24 Isis Pharmaceuticals, Inc. Modulation of alpha synuclein expression
EP2643463B1 (de) * 2010-11-23 2017-09-27 CuRNA, Inc. Behandlung von nanog-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen nanog
WO2012075114A2 (en) * 2010-12-01 2012-06-07 Ablitech, Inc. Nucleic acid-polymer conjugates and uses thereof
EP2649181B1 (de) * 2010-12-06 2016-04-27 Quark Pharmaceuticals, Inc. Doppelsträngige oligonukleotidverbindungen mit positionsmodifikationen
EP2649182A4 (de) 2010-12-10 2015-05-06 Alnylam Pharmaceuticals Inc Zusammensetzungen und verfahren zur erhöhung einer erythropoietin (epo)-herstellung
US9127275B2 (en) * 2010-12-10 2015-09-08 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
CA2820440A1 (en) * 2010-12-17 2012-06-21 Universite Pierre Et Marie Curie (Paris 6) The abcg1 gene as a marker and a target gene for treating obesity
WO2012080509A1 (en) * 2010-12-17 2012-06-21 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nucleic acids targeting tctp for use in the treatment of chemo-or hormone-resistant cancers
US9644042B2 (en) 2010-12-17 2017-05-09 Carnegie Mellon University Electrochemically mediated atom transfer radical polymerization
WO2012094115A1 (en) * 2010-12-17 2012-07-12 Arrowhead Research Corporation Compositions and methods for inhibiting expression of flt3 genes
WO2012083363A1 (en) * 2010-12-22 2012-06-28 Murdoch Childrens Research Institute A method of treatment
AU2011353283A1 (en) * 2010-12-30 2013-07-18 Samyang Biopharmaceuticals Corporation siRNA for inhibition of Hif1alpha expression and anticancer composition containing the same
BR112013018924A2 (en) 2011-01-25 2018-05-08 Almac Diagnostics Limited Colon cancer gene expression signatures and methods of use
US20120197320A1 (en) * 2011-01-28 2012-08-02 Laser Spine Surgical Center, LLC Foraminoplasty Device
JP6177692B2 (ja) 2011-02-02 2017-08-09 エクスカリアード・ファーマシューティカルズ，インク 結合組織増殖因子（ｃｔｇｆ）をターゲティングするアンチセンス化合物を用いた、ケロイドまたは肥厚性瘢痕の治療法
US9157125B2 (en) 2011-02-02 2015-10-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services GRIN2A mutations and use thereof for the diagnosis of melanoma
US8394129B2 (en) * 2011-03-10 2013-03-12 Interventional Spine, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
US8518087B2 (en) 2011-03-10 2013-08-27 Interventional Spine, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
CA2865468C (en) * 2011-03-11 2021-05-04 Sarissa Inc. Methods of treating cancer by inhibition of dna repair proteins
EP2508530A1 (de) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Reinigung von triphosphorylierten Oligonucleotiden mit Einfang-Tags
EP2691121A4 (de) * 2011-03-29 2015-08-26 Alnylam Pharmaceuticals Inc Zusammensetzungen und verfahren zur hemmung der tmprss6-genexpression
WO2012135736A2 (en) 2011-04-01 2012-10-04 Isis Pharmaceuticals, Inc. Modulation of signal transducer and activator of transcription 3 (stat3) expression
CA2832972C (en) 2011-04-13 2019-04-30 Isis Pharmaceuticals, Inc. Antisense modulation of ptp1b expression
US10941399B2 (en) * 2011-04-14 2021-03-09 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for gene-specific demethylation by DNA methyltransferase (DNMT)-RNA interaction
MX347253B (es) 2011-04-21 2017-04-20 Ionis Pharmaceuticals Inc Modulación de la expresión del virus de hepatitis b (vhb).
TW201243330A (en) * 2011-04-22 2012-11-01 Univ Nat Cheng Kung Method for analyzing sectretome, biomarker for lung cancer metastasis, and siRNA compound for inhibiting lung cancer metastasis
DK2717883T3 (en) 2011-05-02 2017-04-24 Stichting Vumc PROTECTION AGAINST ENDOTELIAL BARRIER DYSFUNCTION BY INHIBITION OF THE TYROSINKINASE ABL RELATED GENES (ARG)
CN103501825B (zh) 2011-05-02 2017-03-15 免疫医疗公司 用于小体积施用的同种异型选择的抗体的超滤浓缩
WO2012170284A1 (en) * 2011-06-06 2012-12-13 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of isocitrate dehydrogenase (idh1) gene expression
JP6188686B2 (ja) * 2011-06-09 2017-08-30 カッパーアールエヌエー，インコーポレイテッド フラタキシン（ｆｘｎ）への天然アンチセンス転写物の阻害によるｆｘｎ関連疾患の治療
US9187749B2 (en) 2011-06-10 2015-11-17 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
CA2838984A1 (en) 2011-06-10 2012-12-13 Isis Pharmaceuticals, Inc. Methods for modulating kallikrein (klkb1) expression
CA2839437A1 (en) 2011-06-16 2012-12-20 Isis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
WO2012177921A2 (en) * 2011-06-21 2012-12-27 Alnylam Pharmaceuticals, Inc Compositions and methods for inhibiting hepcidin antimicrobial peptide (hamp) or hamp-related gene expression
KR20260004562A (ko) 2011-06-21 2026-01-08 알닐람 파마슈티칼스 인코포레이티드 아포리포단백질 c-iii(apoc3) 유전자의 발현 억제를 위한 조성물 및 방법
KR102039315B1 (ko) 2011-06-21 2019-11-04 미나 테라퓨틱스 리미티드 알부민 생산 및 세포 증식
WO2012177949A2 (en) 2011-06-21 2012-12-27 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibition of expression of protein c (proc) genes
CN103890000B (zh) 2011-06-21 2017-09-01 阿尔尼拉姆医药品有限公司 血管生成素样3(ANGPTL3)iRNA组合物及其使用方法
FI20115640A0 (fi) * 2011-06-22 2011-06-22 Turun Yliopisto Yhdistelmähoito
EP2723390B1 (de) * 2011-06-23 2017-12-27 Alnylam Pharmaceuticals, Inc. Serpina1-sirnas: materialzusammensetzungen und behandlungsverfahren
WO2013003808A1 (en) 2011-06-29 2013-01-03 Isis Pharmaceuticals, Inc. Methods for modulating kallikrein (klkb1) expression
WO2013010045A1 (en) 2011-07-12 2013-01-17 Biotime Inc. Novel methods and formulations for orthopedic cell therapy
CN103889461B (zh) 2011-07-18 2016-11-09 肯塔基大学研究基金会 保护细胞免于alu-rna诱导的变性和用于保护细胞的抑制剂
US9605019B2 (en) 2011-07-19 2017-03-28 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
US20140328811A1 (en) * 2011-08-01 2014-11-06 Alnylam Pharmaceuticals, Inc. Method for improving the success rate of hematopoietic stem cell transplants
EP2742056B2 (de) 2011-08-11 2020-06-10 Ionis Pharmaceuticals, Inc. Selektive antisense-verbindungen und ihre verwendungen
EP2747753B1 (de) 2011-08-22 2023-03-29 Carnegie Mellon University Radikalische atomtransfer-polymerisation unter biologisch verträglichen bedingungen
KR101275264B1 (ko) * 2011-08-24 2013-06-17 포항공과대학교 산학협력단 샤프로닌 단백질의 조절 물질 탐색 방법
JP5995849B2 (ja) * 2011-08-29 2016-09-21 学校法人 新潟科学技術学園 新潟薬科大学 ヒト白血病細胞のアポトーシスを誘導するヘプタマー型スモールガイド核酸
US10023861B2 (en) 2011-08-29 2018-07-17 Ionis Pharmaceuticals, Inc. Oligomer-conjugate complexes and their use
EP3521432A1 (de) 2011-09-02 2019-08-07 Arrowhead Pharmaceuticals, Inc. Organische zusammensetzungen zur behandlung von hsf1-bedingten erkrankungen
FI20115876A0 (fi) 2011-09-06 2011-09-06 Turun Yliopisto Yhdistelmähoito
US20130064881A1 (en) * 2011-09-08 2013-03-14 Gradalis, Inc. Compositions and methods for treating prostate cancer
US10829828B2 (en) 2011-09-13 2020-11-10 Monsanto Technology Llc Methods and compositions for weed control
WO2013040117A1 (en) * 2011-09-13 2013-03-21 Monsanto Technology Llc Methods and compositions for weed control
EP2755988B1 (de) 2011-09-13 2018-08-22 Monsanto Technology LLC Verfahren und zusammensetzungen zur unkrautbekämpfung
US10806146B2 (en) 2011-09-13 2020-10-20 Monsanto Technology Llc Methods and compositions for weed control
US10760086B2 (en) 2011-09-13 2020-09-01 Monsanto Technology Llc Methods and compositions for weed control
UA115535C2 (uk) 2011-09-13 2017-11-27 Монсанто Текнолоджи Ллс Спосіб та композиція для боротьби з бур'янами (варіанти)
MX377067B (es) 2011-09-13 2025-03-07 Monsanto Technology Llc Métodos y composiciones para el control de malezas.
CA2848680C (en) 2011-09-13 2020-05-19 Monsanto Technology Llc Methods and compositions for weed control
WO2013038907A1 (ja) * 2011-09-14 2013-03-21 日本化薬株式会社 細胞の増殖抑制方法、ｎｅｋ１０バリアント遺伝子に対するｒｎａ干渉作用を有する核酸分子、及び抗癌剤
US11058708B2 (en) * 2011-09-19 2021-07-13 Sweyshen Chen RNA interference of galectin-3 expression and methods of use thereof
US9453261B2 (en) * 2011-09-20 2016-09-27 The George Washington University Alternative splicing variants of genes associated with prostate cancer risk and survival
CA2849273C (en) 2011-09-20 2020-07-21 Isis Pharmaceuticals, Inc. Antisense modulation of gcgr expression
WO2013043442A1 (en) 2011-09-23 2013-03-28 Dharmacon, Inc. The introduction of modular vector elements during production of a lentivirus
US9334500B2 (en) 2011-09-28 2016-05-10 Agency For Science, Technology And Research Methods and pharmaceutical compositions for treating cancer
JP2013079210A (ja) * 2011-10-04 2013-05-02 Nagoya City Univ 治療剤、遺伝子治療剤及び好酸球の浸潤抑制方法
WO2013052432A1 (en) 2011-10-05 2013-04-11 Dharmacon, Inc. Optimization of vectors for effective delivery and expression of genetic content
WO2013063313A1 (en) 2011-10-25 2013-05-02 Isis Pharmaceuticals, Inc. Antisense modulation of gccr expression
US9622779B2 (en) 2011-10-27 2017-04-18 DePuy Synthes Products, Inc. Method and devices for a sub-splenius / supra-levator scapulae surgical access technique
US9773091B2 (en) 2011-10-31 2017-09-26 The Scripps Research Institute Systems and methods for genomic annotation and distributed variant interpretation
CN102373206B (zh) * 2011-10-31 2013-02-27 暨南大学 靶向抑制PPP2R5C基因表达和肿瘤T细胞增殖的PPP2R5C-siRNA799及其应用
EP2773954B1 (de) * 2011-10-31 2018-04-11 The Scripps Research Institute Systeme und verfahren zur genomischen kommentierung und interpretation von verteilten varianten
WO2013067179A2 (en) 2011-11-01 2013-05-10 Synthes Usa, Llc Dilation system
US9725722B2 (en) 2011-11-07 2017-08-08 Ionis Pharmaceuticals, Inc. Modulation of TMPRSS6 expression
US9567585B2 (en) 2011-11-10 2017-02-14 Shire Human Genetic Therapies, Inc. Antisense oligonucleotide modulators of serotonin receptor 2C and uses thereof
EP2725103A3 (de) * 2011-11-14 2016-01-06 Silenseed Ltd Verfahren und Zusammensetzungen zur Behandlung von Prostatakrebs
CA2856117A1 (en) * 2011-11-17 2013-05-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Auto-recognizing therapeutic rna/dna chimeric nanoparticles (np)
WO2013075035A1 (en) 2011-11-18 2013-05-23 Alnylam Pharmaceuticals Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
WO2013075233A1 (en) * 2011-11-21 2013-05-30 The Royal Institution For The Advancement Of Learning / Mcgill University Method for treating brain cancer
US9546367B2 (en) * 2011-12-07 2017-01-17 Jenny Chee Ning Chang siRNA compositions and methods for inhibiting gene expression in tumor initiating cells of breast cancer
CA2860676A1 (en) 2012-01-09 2013-07-18 Novartis Ag Organic compositions to treat beta-catenin-related diseases
US9707235B1 (en) 2012-01-13 2017-07-18 University Of Kentucky Research Foundation Protection of cells from degeneration and treatment of geographic atrophy
ES2907250T3 (es) 2012-01-27 2022-04-22 Biomarin Tech Bv Oligonucleótidos de modulación de ARN con características mejoradas para el tratamiento de la distrofia muscular de Duchenne y de Becker
CN104105473B (zh) * 2012-02-13 2017-09-12 荷兰联合利华有限公司 皮肤美白组合物
NZ700075A (en) 2012-02-24 2016-05-27 Protiva Biotherapeutics Inc Trialkyl cationic lipids and methods of use thereof
US9139829B2 (en) * 2012-02-28 2015-09-22 Medical Diagnostic Laboratories, Llc SiRNA targeting ETS1 and ELK1 and method of using same in the inhibition of CIP2A gene in cancer treatment
WO2013138668A1 (en) * 2012-03-16 2013-09-19 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of mcl1 by double-stranded rna
WO2013142514A1 (en) * 2012-03-19 2013-09-26 Isis Pharmaceuticals, Inc. Methods and compositions for modulating alpha-1-antitrypsin expression
ES2742284T3 (es) 2012-03-28 2020-02-13 Somalogic Inc Aptámeros contra PDGF y VEGF y su utilización en el tratamiento de afecciones mediadas por PDGF y VEGF
WO2013149191A1 (en) * 2012-03-29 2013-10-03 The Trustees Of Columbia University In The City Of New York Methods for regulating hair growth disorders
WO2013147140A1 (ja) * 2012-03-29 2013-10-03 国立大学法人九州大学 ペリオスチン遺伝子の発現抑制核酸分子、ペリオスチン遺伝子の発現抑制方法、およびその用途
US10273474B2 (en) 2012-03-30 2019-04-30 Washington University Methods for modulating Tau expression for reducing seizure and modifying a neurodegenerative syndrome
US9557327B2 (en) * 2012-04-03 2017-01-31 National Center For Child Health And Development DNA controlling miR-140 expression, and screening method of drugs using said DNA
US9133461B2 (en) * 2012-04-10 2015-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
US9265490B2 (en) 2012-04-16 2016-02-23 DePuy Synthes Products, Inc. Detachable dilator blade
WO2013158046A1 (en) * 2012-04-20 2013-10-24 Agency For Science, Technology And Research Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies
US10407677B2 (en) * 2012-04-26 2019-09-10 Intana Bioscience Gmbh High complexity siRNA pools
US9127274B2 (en) * 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
TWI480043B (zh) * 2012-05-01 2015-04-11 高雄醫學大學 用以治療塑化劑引發之雌激素受體陰性型乳癌的醫藥組成物
EP3272868A1 (de) * 2012-05-02 2018-01-24 Arrowhead Pharmaceuticals, Inc. Organische zusammensetzungen zur behandlung von kras-bedingten erkrankungen
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
BR112014028644A2 (pt) 2012-05-16 2017-08-15 Rana Therapeutics Inc Composições e métodos para modulação da expressão de atp2a2
BR112014028634A2 (pt) 2012-05-16 2017-06-27 Rana Therapeutics Inc composições e métodos para modulação da expressão de utrn
CA2873769A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics Inc. Compositions and methods for modulating hemoglobin gene family expression
SG11201407483YA (en) 2012-05-16 2014-12-30 Rana Therapeutics Inc Compositions and methods for modulating smn gene family expression
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
AU2013262709A1 (en) 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating MECP2 expression
WO2013173789A2 (en) 2012-05-17 2013-11-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions
US9574193B2 (en) 2012-05-17 2017-02-21 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating apolipoprotein (a) expression
US10125362B2 (en) 2012-05-22 2018-11-13 Olix Pharmaceuticals, Inc. RNA-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor
EP2852606B1 (de) 2012-05-22 2019-08-07 Ionis Pharmaceuticals, Inc. Modulation der durch verstärker-rns vermittelten genexpression
AR091143A1 (es) 2012-05-24 2015-01-14 Seeds Ltd Ab Composiciones y metodos para silenciar la expresion genetica
US9487780B2 (en) 2012-06-01 2016-11-08 Ionis Pharmaceuticals, Inc. Antisense compounds targeting genes associated with fibronectin
US9828602B2 (en) * 2012-06-01 2017-11-28 Ionis Pharmaceuticals, Inc. Antisense compounds targeting genes associated with fibronectin
US9201916B2 (en) * 2012-06-13 2015-12-01 Infosys Limited Method, system, and computer-readable medium for providing a scalable bio-informatics sequence search on cloud
CN102703452B (zh) * 2012-06-21 2013-06-05 浙江省医学科学院 一种抑制Bcl2基因表达的siRNA双链及其应用
CN102703451B (zh) * 2012-06-21 2013-04-17 浙江省医学科学院 一种抑制Bcl2基因表达的表达盒及含有该表达盒的载体
MX370669B (es) * 2012-06-22 2019-12-19 Syngenta Participations Ag Control biológico de plagas de coleópteros.
ES2809199T3 (es) 2012-06-25 2021-03-03 Ionis Pharmaceuticals Inc Modulación de la expresión de UBE3A-ATS
CA2880896C (en) 2012-06-26 2021-11-16 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
KR20240148947A (ko) 2012-07-13 2024-10-11 웨이브 라이프 사이언시스 리미티드 키랄 제어
US10166241B2 (en) 2012-07-13 2019-01-01 Turun Yliopisto Combination Therapy III
SG11201500239VA (en) 2012-07-13 2015-03-30 Wave Life Sciences Japan Asymmetric auxiliary group
CN103540655A (zh) * 2012-07-16 2014-01-29 复旦大学 Mk5基因在筛选抗肝癌药物中的应用
US8940052B2 (en) 2012-07-26 2015-01-27 DePuy Synthes Products, LLC Expandable implant
WO2014017659A1 (ja) * 2012-07-27 2014-01-30 独立行政法人理化学研究所 急性骨髄性白血病の治療又は再発抑制剤
WO2014022655A1 (en) * 2012-08-01 2014-02-06 The Trustees Of Columbia University In The City Of New York Methods for regulating hair growth disorders
KR101520383B1 (ko) * 2012-08-02 2015-05-15 에이비온 주식회사 Ｈｐｖ 감염과 관련된 암의 치료용 조성물
EP2885002A4 (de) 2012-08-14 2016-04-20 Ibc Pharmaceuticals Inc Umleitung t-zell-bispezifischer antikörper zur behandlung von krankheiten
EP2890986B1 (de) * 2012-08-30 2017-06-21 Turun Yliopisto Verfahren zur auswahl einer individualisierten hirnkrebstherapie
US20140067069A1 (en) 2012-08-30 2014-03-06 Interventional Spine, Inc. Artificial disc
AU2013308519A1 (en) 2012-08-31 2015-04-09 The General Hospital Corporation Biotin complexes for treatment and diagnosis of Alzheimer's disease
US20140066595A1 (en) * 2012-09-04 2014-03-06 Thermo Fisher Scientific Biosciences Inc. Modulators of Protein Production in a Human Cell Line and Cell-free Extracts Produced Therefrom
GB201215857D0 (en) 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
JP2015533792A (ja) 2012-09-05 2015-11-26 シレンティス・エセ・ア・ウ ｓｉＲＮＡならびに眼の状態の処置および／または予防のための方法および組成物におけるその使用
CN104619844A (zh) 2012-09-12 2015-05-13 夸克制药公司 靶向p53的双链寡核苷酸分子及其使用方法
NZ706930A (en) * 2012-09-13 2017-01-27 Seminis Vegetable Seeds Inc Genetic markers for myb28
US9480855B2 (en) 2012-09-26 2016-11-01 DePuy Synthes Products, Inc. NIR/red light for lateral neuroprotection
EP2712870A1 (de) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Neuartige RIG-I-Liganden und Herstellungsverfahren dafür
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
WO2014059364A1 (en) 2012-10-11 2014-04-17 Isis Pharmaceuticals, Inc. Methods of treating kennedy's disease
US9175291B2 (en) * 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
WO2014062736A1 (en) 2012-10-15 2014-04-24 Isis Pharmaceuticals, Inc. Methods for monitoring c9orf72 expression
ES2762326T5 (es) 2012-10-15 2023-04-27 Ionis Pharmaceuticals Inc Métodos para modular la expresión de C9ORF72
US10443052B2 (en) 2012-10-15 2019-10-15 Ionis Pharmaceuticals, Inc. Compositions for modulating C9ORF72 expression
WO2014060392A1 (en) * 2012-10-16 2014-04-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Caspase-6 inhibitors for treating t cell activation and/or proliferation disorders
US10206911B2 (en) 2012-10-26 2019-02-19 Memorial Sloan-Kettering Cancer Center Androgen receptor variants and methods for making and using
WO2014076703A1 (en) * 2012-11-14 2014-05-22 Silenseed Ltd. Methods and compositions for treating cancer
WO2014077693A1 (en) * 2012-11-16 2014-05-22 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Means and methods for reducing an effect of aging in a mammalian cell
PT2925864T (pt) 2012-11-27 2019-02-06 Childrens Medical Ct Corp Elementos reguladores distais de bcl11a como alvo para a reindução de hemoglobina fetal
PT2929031T (pt) 2012-12-05 2018-01-19 Alnylam Pharmaceuticals Inc Composições de irna de pcsk9 e métodos de seu uso
CN105189541A (zh) * 2012-12-14 2015-12-23 戴瑟纳制药公司 用于通过双链rna特异性抑制ckap5的方法和组合物
US9198674B2 (en) * 2012-12-14 2015-12-01 Warsaw Orthopedic, Inc. Surgical instrument and method
CN105358695B (zh) 2013-01-01 2019-07-12 A.B.种子有限公司 将dsRNA引入植物种子以调节基因表达的方法
US10683505B2 (en) 2013-01-01 2020-06-16 Monsanto Technology Llc Methods of introducing dsRNA to plant seeds for modulating gene expression
WO2014110291A1 (en) 2013-01-09 2014-07-17 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of smn2 splicing in a subject
US9593332B2 (en) * 2013-01-15 2017-03-14 Tufts Medical Center Methods and compositions for targeting immunoglobulins
KR101409445B1 (ko) * 2013-01-17 2014-06-24 한국과학기술연구원 ＯＴＵＢ１ 발현을 저해하는 ｓｉＲＮＡ 및 이를 포함하는 약제학적 조성물
KR101480523B1 (ko) * 2013-02-07 2015-01-08 고려대학교 산학협력단 세포 내 rpS3 발현 억제를 위한 siRNA
KR20200123263A (ko) 2013-02-14 2020-10-28 아이오니스 파마수티컬즈, 인코포레이티드 지질단백질 리파제 결핍 (lpld) 모집단에서 아포지질단백질 c-iii (apociii) 발현의 조절
DE102013003869B4 (de) * 2013-02-27 2016-11-24 Friedrich-Schiller-Universität Jena Verfahren zur gezielten Abtötung von Zellen durch zur mRNA-Anbindung ausgerichtete Nukleotid-Moleküle sowie Nukleotid-Moleküle und Applikationskit für solche Verwendung
SG10201706960TA (en) 2013-02-28 2017-10-30 Arrowhead Res Corp Organic compositions to treat epas1-related diseases
US9717601B2 (en) 2013-02-28 2017-08-01 DePuy Synthes Products, Inc. Expandable intervertebral implant, system, kit and method
US9522070B2 (en) 2013-03-07 2016-12-20 Interventional Spine, Inc. Intervertebral implant
US9277928B2 (en) 2013-03-11 2016-03-08 Interventional Spine, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
US9265789B2 (en) * 2013-03-12 2016-02-23 The Medical College Of Wisconsin, Inc. Targeting CLPTM1L by RNA interference for treatment and prevention of cancer
EP2971185A4 (de) 2013-03-13 2017-03-08 Monsanto Technology LLC Verfahren und zusammensetzungen zur unkrautbekämpfung
EP2971183A4 (de) 2013-03-13 2016-10-26 Meso Scale Technologies Llc Verbesserte testverfahren
UA121846C2 (uk) 2013-03-13 2020-08-10 Монсанто Текнолоджи Ллс Спосіб та гербіцидна композиція для контролю видів рослини роду lolium
US20160138027A1 (en) * 2013-03-14 2016-05-19 The Board Of Trustees Of The Leland Stanford Junior University Treatment of diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mtorc1)
AU2014236140B2 (en) 2013-03-14 2019-10-03 Sarepta Therapeutics, Inc. Exon skipping compositions for treating muscular dystrophy
RU2745324C2 (ru) 2013-03-14 2021-03-23 Ионис Фармасьютикалз, Инк. Композиции и способы модулирования экспрессии tau
CN114015692B (zh) 2013-03-14 2024-12-31 阿尔尼拉姆医药品有限公司 补体组分C5 iRNA组合物及其使用方法
US9993353B2 (en) 2013-03-14 2018-06-12 DePuy Synthes Products, Inc. Method and apparatus for minimally invasive insertion of intervertebral implants
US9480574B2 (en) 2013-03-14 2016-11-01 Benvenue Medical, Inc. Spinal fusion implants and devices and methods for deploying such implants
NZ732507A (en) 2013-03-15 2018-08-31 Sarepta Therapeutics Inc Improved compositions for treating muscular dystrophy
WO2014149972A1 (en) 2013-03-15 2014-09-25 The Scripps Research Institute Systems and methods for genomic annotation and distributed variant interpretation
WO2014140856A2 (en) 2013-03-15 2014-09-18 Graham Lord Mir-142 and antagonists thereof for treating disease
WO2014144799A2 (en) 2013-03-15 2014-09-18 New York University siRNA TARGETING HSR1
US9132174B2 (en) 2013-03-15 2015-09-15 Anchored Rsk3 Inhibitors, Llc Treatment of heart disease by inhibition of the action of ribosomal S6 kinase 3 (RSK3)
US9418203B2 (en) 2013-03-15 2016-08-16 Cypher Genomics, Inc. Systems and methods for genomic variant annotation
US11342048B2 (en) 2013-03-15 2022-05-24 The Scripps Research Institute Systems and methods for genomic annotation and distributed variant interpretation
CA2906663A1 (en) * 2013-03-15 2014-09-18 Techulon Inc. Antisense molecules for treatment of staphylococcus aureus infection
US10568328B2 (en) 2013-03-15 2020-02-25 Monsanto Technology Llc Methods and compositions for weed control
JP6346265B2 (ja) 2013-03-21 2018-06-20 ジェニスフィア・エルエルシー Ｄｎａインターカレーティング剤の細胞送達
JP5976922B2 (ja) * 2013-03-21 2016-08-24 学校法人 埼玉医科大学 二本鎖核酸分子、ｄｎａ、ベクター、癌細胞増殖抑制剤、及び医薬
CN103205400B (zh) * 2013-04-19 2014-09-17 青岛大学医学院附属医院 含有人泛素特异性蛋白酶基因USP39-shRNA的重组慢病毒及其应用
US9264644B2 (en) * 2013-04-25 2016-02-16 Forza Silicon Corporation Analog-to-digital conversion for image sensor with non-destructive read pixel
PE20152002A1 (es) 2013-05-01 2016-01-21 Isis Pharmaceuticals Inc Composiciones y metodos para modular la expresion de ttr y vhb
US10294480B2 (en) 2013-05-03 2019-05-21 President And Fellows Of Harvard College Foreign DNA surveillance protein
EP3412774A1 (de) 2013-05-22 2018-12-12 Alnylam Pharmaceuticals, Inc. Serpina1-irna-zusammensetzungen und verfahren zur verwendung davon
TWI727917B (zh) 2013-05-22 2021-05-21 美商阿尼拉製藥公司 ＴＭＰＲＳＳ６ｉＲＮＡ 組成物及其使用方法
WO2014187964A2 (en) * 2013-05-23 2014-11-27 University Of Bremen Novel treatment of metabolic diseases
US9790504B2 (en) * 2013-05-24 2017-10-17 The University Of Chicago Anti-tumor therapy
JP2016524621A (ja) 2013-06-03 2016-08-18 バル−イラン ユニバーシティ ウィスコットアルドリッチ症候群タンパク質を変調するリポソーム
CN113648323A (zh) * 2013-06-05 2021-11-16 再生疗法有限公司 用于哺乳动物物种中诱导性组织再生的组合物和方法
PL3444350T3 (pl) 2013-07-03 2022-03-21 Dicerna Pharmaceuticals, Inc. Sposoby i kompozycje do specyficznego hamowania alfa-1 antytrypsyny przez dwuniciowy rna
US9522028B2 (en) 2013-07-03 2016-12-20 Interventional Spine, Inc. Method and apparatus for sacroiliac joint fixation
US9512430B2 (en) 2013-07-03 2016-12-06 Wisconsin Alumni Research Foundation Compositions and methods to promote erythropoiesis
KR102306656B1 (ko) * 2013-07-03 2021-09-29 삼성전자주식회사 항 c-Met 항체를 이용하는 암의 병용 치료
KR20150006742A (ko) * 2013-07-09 2015-01-19 (주)바이오니아 간암 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 암 예방 또는 치료용 조성물
KR20150006743A (ko) * 2013-07-09 2015-01-19 (주)바이오니아 간암 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 암 예방 또는 치료용 조성물
MX359191B (es) 2013-07-19 2018-09-18 Monsanto Technology Llc Composiciones y métodos para controlar leptinotarsa.
US9850496B2 (en) 2013-07-19 2017-12-26 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
TWI772856B (zh) 2013-07-19 2022-08-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
TW201536329A (zh) 2013-08-09 2015-10-01 Isis Pharmaceuticals Inc 用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
US20150050738A1 (en) * 2013-08-16 2015-02-19 Rana Therapeutics, Inc. Compositions and methods for modulating rna
US10144928B2 (en) 2013-08-23 2018-12-04 Quark Pharmaceuticals, Inc. Double stranded oligonucleotide compounds comprising positional modifications
RU2712559C9 (ru) * 2013-08-28 2020-10-08 Ионис Фармасьютикалз, Инк. Модуляция экспрессии прекалликреина (пкк)
IL282239B2 (en) * 2013-09-05 2023-10-01 Sarepta Therapeutics Inc Antisense-induced exon2 inclusion in acid alpha-glucosidase
US10385114B2 (en) * 2013-09-05 2019-08-20 Inis Biotech Llc SPARC (secreted protein, acidic and rich in cysteine), a new target for the treatment and prevention of acute liver failure
CA3221709A1 (en) 2013-09-09 2015-03-12 Somalogic Operating Co., Inc. Pdgf and vegf aptamers having improved stability and their use in treating pdgf and vegf mediated diseases and disorders
CN112359042A (zh) * 2013-09-13 2021-02-12 Ionis制药公司 补体因子b的调节剂
EP2853596A1 (de) * 2013-09-30 2015-04-01 IKBT (Institut für Klinische Biomedizinische Forschung Thurgau) Proteinphosphatasehemmer
EP3052117B1 (de) * 2013-10-02 2020-04-22 Albert Einstein College of Medicine Verfahren und zusammensetzungen zur hemmung von metastasen, zur behandlung von fibrose und zur wundheilungsförderung
TWI669393B (zh) * 2013-10-02 2019-08-21 艾爾妮蘭製藥公司 抑制ｌｅｃｔ２基因表現之組合物及方法
BR122020001264B1 (pt) 2013-10-04 2022-11-22 Icahn School Of Medicine At Mount Sinai Ácido ribonucleico de fita dupla (dsrna) para inibição da expressão de alas1, composição farmacêutica para inibição da expressão de um gene alas1, métodos de inibição da expressão de alas1 em uma célula e para diminuir um nível de uma porfirina ou de um precursor de porfirina em uma célula, usos de um dsrna, método para avaliar o nível de mrna de alas1 extracelular em circulação em um indivíduo, composição e uso da mesma
MX2016004651A (es) 2013-10-11 2016-08-05 Ionis Pharmaceuticals Inc Composiciones para modular la expresion de c9orf72.
US11162096B2 (en) 2013-10-14 2021-11-02 Ionis Pharmaceuticals, Inc Methods for modulating expression of C9ORF72 antisense transcript
EP2865757A1 (de) * 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA und deren Verwendung in Verfahren und Zusammensetzungen zur Hemmung der Expression des PDK1-Gens
EP2865758A1 (de) * 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA und deren Verwendung in Verfahren und Zusammensetzungen zur Hemmung der Expression des ORAI1-Gens
UY35817A (es) 2013-11-04 2015-05-29 Us Agriculture ?composiciones y métodos para controlar infestaciones de plagas y parásitos de los artrópodos?.
EP3068407A1 (de) * 2013-11-11 2016-09-21 Sirna Therapeutics, Inc. Systemische verabreichung von myostatin und kurzen interferierenden nukleinsäuren, konjugiert an eine lipophile gruppe
KR102507624B1 (ko) 2013-11-22 2023-03-09 미나 테라퓨틱스 리미티드 Ｃ/ｅｂｐ 알파 짧은 활성화 ｒｎａ 조성물 및 사용 방법
CN106061488B (zh) 2013-12-02 2021-04-09 菲奥医药公司 癌症的免疫治疗
AU2014360314B2 (en) 2013-12-06 2018-04-26 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA
UA119253C2 (uk) 2013-12-10 2019-05-27 Біолоджикс, Інк. Спосіб боротьби із вірусом у кліща varroa та у бджіл
IL314045A (en) * 2013-12-12 2024-09-01 Alnylam Pharmaceuticals Inc Complement component irna compositions and methods of use thereof
CN105814204B (zh) 2013-12-24 2020-04-28 Ionis制药公司 促血管生成素样3表达的调节
RS61892B1 (sr) 2013-12-27 2021-06-30 Dicerna Pharmaceuticals Inc Postupci i kompozicije za specifičnu inhibiciju glikolat oksidaze (hao1) pomoću dvolančane rnk
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
EP3116303B1 (de) 2014-01-15 2020-07-22 Monsanto Technology LLC Verfahren und zusammensetzungen zur bekämpfung von unkraut unter verwendung von epsps-polynukleotiden
ES2917473T3 (es) 2014-01-16 2022-07-08 Wave Life Sciences Ltd Diseño quiral
CN104805085A (zh) * 2014-01-29 2015-07-29 江苏命码生物科技有限公司 串联表达的siRNA及其在治疗慢性淋巴细胞白血病中的应用
KR102592370B1 (ko) 2014-02-11 2023-10-25 알닐람 파마슈티칼스 인코포레이티드 케토헥소키나제(ＫＨＫ) ｉＲＮＡ 조성물 및 그의 사용 방법
US11078462B2 (en) 2014-02-18 2021-08-03 ReCyte Therapeutics, Inc. Perivascular stromal cells from primate pluripotent stem cells
KR101425140B1 (ko) * 2014-02-19 2014-08-13 한국과학기술원 Lin28a 메틸화 억제제를 포함하는 줄기세포 전능화 조절용 조성물 및 lin28a 메틸화 억제제의 스크리닝 방법
EP3107577B1 (de) 2014-02-21 2024-03-20 IBC Pharmaceuticals, Inc. Krankheitstherapie durch induktion einer immunantwort gegen trop-2-exprimierende zellen
CN106029098A (zh) 2014-02-25 2016-10-12 免疫医疗公司 人源化rfb4抗cd22抗体
US10011837B2 (en) 2014-03-04 2018-07-03 Sylentis Sau SiRNAs and their use in methods and compositions for the treatment and/or prevention of eye conditions
CN104894223B (zh) * 2014-03-07 2019-03-26 上海吉凯基因化学技术有限公司 人copb2基因的用途及其相关药物
JPWO2015137459A1 (ja) * 2014-03-13 2017-04-06 協和発酵キリン株式会社 Ｉｒｆ５の発現を抑制する核酸
AU2015231294B2 (en) 2014-03-18 2020-10-29 University Of Massachusetts rAAV-based compositions and methods for treating amyotrophic lateral sclerosis
US10006027B2 (en) 2014-03-19 2018-06-26 Ionis Pharmaceuticals, Inc. Methods for modulating Ataxin 2 expression
EP3119888B1 (de) 2014-03-19 2021-07-28 Ionis Pharmaceuticals, Inc. Zusammensetzungen zur modulierung der ataxin-2-expression
ES2727078T3 (es) * 2014-03-20 2019-10-14 Oommen Varghese Moléculas de ácido ribonucleico pequeño de interferencia mejoradas
EP3420809A1 (de) 2014-04-01 2019-01-02 Monsanto Technology LLC Zusammensetzungen und verfahren zur bekämpfung von insektenbefall
SI3757214T1 (sl) 2014-04-01 2022-08-31 Biogen Ma Inc. Sestave za moduliranje izražanja SOD-1
JP6426268B2 (ja) * 2014-04-04 2018-11-21 バイオニア コーポレーションＢｉｏｎｅｅｒ Ｃｏｒｐｏｒａｔｉｏｎ 新規の二重らせんオリゴｒｎａおよびこれを含む線維症または呼吸器疾患の予防または治療用薬学組成物
MA39835A (fr) 2014-04-17 2017-02-22 Biogen Ma Inc Compositions et procédés de modulation de l'épissage du smn2 chez un patient
CN106794260B (zh) 2014-04-25 2021-02-23 儿童医疗中心有限公司 治疗血红蛋白病的组合物和方法
CA2947270A1 (en) 2014-04-28 2015-11-05 Rxi Pharmaceuticals Corporation Methods for treating cancer using nucleic acids targeting mdm2 or mycn
RS59182B1 (sr) * 2014-05-01 2019-10-31 Ionis Pharmaceuticals Inc Kompozicije i postupci za modulaciju ekspresije faktora b komplementa
ES2844593T3 (es) 2014-05-01 2021-07-22 Ionis Pharmaceuticals Inc Composiciones y procedimientos para modular la expresión de la angiopoyetina de tipo 3
HUE052709T2 (hu) 2014-05-01 2021-05-28 Ionis Pharmaceuticals Inc Módosított antiszensz oligonukleotidok konjugátumai és azok alkalmazása PKK expressziójának módosítására
ES2812099T3 (es) 2014-05-01 2021-03-16 Ionis Pharmaceuticals Inc Composiciones y métodos para modular la expresión del receptor de la hormona del crecimiento
KR20250011724A (ko) 2014-05-15 2025-01-21 메소 스케일 테크놀러지즈, 엘엘시 개선된 분석 방법
WO2015177743A1 (en) * 2014-05-23 2015-11-26 Università Degli Studi Dell'aquila Small interfering rna (sirna) for the therapy of type 2 (ado2) autosomal dominant osteopetrosis caused by clcn7 (ado2 clcn7-dependent) gene mutation
KR20150137473A (ko) * 2014-05-29 2015-12-09 한국과학기술연구원 USP15의 발현을 저해하는 siRNA 및 이를 포함하는 약제학적 조성물
US20170101639A1 (en) * 2014-06-04 2017-04-13 Kyowa Hakko Kirin Co., Ltd. RNAi PHARMACEUTICAL COMPOSITION FOR SUPPRESSING EXPRESSION OF CKAP5 GENE
US9452242B2 (en) 2014-06-11 2016-09-27 Silver Bullet Therapeutics, Inc. Enhancement of antimicrobial silver, silver coatings, or silver platings
TW201620526A (zh) 2014-06-17 2016-06-16 愛羅海德研究公司 用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
AU2015280252A1 (en) 2014-06-23 2017-01-12 Monsanto Technology Llc Compositions and methods for regulating gene expression via RNA interference
WO2015200539A1 (en) 2014-06-25 2015-12-30 Monsanto Technology Llc Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression
US10240127B2 (en) 2014-07-03 2019-03-26 ReCyte Therapeutics, Inc. Exosomes from clonal progenitor cells
US10314605B2 (en) 2014-07-08 2019-06-11 Benvenue Medical, Inc. Apparatus and methods for disrupting intervertebral disc tissue
WO2016018887A1 (en) 2014-07-29 2016-02-04 Monsanto Technology Llc Compositions and methods for controlling insect pests
US9980737B2 (en) 2014-08-04 2018-05-29 Medos International Sarl Flexible transport auger
WO2016022536A2 (en) * 2014-08-04 2016-02-11 MiRagen Therapeutics, Inc. Inhibitors of myh7b and uses thereof
US20170137820A1 (en) * 2014-08-06 2017-05-18 Bavarian Nordic A/S Agonists and antagonists of toll-like receptor (tlr) 13
GB2547586A (en) * 2014-08-20 2017-08-23 Lifesplice Pharma Llc Splice modulating oligonucleotides and methods of use thereof(In the PCT request)
LT3185957T (lt) 2014-08-29 2022-09-26 Alnylam Pharmaceuticals, Inc. Patisiranas, skirtas naudoti transtiretino amiloidozei gydyti
EP3185910A4 (de) * 2014-08-29 2018-01-10 Children's Medical Center Corporation Verfahren und zusammensetzungen zur krebsbehandlung
WO2016034611A1 (en) * 2014-09-02 2016-03-10 Max-Delbrück-Centrum für Molekulare Medizin Antisense oligonucleotides targeting 3'utr region of a20
KR102506169B1 (ko) 2014-09-05 2023-03-08 피오 파마슈티칼스 코프. Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
WO2016040167A1 (en) * 2014-09-08 2016-03-17 Brandon Higgs Compositions and methods for detecting and treating small cell lung cancer
US9924979B2 (en) 2014-09-09 2018-03-27 Medos International Sarl Proximal-end securement of a minimally invasive working channel
US10111712B2 (en) 2014-09-09 2018-10-30 Medos International Sarl Proximal-end securement of a minimally invasive working channel
US10264959B2 (en) 2014-09-09 2019-04-23 Medos International Sarl Proximal-end securement of a minimally invasive working channel
US10436802B2 (en) 2014-09-12 2019-10-08 Biogen Ma Inc. Methods for treating spinal muscular atrophy
WO2016040589A1 (en) 2014-09-12 2016-03-17 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting complement component c5 and methods of use thereof
KR20170058979A (ko) * 2014-09-18 2017-05-29 더 유니버시티 오브 브리티쉬 콜롬비아 헌팅턴병 일배체형에 대한 대립 유전자-특이적 치료
US9777279B2 (en) * 2014-09-24 2017-10-03 University Of Cincinnati Methods and compositions for treating autoimmune disorders by targeting Kv1.3 ion channels with functionalized lipid-derived nanovesicles
TWI755351B (zh) 2014-10-10 2022-02-21 美商艾爾妮蘭製藥公司 用於抑制ｈａｏ１（羥酸氧化酶１（乙醇酸鹽氧化酶））基因表現的組合物及方法
EP3207138B1 (de) * 2014-10-17 2020-07-15 Alnylam Pharmaceuticals, Inc. Gegen aminolävulinsäuresynthase-1 (alas1) gerichtete polynukleotidmittel und verwendungen davon
KR101646609B1 (ko) * 2014-10-24 2016-08-08 한국원자력의학원 후두암 또는 후두암의 방사선 저항성의 진단을 위한 조성물 및 진단 방법
WO2016069694A2 (en) 2014-10-30 2016-05-06 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
WO2016070060A1 (en) 2014-10-30 2016-05-06 The General Hospital Corporation Methods for modulating atrx-dependent gene repression
US10302644B2 (en) * 2014-11-04 2019-05-28 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating multiple myeloma
JOP20200092A1 (ar) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
WO2016077566A1 (en) * 2014-11-12 2016-05-19 Research Institute At Nationwide Children's Hospital Modulation of alternative mdm2 splicing
US10287584B2 (en) * 2014-11-12 2019-05-14 Ionis Pharmaceuticals, Inc. Compounds and methods for the modulation of COMP
WO2016077704A1 (en) 2014-11-14 2016-05-19 The Regents Of The University Of California Modulation of agpat5 expression
RU2020108189A (ru) 2014-11-14 2020-03-11 Вояджер Терапьютикс, Инк. Композиции и способы лечения бокового амиотрофического склероза (als)
CN107250362B (zh) 2014-11-17 2021-10-22 阿尔尼拉姆医药品有限公司 载脂蛋白C3(APOC3)iRNA组合物及其使用方法
WO2016085852A1 (en) 2014-11-24 2016-06-02 Alnylam Pharmaceuticals, Inc. Tmprss6 irna compositions and methods of use thereof
US10400243B2 (en) 2014-11-25 2019-09-03 Ionis Pharmaceuticals, Inc. Modulation of UBE3A-ATS expression
CN104450710B (zh) * 2014-11-28 2018-06-05 广州市锐博生物科技有限公司 抑制myd88基因的寡聚核酸及其应用
US9714424B1 (en) * 2014-12-16 2017-07-25 Icahn School Of Medicine At Mount Sinai RNAi inhibition of USP10 to treat ocular disorders
CA2969105A1 (en) 2014-12-23 2016-06-30 Syngenta Participations Ag Biological control of coleopteran pests
US10774326B2 (en) * 2014-12-24 2020-09-15 Massachusetts Institute Of Technology Compositions and methods for manipulation of adipocyte energy consumption regulatory pathway
DK3237619T3 (da) * 2014-12-25 2020-11-09 Guangzhou Ribobio Co Ltd Sammensætninger og fremgangsmåder til at inhibere ekspression af adamts-5 og adam17
US11045488B2 (en) 2014-12-26 2021-06-29 Nitto Denko Corporation RNA interference agents for GST-π gene modulation
US10792299B2 (en) 2014-12-26 2020-10-06 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
US10264976B2 (en) 2014-12-26 2019-04-23 The University Of Akron Biocompatible flavonoid compounds for organelle and cell imaging
US20180002702A1 (en) 2014-12-26 2018-01-04 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
US10793855B2 (en) * 2015-01-06 2020-10-06 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of C9ORF72 antisense transcript
US9982070B2 (en) 2015-01-12 2018-05-29 Carnegie Mellon University Aqueous ATRP in the presence of an activator regenerator
WO2016115490A1 (en) 2015-01-16 2016-07-21 Ionis Pharmaceuticals, Inc. Compounds and methods for modulation of dux4
US9434947B2 (en) 2015-01-20 2016-09-06 Oregon Health & Science University Modulation of KCNH2 isoform expression by oligonucleotides as a therapeutic approach for long QT syndrome
PL3256589T3 (pl) 2015-01-22 2022-02-21 Monsanto Technology Llc Kompozycje i sposoby kontrolowania leptinotarsa
US10022243B2 (en) 2015-02-06 2018-07-17 Benvenue Medical, Inc. Graft material injector system and method
EP3256591A4 (de) 2015-02-13 2018-08-08 Translate Bio Ma, Inc. Hybride oligonukleotide und verwendungen davon
JP2018510621A (ja) * 2015-02-13 2018-04-19 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． パタチン様ホスホリパーゼドメイン含有３（ＰＮＰＬＡ３）ｉＲＮＡ組成物およびその使用方法
US10036017B2 (en) 2015-02-17 2018-07-31 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of complement component 5(C5) by double-stranded RNA
US9840709B2 (en) * 2015-02-20 2017-12-12 Rosalind Franklin University Of Medicine And Science Antisense compounds targeting genes associated with cystic fibrosis
US10525076B2 (en) * 2015-02-20 2020-01-07 Rosalind Franklin University Of Medicine And Science Antisense compounds targeting genes associated with cystic fibrosis
WO2016137937A1 (en) * 2015-02-24 2016-09-01 Dcb-Usa Llc Short interfering rna for treating cancer
ES2848377T3 (es) 2015-02-26 2021-08-09 Ionis Pharmaceuticals Inc Moduladores específicos de alelo de RODOPSINA P23H
US11129844B2 (en) 2015-03-03 2021-09-28 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating MECP2 expression
US11426290B2 (en) 2015-03-06 2022-08-30 DePuy Synthes Products, Inc. Expandable intervertebral implant, system, kit and method
EP3271460A4 (de) 2015-03-17 2019-03-13 The General Hospital Corporation Rna-interaktom des polycomb-repressiven komplexes 1 (prc1)
BR112017018029B1 (pt) 2015-03-20 2021-06-15 Unilever Ip Holdings B.V. Molécula de sirna, método para a redução da perspiração, composição antiperspirante e uso de uma composição antiperspirante
EP3072969A1 (de) * 2015-03-23 2016-09-28 DKFZ Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Oligonukleotidsequenzen mit abzielung auf den transkriptionsfaktor tsc22d4 zur behandlung von insulinresistenz
CA2981068C (en) 2015-03-26 2021-12-14 Women & Infants Hospital Of Rhode Island Therapy for malignant disease comprising the inhibition of human epididymal secretory protein e4 and immune checkpoint inhibitors
US10786264B2 (en) 2015-03-31 2020-09-29 Medos International Sarl Percutaneous disc clearing device
WO2016159789A1 (en) * 2015-04-01 2016-10-06 Institute Of Environmental Science And Research Limited Methods and materials for detecting rna sequences
WO2016161429A1 (en) 2015-04-03 2016-10-06 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating tmprss6 expression
CN107980062B (zh) * 2015-04-03 2022-11-25 马萨诸塞大学 用于靶向亨廷汀mRNA的寡核苷酸化合物
DK3277815T3 (da) 2015-04-03 2021-12-13 Univ Massachusetts Oligonukleotidforbindelser til behandling af præeklampsi og andre angiogene lidelser
WO2016161388A1 (en) 2015-04-03 2016-10-06 University Of Massachusetts Fully stabilized asymmetric sirna
WO2016164746A1 (en) 2015-04-08 2016-10-13 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the lect2 gene
KR20250005546A (ko) 2015-04-13 2025-01-09 알닐람 파마슈티칼스 인코포레이티드 안지오포이에틴-유사 3(angptl3) irna 조성물 및 이의 이용 방법
EP3722424A1 (de) 2015-04-16 2020-10-14 Ionis Pharmaceuticals, Inc. Zusammensetzungen zur modulierung der c9orf72 -expression
WO2016168578A1 (en) * 2015-04-17 2016-10-20 Genisphere, Llc siRNA INHIBITION OF HUMAN ANTIGEN R EXPRESSION FOR TREATMENT OF CANCER
JP2018512876A (ja) * 2015-04-22 2018-05-24 ミナ セラピューティクス リミテッド ｓａＲＮＡ組成物および使用方法
JP7288302B2 (ja) 2015-05-08 2023-06-07 ザ チルドレンズ メディカル センター コーポレーション 胎児型ヘモグロビン再誘導のための、ｂｃｌ１１ａエンハンサー機能性領域を標的とする方法
MX2017015239A (es) 2015-05-29 2018-02-19 Juno Therapeutics Inc Composicion y metodos para regular interacciones inhibitorias en celulas geneticamente modificadas.
EP3302053B1 (de) 2015-06-02 2021-03-17 Monsanto Technology LLC Zusammensetzungen und verfahren zur abgabe eines polynukleotids in eine pflanze
EP3302030A4 (de) 2015-06-03 2019-04-24 Monsanto Technology LLC Verfahren und zusammensetzungen zum einführen von nukleinsäuren in pflanzen
CA2989400A1 (en) 2015-06-15 2016-12-22 Angiochem Inc. Ang1005 for the treatment of leptomeningeal carcinomatosis
WO2016209862A1 (en) * 2015-06-23 2016-12-29 Alnylam Pharmaceuticals, Inc. Glucokinase (gck) irna compositions and methods of use thereof
WO2016210098A1 (en) * 2015-06-24 2016-12-29 Board Of Regents, The University Of Texas System Dual assembly nanoparticles
US9833338B2 (en) * 2015-06-30 2017-12-05 Expanding Orthopedics Inc. Tool for intervertebral cage
EP3112466A1 (de) * 2015-07-01 2017-01-04 Samsung Electronics Co., Ltd. Zusammensetzung zur verringerung des zellseneszenzwerts einschliesslich aktivitätsinhibitor mit hemmung der dcun1d3-aktivität oder expressionsinhibitor mit hemmung des dcun1d3-decodierungsgens und verwendung davon
US9913727B2 (en) 2015-07-02 2018-03-13 Medos International Sarl Expandable implant
US10808247B2 (en) 2015-07-06 2020-10-20 Phio Pharmaceuticals Corp. Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
KR20180026739A (ko) 2015-07-06 2018-03-13 알엑스아이 파마슈티칼스 코포레이션 슈퍼옥시드 디스뮤타제 1 (sod1)을 표적화하는 핵산 분자
WO2017011286A1 (en) * 2015-07-10 2017-01-19 Alnylam Pharmaceuticals, Inc. Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
MY192997A (en) 2015-07-10 2022-09-20 Ionis Pharmaceuticals Inc Modulators of diacyglycerol acyltransferase 2 (dgat2)
EP3323892A4 (de) * 2015-07-13 2019-07-17 Kyowa Hakko Kirin Co., Ltd. Antisense-oligonukleotid-inhibition der 2gpi-expression
US20170051282A1 (en) * 2015-07-23 2017-02-23 Cold Spring Harbor Laboratory Extracellular vesicle methods and compositions
US20180216114A1 (en) * 2015-07-27 2018-08-02 Alnylam Pharmaceuticals, Inc. Xanthine dehydrogenase (xdh) irna compositions and methods of use thereof
WO2017016963A1 (en) * 2015-07-30 2017-02-02 Bayer Cropscience Aktiengesellschaft Methods and compositions for the control of rust fungi by inhibiting expression of the hxt1 gene
PL3329002T3 (pl) 2015-07-31 2021-04-19 Alnylam Pharmaceuticals, Inc. Kompozycje irna transtyretyny (ttr) i sposoby ich zastosowania do leczenia lub zapobiegania chorobom związanym z ttr
CN105063048A (zh) * 2015-08-13 2015-11-18 吉林大学 一种抑制Survivin基因表达的siRNA及其应用
EP3334499A4 (de) 2015-08-14 2019-04-17 University of Massachusetts Bioaktive konjugaten zur freisetzung von oligonukleotiden
WO2017027910A1 (en) * 2015-08-14 2017-02-23 The University Of Sydney Connexin 45 inhibition for therapy
CN106467914A (zh) * 2015-08-18 2017-03-01 华东理工大学 靶向人TSPAN8基因的siRNA及其应用
WO2017029391A1 (en) * 2015-08-20 2017-02-23 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating cancer
IL293355B2 (en) 2015-08-25 2024-07-01 Alnylam Pharmaceuticals Inc Methods and compositions for treating a proprotein convertase subtilisin kexin (pcsk9) gene-associated disorder
SG10202007937SA (en) 2015-09-02 2020-09-29 Alnylam Pharmaceuticals Inc PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
US12150636B2 (en) 2015-09-04 2024-11-26 Medos International Sárl Surgical instrument connectors and related methods
US11672562B2 (en) 2015-09-04 2023-06-13 Medos International Sarl Multi-shield spinal access system
US11439380B2 (en) 2015-09-04 2022-09-13 Medos International Sarl Surgical instrument connectors and related methods
US11744447B2 (en) 2015-09-04 2023-09-05 Medos International Surgical visualization systems and related methods
CN113143355A (zh) 2015-09-04 2021-07-23 美多斯国际有限公司 多护罩脊柱进入系统
US10987129B2 (en) 2015-09-04 2021-04-27 Medos International Sarl Multi-shield spinal access system
WO2017042239A1 (en) * 2015-09-08 2017-03-16 Sylentis Sau siRNA and their use in methods and compositions for inhibiting the expression of the CHI3L1 gene
CA2997648A1 (en) * 2015-09-08 2017-03-16 Sylentis Sau Sirna and their use in methods and compositions for inhibiting the expression of the nrarp gene
GB201516685D0 (en) * 2015-09-21 2015-11-04 Varghese Oommen P And Oommen Oommen P Nucleic acid molecules with enhanced activity
US10584315B2 (en) 2015-09-24 2020-03-10 Wisconsin Alumni Research Foundation Methods of expanding hematopoietic stem cells, compositions, and methods of use thereof
US10533175B2 (en) 2015-09-25 2020-01-14 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating Ataxin 3 expression
CN106554962B (zh) * 2015-09-30 2021-06-04 中国科学院上海药物研究所 过表达gpr160的癌症的预防、诊断和治疗
WO2017062422A1 (en) 2015-10-07 2017-04-13 The Research Foundation For The State University Of New York METHODS FOR INCREASING PLATELET COUNT BY INHIBITING BILIVERDIN IXβ REDUCTASE
JP2018530325A (ja) 2015-10-08 2018-10-18 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． アンジオテンシノーゲンの発現を調節するための化合物及び方法
JP2018531046A (ja) * 2015-10-14 2018-10-25 アクイナ ファーマシューティカルズ， インコーポレイテッド 核酸ベースのｔｉａ−１阻害剤
WO2017066697A1 (en) * 2015-10-14 2017-04-20 Dou Qingping Treatments and diagnostics for cancers
SG11201802718PA (en) 2015-10-14 2018-05-30 Bio Path Holdings Inc P-ethoxy nucleic acids for liposomal formulation
WO2017065369A1 (ko) * 2015-10-15 2017-04-20 한국과학기술원 Rna 올리고뉴클레오티드 및 이를 포함하는 면역 활성제
KR101842679B1 (ko) * 2015-10-15 2018-03-28 한국과학기술원 Rna 올리고뉴클레오티드 및 이를 포함하는 면역 활성제
US11021707B2 (en) 2015-10-19 2021-06-01 Phio Pharmaceuticals Corp. Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
WO2017068791A1 (ja) * 2015-10-23 2017-04-27 レナセラピューティクス株式会社 少なくとも１つのバルジ構造を有する核酸複合体
US12318489B2 (en) 2015-10-26 2025-06-03 Translate Bio Ma, Inc. Nanoparticle formulations for delivery of nucleic acid complexes
WO2017079291A1 (en) 2015-11-02 2017-05-11 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating c90rf72
WO2017079227A1 (en) 2015-11-05 2017-05-11 University Of Connecticut Compositions and methods for the treatment of liver fibrosis
KR20250078597A (ko) 2015-11-06 2025-06-02 아이오니스 파마수티컬즈, 인코포레이티드 아포리포프로테인 (a) 발현 조정
EP3373939A4 (de) 2015-11-10 2019-06-26 B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University Mittel und verfahren zur verringerung der tumorigenität von krebsstammzellen
CN108699556B (zh) 2015-11-16 2023-02-17 奥利克斯医药有限公司 使用靶向myd88或tlr3的rna复合物治疗老年性黄斑变性
WO2017086467A1 (ja) * 2015-11-19 2017-05-26 公立大学法人名古屋市立大学 抗腫瘍性ドラッグデリバリー製剤
WO2017086436A1 (ja) * 2015-11-20 2017-05-26 国立大学法人九州大学 免疫制御剤
ES2893294T3 (es) 2015-11-30 2022-02-08 Univ British Columbia Inhibidores de oligonucleótidos antisentido (ASO) del transportador de monocarboxilato4 (MCT4) para su uso como agentes terapéuticos en el tratamiento de cáncer
WO2017096395A1 (en) 2015-12-04 2017-06-08 Ionis Pharmaceuticals, Inc. Methods of treating breast cancer
EP3387112A4 (de) 2015-12-07 2019-08-21 BioTime, Inc. Verfahren zur erneuten gewinnung von brauen fettzellen, die aus verschiedenen pluripotenten stammzellen gewonnen werden
KR20210157474A (ko) 2015-12-07 2021-12-28 젠자임 코포레이션 Serpinc1-연관 장애의 치료를 위한 방법 및 조성물
WO2017100542A1 (en) * 2015-12-10 2017-06-15 Alnylam Pharmaceuticals, Inc. Sterol regulatory element binding protein (srebp) chaperone (scap) irna compositions and methods of use thereof
WO2017100193A1 (en) 2015-12-10 2017-06-15 Fibrogen, Inc. Methods for treatment of motor neuron diseases
CN108367022A (zh) 2015-12-13 2018-08-03 日东电工株式会社 具有高活性和降低脱靶的sirna结构
EP3181698A1 (de) 2015-12-16 2017-06-21 European Molecular Biology Laboratory (EMBL) Microrna mir-142 als stammzellenmarker
WO2017117496A1 (en) 2015-12-31 2017-07-06 Ionis Pharmaceuticals, Inc. Methods for reducing ataxin-2 expression
AU2017205462A1 (en) 2016-01-05 2018-06-07 Ionis Pharmaceuticals, Inc. Methods for reducing LRRK2 expression
US10478503B2 (en) 2016-01-31 2019-11-19 University Of Massachusetts Branched oligonucleotides
CN108779464B (zh) 2016-02-02 2022-05-17 奥利克斯医药有限公司 使用靶向angpt2和pdgfb的rna复合物治疗血管生成相关性疾病
CA3022874A1 (en) * 2016-02-02 2017-08-10 Olix Pharmaceuticals, Inc. Treatment of atopic dermatitis and asthma using rna complexes that target il4ra, trpa1, or f2rl1
US10299838B2 (en) 2016-02-05 2019-05-28 Medos International Sarl Method and instruments for interbody fusion and posterior fixation through a single incision
US10519442B2 (en) * 2016-02-11 2019-12-31 City Of Hope Twist signaling inhibitor compositions and methods of using the same
KR20180114008A (ko) * 2016-02-19 2018-10-17 더 리전츠 오브 더 유니버시티 오브 캘리포니아 짧은 헤어핀 rna(shrna734) 및 유전자 변형된 세포를 양성으로 선택하고 제거하기 위한 이의 용도
IL260983B (en) 2016-02-19 2022-07-01 Genisphere Llc Nucleic acid carriers and methods of medical use
CA3013797A1 (en) 2016-03-09 2017-09-14 Ionis Pharmaceuticals, Inc. Methods and compositions for inhibiting pmp22 expression
US10961271B2 (en) 2016-03-16 2021-03-30 Ionis Pharmaceuticals, Inc. Methods of modulating KEAP1
WO2017161168A1 (en) 2016-03-16 2017-09-21 Ionis Pharmaceuticals, Inc. Modulation of dyrk1b expression
CN105925576B (zh) * 2016-03-24 2018-04-20 嘉兴市第一医院 针对哺乳动物R‑Spondin3基因靶点的小干扰RNA、短发卡RNA及载体和应用
WO2017173300A1 (en) * 2016-04-01 2017-10-05 Avidity Biosciences Llc Androgen receptor nucleic acids and uses thereof
ES2640524B1 (es) * 2016-04-01 2018-09-24 Universidad Autónoma de Madrid Uso de tcfl5/cha como nuevo marcador para el pronóstico y/o diagnóstico diferencial de leucemias linfoblásticas agudas
KR102775461B1 (ko) 2016-04-01 2025-02-28 어비디티 바이오사이언시스 인크. 핵산-폴리펩타이드 조성물 및 이의 용도
CN109072238B (zh) 2016-04-11 2022-05-24 奥利克斯医药有限公司 使用靶向结缔组织生长因子的rna复合物治疗特发性肺纤维化
RU2755544C2 (ru) * 2016-04-14 2021-09-17 Бенитек Биофарма Лимитед Реагенты для лечения окулофарингеальной мышечной дистрофии (OPMD) и их применение
WO2017184529A1 (en) 2016-04-18 2017-10-26 Sarepta Therapeutics, Inc. Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
CN107345230A (zh) 2016-05-05 2017-11-14 江苏命码生物科技有限公司 一种抑制K-RAS基因表达的siRNA及其前体和应用
CN105969771A (zh) * 2016-05-30 2016-09-28 东北师范大学 靶向沉默FOXG1的shRNA
US20230348911A1 (en) * 2016-06-08 2023-11-02 Aalborg Universitet Antisense oligonucleotides for modulation of long noncoding rnas
PT109454A (pt) * 2016-06-14 2017-12-14 Phyzat Biopharmaceuticals Lda Ácidos nucleicos de interferência e composições que os compreendem
US11198867B2 (en) 2016-06-16 2021-12-14 Ionis Pharmaceuticals, Inc. Combinations for the modulation of SMN expression
EP3472346B1 (de) 2016-06-17 2023-01-18 F. Hoffmann-La Roche AG Papd5- und papd7-inhibitoren zur behandlung einer hepatitis-b-infektion
CA3023514A1 (en) 2016-06-17 2017-12-21 Ionis Pharmaceuticals, Inc. Modulation of gys1 expression
US11510788B2 (en) 2016-06-28 2022-11-29 Eit Emerging Implant Technologies Gmbh Expandable, angularly adjustable intervertebral cages
JP7023877B2 (ja) 2016-06-28 2022-02-22 イーアイティー・エマージング・インプラント・テクノロジーズ・ゲーエムベーハー 拡張可能かつ角度調節可能な関節運動式の椎間ケージ
KR101916652B1 (ko) 2016-06-29 2018-11-08 올릭스 주식회사 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도
CN107557363B (zh) * 2016-06-30 2021-03-12 中国科学院分子细胞科学卓越创新中心 可诱导型siRNA表达载体及其制备和应用
WO2018009547A1 (en) * 2016-07-05 2018-01-11 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Diagnosing col6-related disorders and methods for treating same
WO2018013801A1 (en) * 2016-07-13 2018-01-18 Indiana University Research And Technology Corporation Rnai insecticide materials and methods
AR109207A1 (es) * 2016-08-05 2018-11-07 Syngenta Participations Ag Control de plagas de coleópteros utilizando moléculas de arn
WO2018031933A2 (en) 2016-08-12 2018-02-15 University Of Massachusetts Conjugated oligonucleotides
UY37376A (es) * 2016-08-26 2018-03-23 Amgen Inc Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso
EP3512527A4 (de) * 2016-09-15 2020-05-20 The Brigham and Women's Hospital, Inc. Modulation von pcsk9 und ldlr durch drp1-hemmung
SG10202008771WA (en) 2016-09-16 2020-10-29 Bio Path Holdings Inc Combination therapy with liposomal antisense oligonucleotides
US10933081B2 (en) 2016-09-21 2021-03-02 Alnylam Pharmaceuticals, Inc. Myostatin iRNA compositions and methods of use thereof
JOP20190065A1 (ar) 2016-09-29 2019-03-28 Ionis Pharmaceuticals Inc مركبات وطرق لتقليل التعبير عن tau
KR20190065341A (ko) 2016-10-06 2019-06-11 아이오니스 파마수티컬즈, 인코포레이티드 올리고머 화합물들의 접합 방법
WO2018071873A2 (en) 2016-10-13 2018-04-19 Juno Therapeutics, Inc. Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
US10806715B2 (en) * 2016-10-25 2020-10-20 Council Of Scientific & Industrial Research Gold nanoparticle based formulation for use in cancer therapy
US10537436B2 (en) 2016-11-01 2020-01-21 DePuy Synthes Products, Inc. Curved expandable cage
JOP20190104A1 (ar) 2016-11-10 2019-05-07 Ionis Pharmaceuticals Inc مركبات وطرق لتقليل التعبير عن atxn3
US10646540B2 (en) 2016-11-18 2020-05-12 City Of Hope Peptide inhibitors of twist
TW202313978A (zh) 2016-11-23 2023-04-01 美商阿尼拉製藥公司 絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法
CN106421790B (zh) * 2016-11-25 2018-12-25 复旦大学附属金山医院 Cmpk的抑制剂在制备治疗卵巢癌的药物中的应用
WO2018102745A1 (en) 2016-12-02 2018-06-07 Cold Spring Harbor Laboratory Modulation of lnc05 expression
BR112019011207A2 (pt) 2016-12-05 2019-10-08 Juno Therapeutics Inc produção de células modificadas para terapia celular adotiva
US10888433B2 (en) 2016-12-14 2021-01-12 DePuy Synthes Products, Inc. Intervertebral implant inserter and related methods
TW201827596A (zh) * 2016-12-23 2018-08-01 日商協和醱酵麒麟有限公司 抑制補體b因子之表現之核酸
SG10202107429WA (en) 2017-01-06 2021-08-30 Avidity Biosciences Inc Nucleic acid-polypeptide compositions and methods of inducing exon skipping
MX2019008252A (es) 2017-01-10 2019-09-06 Arrowhead Pharmaceuticals Inc Agentes de interferencia de acido ribonucleico (iarn) de alfa-1 antitripsina (aat), composiciones que incluyen agentes de iarn aat y metodos de uso.
US11174325B2 (en) 2017-01-12 2021-11-16 Carnegie Mellon University Surfactant assisted formation of a catalyst complex for emulsion atom transfer radical polymerization processes
WO2018130584A1 (en) * 2017-01-13 2018-07-19 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides for modulating nfkb2 expression
WO2018146557A2 (en) 2017-02-10 2018-08-16 Dong Ki Lee Long double-stranded rna for rna interference
CN106668863B (zh) * 2017-02-21 2019-04-23 南方医科大学 靶向ktn1治疗皮肤鳞状细胞癌的药物
WO2018164186A1 (ja) * 2017-03-09 2018-09-13 協和発酵キリン株式会社 Ｍａｓｐ２の発現を抑制する核酸
US10758286B2 (en) * 2017-03-22 2020-09-01 Benvenue Medical, Inc. Minimal impact access system to disc space
US11261441B2 (en) 2017-03-29 2022-03-01 Bluebird Bio, Inc. Vectors and compositions for treating hemoglobinopathies
SI3607068T1 (sl) * 2017-04-05 2023-02-28 Silence Therapeutics Gmbh Z RNA interferenco posredovano inhibiranje TMPRSS6
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
EP3612160A4 (de) 2017-04-19 2021-01-20 Bio-Path Holdings, Inc. P-ethoxy-nukleinsäuren zur bcl2-hemmung
EP3612152A4 (de) 2017-04-19 2021-02-17 Phio Pharmaceuticals Corp. Topische verabreichung von nukleinsäureverbindungen
SG11201909336VA (en) * 2017-04-19 2019-11-28 Bio Path Holdings Inc P-ethoxy nucleic acids for stat3 inhibition
NO344051B1 (en) * 2017-05-04 2019-08-26 Patogen As Novel virus in Fish and Method for detection
CA3061652A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
US10398563B2 (en) 2017-05-08 2019-09-03 Medos International Sarl Expandable cage
EP3622073A4 (de) 2017-05-09 2021-01-06 University of Massachusetts Verfahren zur behandlung von amyotropher lateralsklerose (als)
WO2018218135A1 (en) 2017-05-25 2018-11-29 The Children's Medical Center Corporation Bcl11a guide delivery
KR20200014320A (ko) * 2017-05-31 2020-02-10 쿄와 기린 가부시키가이샤 Apcs의 발현을 억제하는 핵산
KR101940061B1 (ko) * 2017-06-02 2019-01-21 김준 리보솜 단백질 S3에 대한 siRNA를 포함하는 암 세포 전이 억제용 약학 조성물
CN107177594B (zh) * 2017-06-07 2020-03-03 浙江大学 特异性抑制CA7基因表达的siRNA及其重组载体和应用
US11344424B2 (en) 2017-06-14 2022-05-31 Medos International Sarl Expandable intervertebral implant and related methods
FR3067933B1 (fr) * 2017-06-21 2020-07-17 L'oreal Modulateurs de l’opsine 3 dans la modulation de la pigmentation de la peau
CN110799647A (zh) 2017-06-23 2020-02-14 马萨诸塞大学 双尾自递送sirna及相关的方法
CA3068312A1 (en) * 2017-06-30 2019-01-03 The Trustees Of Princeton University Genetic variants associated with human-directed hyper-social behavior in domestic dogs
US10940016B2 (en) 2017-07-05 2021-03-09 Medos International Sarl Expandable intervertebral fusion cage
KR20200024793A (ko) 2017-07-06 2020-03-09 애로우헤드 파마슈티컬스 인코포레이티드 알파-ENaC의 발현을 억제하기 위한 RNAi 작용제 및 사용 방법
AU2018297274B2 (en) * 2017-07-06 2023-05-18 Michael S. Kapiloff Treatment of heart disease by inhibition of the action of muscle A-kinase anchoring protein (mAKAP)
AU2018301829B2 (en) 2017-07-13 2024-08-01 Alnylam Pharmaceuticals, Inc. Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase) gene expression
WO2019018383A1 (en) 2017-07-18 2019-01-24 Calimmune, Inc. COMPOSITIONS AND METHODS FOR TREATING BETA-HEMOGLOBINOPATHIES
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
CN111201024A (zh) * 2017-08-07 2020-05-26 菲奥医药公司 经化学修饰的寡核苷酸
CN110020273B (zh) * 2017-08-16 2021-06-29 北京京东尚科信息技术有限公司 用于生成热力图的方法、装置以及系统
EP3668984A4 (de) 2017-08-18 2021-09-08 Ionis Pharmaceuticals, Inc. Modulation des notch-signalweges zur behandlung von atemwegserkrankungen
ES3014709T3 (en) * 2017-09-06 2025-04-24 Baylor College Medicine Park2 nucleic acid and/or park2 polypeptide and salvador shrna for use in the treatment of cardiac conditions
EP3680334B1 (de) 2017-09-07 2026-03-25 Beijing Tide Pharmaceutical Co., Ltd. Gegen ckip-1 gerichtetes doppelsträngiges rna-molekül und seine verwendung
EP4183882A1 (de) 2017-09-08 2023-05-24 MiNA Therapeutics Limited Stabilisierte hnf4a-sarna-zusammensetzungen und verfahren zur verwendung
WO2019051173A1 (en) 2017-09-08 2019-03-14 Ionis Pharmaceuticals, Inc. MODULATORS OF SMAD7 EXPRESSION
JOP20200054A1 (ar) 2017-09-11 2020-03-10 Arrowhead Pharmaceuticals Inc عوامل RNAi وتركيبات لتثبيط تعبير صَميمُ البروتينِ الشَّحْمِيّ C-III (APOC3)
AU2018331383B2 (en) 2017-09-14 2024-12-05 Arrowhead Pharmaceuticals, Inc. RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use
BR112020005230A2 (pt) 2017-09-19 2020-09-24 Alnylam Pharmaceuticals, Inc. composições e métodos para o tratamento da amiloidose mediada por transtiretina (ttr)
JP7397488B2 (ja) 2017-09-22 2023-12-13 ユニバーシティ オブ マサチューセッツ Ｓｏｄ１二重発現ベクターおよびその使用
EP3688160A2 (de) * 2017-09-28 2020-08-05 Secarna Pharmaceuticals GmbH & Co. KG Oligonukleotid mit hemmung der expression von chop
US20200345756A1 (en) * 2017-10-10 2020-11-05 University Of Virginia Patent Foundation Compositions and methods for treating age-related macular degeneration and geographic atrophy
CN111479924B (zh) 2017-10-16 2024-06-14 沃雅戈治疗公司 肌萎缩性侧索硬化症(als)的治疗
TW202424191A (zh) * 2017-10-16 2024-06-16 瑞士商赫孚孟拉羅股份公司 用於降低PAPD5及PAPD7 mRNA以治療B型肝炎感染之核酸分子
MY201698A (en) 2017-10-20 2024-03-13 Dicerna Pharmaceuticals Inc Methods for treating hepatitis b infection
WO2019089884A2 (en) * 2017-11-01 2019-05-09 Editas Medicine, Inc. Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
SG11202002940QA (en) 2017-11-01 2020-04-29 Alnylam Pharmaceuticals Inc Complement component c3 irna compositions and methods of use thereof
US20230201357A1 (en) * 2017-11-08 2023-06-29 Aptamer Diagnostic, Inc. D-dimer-specific aptamers and methods of use in diagnostics, therapeutic and theranostic purposes
TWI809004B (zh) 2017-11-09 2023-07-21 美商Ionis製藥公司 用於降低snca表現之化合物及方法
GB201718701D0 (en) * 2017-11-13 2017-12-27 Syngenta Participations Ag Improvements in or relating to gene silencing
CN109777800A (zh) * 2017-11-15 2019-05-21 信雅生物科技（苏州）有限公司 一种能够特异性抑制ZBED1基因的siRNA的构建方法及其应用
WO2019100039A1 (en) * 2017-11-20 2019-05-23 Alnylam Pharmaceuticals, Inc. Serum amyloid p component (apcs) irna compositions and methods of use thereof
GB201719680D0 (en) * 2017-11-27 2018-01-10 Devgen Nv Improvements in or relating to gene silencing
KR20250107294A (ko) 2017-12-01 2025-07-11 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 핵산, 이를 포함하는 조성물과 컨쥬게이트, 및 그의 제조 방법과 용도
WO2019105418A1 (zh) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途
US11414661B2 (en) 2017-12-01 2022-08-16 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
WO2019105419A1 (zh) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
JP7273417B2 (ja) 2017-12-01 2023-05-15 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用
CN118638787A (zh) * 2017-12-06 2024-09-13 艾维迪提生物科学公司 治疗肌萎缩和强直性肌营养不良的组合物和方法
CN111344408A (zh) * 2017-12-11 2020-06-26 哥本哈根罗氏创新中心 用于调控fndc3b表达的寡核苷酸
WO2019126641A2 (en) 2017-12-21 2019-06-27 Ionis Pharmaceuticals, Inc. Modulation of frataxin expression
DK3732185T3 (da) 2017-12-29 2025-03-31 Suzhou Ribo Life Science Co Ltd Konjugater og fremstilling og anvendelse heraf
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
US12104172B2 (en) 2018-01-08 2024-10-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific t-cells
CN108387621B (zh) * 2018-01-10 2019-11-26 暨南大学 镉离子核酸适配体及丝网印刷电极电化学生物传感器
GB201800370D0 (en) * 2018-01-10 2018-02-21 Ucl Business Plc Anionic nanocomplexes for nucleic acid delivery
MX2020007369A (es) 2018-01-15 2020-10-28 Ionis Pharmaceuticals Inc Moduladores de la expresion de dnm2.
JP2021511042A (ja) * 2018-01-16 2021-05-06 ディセルナ ファーマシューティカルズ インコーポレイテッド Ａｌｄｈ２発現を阻害するための組成物及び方法
US11583327B2 (en) 2018-01-29 2023-02-21 Spinal Elements, Inc. Minimally invasive interbody fusion
WO2019155387A1 (en) * 2018-02-07 2019-08-15 St. Jude Children's Research Hospital Epigenetic histone regulation mediated by cxorf67
KR20200108315A (ko) 2018-02-09 2020-09-17 제넨테크, 인크. Tmem106b의 발현을 조절하기 위한 올리고뉴클레오티드
TWI840345B (zh) 2018-03-02 2024-05-01 美商Ionis製藥公司 Irf4表現之調節劑
WO2019168687A1 (en) 2018-03-02 2019-09-06 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting gys2 expression
EP3759127A4 (de) 2018-03-02 2022-03-30 Ionis Pharmaceuticals, Inc. Verbindungen und verfahren zur modulation des amyloid-beta-vorläuferproteins
AU2019236204B2 (en) * 2018-03-15 2026-02-26 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
WO2019178575A1 (en) 2018-03-16 2019-09-19 Benvenue Medical, Inc. Articulated instrumentation and methods of using the same
AU2019239971B2 (en) * 2018-03-21 2025-09-11 Regeneron Pharmaceuticals, Inc. 17beta-hydroxysteroid dehydrogenase type 13 (HSD17b13) iRNA compositions and methods of use thereof
US11661601B2 (en) 2018-03-22 2023-05-30 Ionis Pharmaceuticals, Inc. Methods for modulating FMR1 expression
US11648260B2 (en) * 2018-03-29 2023-05-16 Technion Research And Development Foundation Limitted Vesicles comprising a PTEN inhibitor and uses of same
PE20201349A1 (es) 2018-04-11 2020-11-30 Ionis Pharmaceuticals Inc Moduladores de la expresion de ezh2
EP3788144B1 (de) 2018-05-01 2025-09-24 The Children's Medical Center Corporation Abgabe und editing von erweitertem bcl11a-rnp/crispr unter verwendung einer 3xnls-cas9
EP3787600A4 (de) 2018-05-02 2022-02-16 The Children's Medical Center Corporation Verbesserte bcl11a-mikrornas zur behandlung von hämoglobinopathien
WO2019217708A1 (en) 2018-05-09 2019-11-14 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing atxn3 expression
SG11202010012PA (en) 2018-05-09 2020-11-27 Ionis Pharmaceuticals Inc Compounds and methods for reducing fxi expression
AU2019287635B2 (en) * 2018-06-14 2026-02-12 Ionis Pharmaceuticals, Inc. Compounds and methods for increasing STMN2 expression
NO344698B1 (en) * 2018-06-15 2020-03-09 Patogen As Novel fish virus
MX2020013930A (es) 2018-06-22 2021-03-09 Hoffmann La Roche Oligonucleotidos para modular la expresion del canal de sodio dependiente de voltaje alfa subunidad 9 (scn9a).
TWI833770B (zh) 2018-06-27 2024-03-01 美商Ionis製藥公司 用於減少 lrrk2 表現之化合物及方法
PE20220013A1 (es) 2018-07-03 2022-01-11 Hoffmann La Roche Oligonucleotidos para modular la expresion de tau
WO2020011653A1 (en) * 2018-07-09 2020-01-16 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting kynu
WO2020011744A2 (en) * 2018-07-11 2020-01-16 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting cers5
WO2020018558A1 (en) 2018-07-17 2020-01-23 Aronora, Inc. Methods for safely reducing thrombopoietin
CA3106986A1 (en) 2018-07-25 2020-01-30 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing atxn2 expression
EP3598995A1 (de) * 2018-07-26 2020-01-29 Silence Therapeutics GmbH Produkte und zusammensetzungen
AU2019316103B2 (en) 2018-08-02 2026-02-19 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
AU2019316640B2 (en) 2018-08-10 2026-03-12 University Of Massachusetts Modified oligonucleotides targeting SNPs
MX2021001056A (es) 2018-08-13 2021-04-12 Alnylam Pharmaceuticals Inc Composiciones de agente de acido ribonucleico bicatenario (arnbc) de virus de la hepatitis b (vhb) y metodos de uso de las mismas.
EP3836913A4 (de) * 2018-08-14 2022-05-18 Emory University Induktion der proliferation von kardiomyozyten und damit verbundene therapeutische verwendungen
EP3842534A4 (de) 2018-08-21 2022-07-06 Suzhou Ribo Life Science Co., Ltd. Nukleinsäure, pharmazeutische zusammensetzung und konjugat mit der nukleinsäure sowie deren verwendung
EP3840759A4 (de) 2018-08-23 2022-06-01 University Of Massachusetts O-methyl-reiche vollstabilisierte oligonukleotide
CN111500576B (zh) * 2018-08-27 2021-07-27 山东农业大学 siRNA在制备抑制高致病性猪繁殖与呼吸障碍综合症病毒感染的阻断剂中的应用
EP3844278A4 (de) * 2018-08-27 2022-05-25 North Carolina State University Targeting-kit mit splice-switching-oligonukleotiden zur induktion der apoptose von mastzellen
CN120350002A (zh) * 2018-08-31 2025-07-22 佛罗里达大学研究基金会有限公司 用于治疗卵黄状黄斑变性的腺相关病毒载体
US20220280545A1 (en) * 2018-09-10 2022-09-08 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating cln3 expression
CA3109553A1 (en) 2018-09-19 2020-03-26 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of 17beta-hsd type 13 (hsd17b13), compositions thereof, and methods of use
WO2020063198A1 (zh) 2018-09-30 2020-04-02 苏州瑞博生物技术有限公司 一种siRNA缀合物及其制备方法和用途
JP7191301B2 (ja) * 2018-10-02 2022-12-19 小胞体ストレス研究所株式会社 予後不良のがん細胞の増殖抑制剤
US11446156B2 (en) 2018-10-25 2022-09-20 Medos International Sarl Expandable intervertebral implant, inserter instrument, and related methods
EP3874044A1 (de) * 2018-11-02 2021-09-08 BioMarin Technologies B.V. Bispezifische antisense-oligonukleotide für dystrophin-exon-skipping
TW202028222A (zh) 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
AU2019380940A1 (en) 2018-11-15 2021-06-03 Ionis Pharmaceuticals, Inc. Modulators of IRF5 expression
EP3884053A4 (de) 2018-11-21 2023-02-01 Ionis Pharmaceuticals, Inc. Verbindungen und verfahren zur verringerung der prionenexpression
CN113166760A (zh) * 2018-11-23 2021-07-23 赛诺菲 用于抑制angptl8的新型rna组合物和方法
CN111228289A (zh) * 2018-11-28 2020-06-05 中国科学院大连化学物理研究所 Plin2抑制剂的应用和治疗肿瘤药物混合物
ES2766855A1 (es) * 2018-12-14 2020-06-15 Consejo Superior Investigacion Rhoq como diana farmacéutica para trastornos neurológicos
ES2766950A1 (es) * 2018-12-14 2020-06-15 Consejo Superior Investigacion ARHGEF6 como diana farmacéutica para trastornos neurológicos
EA202191730A1 (ru) 2018-12-20 2021-08-24 Эмджен Инк. Ингибиторы kif18a
IL319265A (en) 2018-12-21 2025-04-01 Avidity Biosciences Inc Anti-transferrin receptor antibodies and their uses
JP7507495B2 (ja) 2018-12-28 2024-06-28 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
US11452738B2 (en) * 2019-01-04 2022-09-27 Empirico Inc. Treatment of thymic stromal lymphopoietin (TSLP) related diseases by inhibition of long-form TSLP transcripts
CA3120580A1 (en) 2019-01-09 2020-07-16 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of hif-2 alpha (epas1), compositions thereof, and methods of use
WO2020144295A1 (en) 2019-01-10 2020-07-16 Biontech Rna Pharmaceuticals Gmbh Localized administration of rna molecules for therapy
US20220088051A1 (en) * 2019-01-15 2022-03-24 Bioneer Corporation Double-stranded oligonucleotide targeting dkk1 gene, construct including same, and hair loss prevention or hair growth composition containing same
AU2020207935A1 (en) * 2019-01-18 2021-08-26 University Of Massachusetts Dynamic pharmacokinetic-modifying anchors
TW202214854A (zh) 2019-01-31 2022-04-16 美商Ionis製藥公司 Yap1表現之調節劑
MX2021010152A (es) * 2019-02-27 2021-09-14 Ionis Pharmaceuticals Inc Moduladores de la expresion de malat1.
CN113748209A (zh) 2019-02-27 2021-12-03 斯托克制药公司 用于治疗病况和疾病的反义寡聚体
CN114144422B (zh) 2019-03-01 2025-03-07 中尺度技术有限责任公司 用于免疫方法的被电化学发光标记的探针、使用这类探针的方法和包含这类探针的试剂盒
US11013530B2 (en) 2019-03-08 2021-05-25 Medos International Sarl Surface features for device retention
AU2020239987A1 (en) * 2019-03-15 2021-11-04 University Of Massachusetts Oligonucleotides for tissue specific ApoE modulation
AU2020241251A1 (en) * 2019-03-15 2021-10-07 University Of Washington Improved survival of human cells differentiated in vitro by PRPF31 gene expression knockdown
US11241252B2 (en) 2019-03-22 2022-02-08 Medos International Sarl Skin foundation access portal
US11129727B2 (en) 2019-03-29 2021-09-28 Medos International Sari Inflatable non-distracting intervertebral implants and related methods
MD3947684T2 (ro) 2019-03-29 2025-10-31 Ionis Pharmaceuticals Inc Compuși și metode pentru modularea UBE3A-ATS
US11813026B2 (en) 2019-04-05 2023-11-14 Medos International Sarl Systems, devices, and methods for providing surgical trajectory guidance
CN114007654A (zh) 2019-04-17 2022-02-01 阿迪根有限公司 用于分子的细胞内递送的肽和纳米颗粒
WO2020214820A2 (en) * 2019-04-18 2020-10-22 University Of Massachusetts Aim2 inhibitors and uses thereof
EP3959319A4 (de) 2019-04-25 2023-06-07 Avidity Biosciences, Inc. Nukleinsäurezusammensetzungen und verfahren für multi-exon-skipping
CN111849968A (zh) * 2019-04-30 2020-10-30 中美瑞康核酸技术(南通)研究院有限公司 寡核苷酸分子及其在急性间歇性卟啉症治疗中的应用
CA3132838A1 (en) * 2019-05-05 2020-11-12 Bat Sheva KEREM Restoration of the cftr function by splicing modulation
SG11202112499VA (en) 2019-05-15 2021-12-30 Univ Miami Treatment of heart disease by disruption of the anchoring of pp2a
CA3139195A1 (en) * 2019-05-22 2020-11-26 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
EP3974530A4 (de) 2019-05-22 2023-07-12 Suzhou Ribo Life Science Co., Ltd. Nukleinsäure, pharmazeutische zusammensetzung, konjugat, herstellungsverfahren und verwendung
US20200369759A1 (en) 2019-05-23 2020-11-26 Fibrogen, Inc. Methods of treatment of muscular dystrophies
EP3976059A4 (de) * 2019-05-24 2024-09-11 Empirico Inc. Behandlung von mit angiopoietin-like 7 (angptl7) assoziierten krankheiten
JP7610849B2 (ja) 2019-05-24 2025-01-09 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、薬物組成物及び複合体ならびに調製方法と使用
JP7614650B2 (ja) * 2019-05-24 2025-01-16 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、薬物組成物及び複合体並びに調製方法と使用
US20220251567A1 (en) * 2019-07-10 2022-08-11 Inserm (Institut National De La Santè Et De La Recherche Médicale) Methods for the treatment of epilepsy
EP4660307A2 (de) 2019-07-26 2025-12-10 Ionis Pharmaceuticals, Inc. Verbindungen und verfahren zur gfap-modulation
JP7692829B2 (ja) 2019-07-30 2025-06-16 塩野義製薬株式会社 Ｍｕｒｆ１を標的とする核酸医薬
KR20220047989A (ko) 2019-08-09 2022-04-19 유니버시티 오브 매사추세츠 Snp를 표적화하는 화학적으로 변형된 올리고뉴클레오타이드
EP4013494A1 (de) 2019-08-12 2022-06-22 Regeneron Pharmaceuticals, Inc. Varianten von makrophagenstimulierendem 1-rezeptor (mst1r) und verwendungen davon
CA3149147A1 (en) * 2019-08-23 2021-03-04 Jayakrishna Ambati Ddx17 and nlrc4 targeting for inflammatory diseases
CN114173783A (zh) * 2019-08-30 2022-03-11 新加坡科技研究局 促进运动神经元的存活和/或功能的方法及相关试剂、用途和方法
WO2021041846A1 (en) * 2019-08-30 2021-03-04 Inari Agriculture, Inc. Rna-guided nucleases and dna binding proteins
CA3152513A1 (en) * 2019-08-30 2021-03-04 Baylor College Of Medicine System for regulating gene expression
EP3791930A1 (de) * 2019-09-13 2021-03-17 Secarna Pharmaceuticals GmbH & Co. KG Inhibitor der metadherin-expression
US12365894B2 (en) 2019-09-16 2025-07-22 University Of Massachusetts Branched lipid conjugates of siRNA for specific tissue delivery
KR102100163B1 (ko) 2019-09-24 2020-04-13 테고사이언스 (주) 켈로이드 또는 비후성 반흔 예방 또는 치료용 조성물
EP4045031A4 (de) * 2019-10-16 2023-11-29 Brown University Muskelregeneration und -wachstum
AU2020369515A1 (en) 2019-10-22 2022-04-21 Alnylam Pharmaceuticals, Inc. Complement component C3 iRNA compositions and methods of use thereof
TW202130809A (zh) * 2019-10-29 2021-08-16 美商愛羅海德製藥公司 用於抑制β-ENaC表現之RNAi藥劑、其組合物及使用方法
WO2021087325A1 (en) * 2019-11-01 2021-05-06 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing dnajb1-prkaca fusion gene expression
EP4054655A4 (de) * 2019-11-08 2024-02-28 Ionis Pharmaceuticals, Inc. Verbindungen und verfahren zur verringerung der spdef-expression
WO2021092459A1 (en) * 2019-11-08 2021-05-14 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing spdef expression
CN110859960B (zh) * 2019-11-26 2022-03-04 深圳先进技术研究院 靶向AMPK的抑制剂/siRNA与蛋白酶体抑制剂组合在制备抗肿瘤药物中的应用
JP2023514000A (ja) * 2019-12-09 2023-04-05 エンピリコ インク． アンジオポエチン様４（ａｎｇｐｔｌ４）関連疾患の処置のためのオリゴヌクレオチド
MX2022007144A (es) 2019-12-16 2022-07-11 Alnylam Pharmaceuticals Inc Composiciones de acido ribonucleico de interferencia (arni) que contienen un dominio fosfolipasa tipo patatina 3 (pnpla3) y sus metodos de uso.
US20210214727A1 (en) * 2019-12-20 2021-07-15 Hoffmann-La Roche Inc. Enhanced oligonucleotides for inhibiting scn9a expression
WO2021130537A2 (en) * 2019-12-23 2021-07-01 Versameb Ag Compositions and methods for simultaneously modulating expression of genes
AU2020415455A1 (en) * 2019-12-23 2022-07-14 University Of Massachusetts Oligonucleotides for tissue specific gene expression modulation
WO2021137506A1 (ko) * 2019-12-31 2021-07-08 한국원자력연구원 Wdr34 억제제를 포함하는 암줄기세포 성장 억제용 조성물 및 그 용도
US20230073368A1 (en) 2020-02-11 2023-03-09 Turun Yliopisto Therapy of ras-dependent cancers
JP7735288B2 (ja) 2020-02-18 2025-09-08 アルナイラム ファーマシューティカルズ， インコーポレイテッド アポリポタンパク質Ｃ３（ＡＰＯＣ３）ｉＲＮＡ組成物およびその使用法
US20230056788A1 (en) * 2020-02-21 2023-02-23 Replicor Inc. Methods and compositions for the inhibition of hepatitis b and hepatitis d virus infections
US12258566B2 (en) * 2020-02-28 2025-03-25 University Of Massachusetts Oligonucleotides for PRNP modulation
CN120505310A (zh) 2020-02-28 2025-08-19 Ionis制药公司 用于调节smn2的化合物和方法
WO2021178736A1 (en) * 2020-03-06 2021-09-10 Alnylam Pharmaceuticals, Inc. KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
US11426286B2 (en) 2020-03-06 2022-08-30 Eit Emerging Implant Technologies Gmbh Expandable intervertebral implant
US20230124616A1 (en) * 2020-03-06 2023-04-20 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating kcnq2
AU2021237465A1 (en) 2020-03-19 2022-10-13 Avidity Biosciences, Inc. Compositions and methods of treating Facioscapulohumeral muscular dystrophy
IL296393B1 (en) 2020-03-27 2025-12-01 Avidity Biosciences Inc Compositions and methods of treating muscle dystrophy
EP4127173A4 (de) * 2020-03-27 2024-07-17 Alnylam Pharmaceuticals, Inc. Fc-fragment von igg-rezeptor- und transporter-irna-zusammensetzungen und verfahren zur verwendung davon
CN113444723A (zh) * 2020-03-27 2021-09-28 北京键凯科技股份有限公司 一种抑制血管内皮生长因子受体2基因表达的干扰rna及其应用
CA3179678A1 (en) * 2020-04-07 2021-10-14 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing scn9a expression
CN115667551A (zh) * 2020-04-14 2023-01-31 美国安进公司 用于治疗赘生性疾病的kif18a抑制剂
US20230151369A1 (en) * 2020-04-17 2023-05-18 The University Of British Columbia Compositions and methods for inhibiting tdp-43 and fus aggregation
IL297435A (en) 2020-05-01 2022-12-01 Ionis Pharmaceuticals Inc Compounds and methods for modulating atxn1
AU2021270720A1 (en) 2020-05-11 2022-12-08 Stoke Therapeutics, Inc. OPA1 antisense oligomers for treatment of conditions and diseases
EP4150083A1 (de) * 2020-05-13 2023-03-22 F. Hoffmann-La Roche AG Oligonukleotidagonisten zum targeting von progranulin
EP4150093A4 (de) 2020-05-14 2024-06-19 Ariz Precision Medicine, Inc. Krebsbehandlung mit sirna zur modulation der expression von prdm2/riz-protein
CN111714510B (zh) * 2020-05-18 2021-07-06 北京航空航天大学 长链非编码rna snhg12抑制剂在制备对抗骨质疏松药物中的应用
EP4153746A1 (de) * 2020-05-21 2023-03-29 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur hemmung der marc1-genexpression
US12534724B2 (en) 2020-05-26 2026-01-27 University Of Massachusetts Synthetic oligonucleotides having regions of block and cluster modifications
WO2021252523A2 (en) * 2020-06-09 2021-12-16 Alnylam Pharmaceuticals, Inc. TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6 (TRAF6) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
JP2023529903A (ja) * 2020-06-09 2023-07-12 アルナイラム ファーマシューティカルズ， インコーポレイテッド ＧＰＡＭ（グリセロール－３－リン酸アシルトランスフェラーゼ１、ミトコンドリア）発現をサイレンシングするためのｓｉＲＮＡ組成物および方法
WO2021252903A2 (en) * 2020-06-11 2021-12-16 Genetic Intelligence, Inc, New York, Ny Compositions for flcn gene modulation and methods thereof
US11459567B2 (en) 2020-06-24 2022-10-04 Patricia Virginia Elizalde Specific siRNA molecules, composition and use thereof for the treatment of triple negative breast cancer
JP7799640B2 (ja) 2020-06-29 2026-01-15 アイオーニス ファーマシューティカルズ， インコーポレーテッド Ｐｌｐ１を調節するための化合物及び方法
US20230313196A1 (en) * 2020-07-23 2023-10-05 John Mansell Compositions and methods for treating pain and anxiety disorders
US12384814B2 (en) 2020-07-28 2025-08-12 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing app expression
CA3187977A1 (en) * 2020-07-28 2022-02-03 Knc Laboratories Co., Ltd. Antisense oligonucleotide inducing exon skipping of angiotensin converting enzyme 2 gene
WO2022031591A2 (en) * 2020-08-03 2022-02-10 University Of Massachusetts Oligonucleotides for htt-1a modulation
JP2023538284A (ja) * 2020-08-04 2023-09-07 ダイセルナ ファーマシューティカルズ， インコーポレイテッド Ｐｌｐ１発現を阻害するための組成物及び方法
PE20231567A1 (es) 2020-08-07 2023-10-04 Ionis Pharmaceuticals Inc Compuestos y metodos para modular el scn2a
EP4196587A4 (de) * 2020-08-13 2025-07-23 Nevada Res & Innovation Corporation Klf11-sirna zur behandlung von diabetes und adipositas
US20230348906A1 (en) * 2020-09-01 2023-11-02 Ultragenyx Pharmaceutical Inc. Dux4 inhibitors and methods of use thereof
JP7541100B2 (ja) * 2020-09-09 2024-08-27 大原薬品工業株式会社 ｓｉＲＮＡおよびその用途
TW202227627A (zh) 2020-09-11 2022-07-16 美商愛羅海德製藥公司 用於抑制DUX4表現之RNAi藥劑、其組合物及使用方法
CA3195722A1 (en) 2020-09-17 2022-03-24 Q-State Biosciences, Inc. Therapeutic compositions for treating pain via multiple targets
CN116249538A (zh) * 2020-09-30 2023-06-09 富士胶片株式会社 抑制乙型肝炎病毒蛋白质的产生的双链rna及药物组合物
WO2022089486A1 (zh) * 2020-10-28 2022-05-05 江苏柯菲平医药股份有限公司 抑制PCSK9基因表达的siRNA及其修饰物与应用
IL302709A (en) 2020-11-13 2023-07-01 Alnylam Pharmaceuticals Inc Coagulation factor iRNA compositions (F5) and methods of using them
EP4244359A4 (de) * 2020-11-13 2025-05-21 The George Washington University, A Congressionally Chartered Not-For-Profit Corporation B-spektrin (sptbn1)-mangelschützende mäuse vor fettreicher ernährungsinduzierter lebererkrankung und krebsentwicklung
MX2023005736A (es) 2020-11-18 2023-05-25 Ionis Pharmaceuticals Inc Compuestos y metodos para modular la expresion de angiotensinogeno.
US20240024492A1 (en) * 2020-12-07 2024-01-25 Olix Pharmaceuticals, Inc. Nucleic acid molecule for induction of asymmetric rnai for inhibiting expression of ror-beta
CA3205040A1 (en) 2020-12-18 2022-06-23 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating factor xii
EP4288542A4 (de) * 2021-02-08 2025-08-20 Ractigen Therapeutics Multivalentes oligonukleotidmittel und verfahren zur verwendung davon
IL305418A (en) 2021-03-04 2023-10-01 Alnylam Pharmaceuticals Inc Angiopoietin-like 3 (ANGPTL3) IRNA compositions and methods of using them
US11771517B2 (en) 2021-03-12 2023-10-03 Medos International Sarl Camera position indication systems and methods
WO2022197953A2 (en) * 2021-03-17 2022-09-22 Sirnaomics, Inc. Methods of cancer treatment by delivery of sirnas against nsd3
WO2022204440A1 (en) * 2021-03-26 2022-09-29 Alnylam Pharmaceuticals, Inc. ELONGATION OF VERY LONG CHAIN FATTY ACIDS PROTEIN 1 (ELOVL1) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
US11850160B2 (en) 2021-03-26 2023-12-26 Medos International Sarl Expandable lordotic intervertebral fusion cage
WO2022212208A1 (en) * 2021-03-29 2022-10-06 University Of Massachusetts Oligonucleotides for syngr-3 modulation
US11752009B2 (en) 2021-04-06 2023-09-12 Medos International Sarl Expandable intervertebral fusion cage
MX2023011909A (es) 2021-04-08 2023-10-18 Arrowhead Pharmaceuticals Inc Agentes de rnai para inhibir la expresion del receptor para productos finales de glicacion avanzada, composiciones de estos y metodos de uso.
KR20240031947A (ko) * 2021-04-14 2024-03-08 에이알오 바이오테라퓨틱스 컴패니 Fn3 도메인-시르나 접합체 및 이의 용도
JP2024515289A (ja) * 2021-04-16 2024-04-08 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア Ｈ－ａｂｃ白質ジストロフィーの治療に有用な組成物および方法
CA3213775A1 (en) * 2021-04-19 2022-10-27 Utsav SAXENA Compositions and methods for inhibiting nuclear receptor subfamily 1 group h member 3 (nr1h3) expression
JP2024515344A (ja) * 2021-04-20 2024-04-09 アストラゼネカ アイルランド リミテッド 補体成分３の発現を阻害するための組成物及び方法
KR20240032184A (ko) * 2021-04-22 2024-03-11 몰레큘라 악시옴, 엘엘씨 Sos 유전자 발현을 조절하기 위한 조성물 및 방법
TW202309280A (zh) 2021-04-26 2023-03-01 美商艾拉倫製藥股份有限公司 跨膜絲胺酸蛋白酶６（ＴＭＰＲＳＳ６）ｉＲＮＡ組成物及其使用方法
AU2022280088A1 (en) * 2021-05-27 2023-11-23 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing carbonic anhydrase 2 expression
AR125992A1 (es) * 2021-05-28 2023-08-30 Novo Nordisk As Composiciones y métodos para inhibir la expresión del componente 1 de reducción de amidoxima mitocondrial (marc1)
PE20250265A1 (es) * 2021-05-28 2025-01-29 Arrowhead Pharmaceuticals Inc Agentes de rnai para inhibir la expresion de mucina 5ac (muc5ac), composiciones de estos y metodos de uso
EP4352086A4 (de) * 2021-06-03 2025-09-17 Univ Chicago Verfahren und zusammensetzungen zur behandlung von fibrose
WO2022266042A1 (en) * 2021-06-16 2022-12-22 Empirico Inc. Treatment of mst1r related diseases and disorders
KR20240023602A (ko) 2021-06-18 2024-02-22 아이오니스 파마수티컬즈, 인코포레이티드 Ifnar1 발현을 감소시키기 위한 화합물 및 방법
US11549112B1 (en) 2021-06-21 2023-01-10 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of xanthine dehydrogenase (XDH), pharmaceutical compositions thereof, and methods of use
CN113416776B (zh) * 2021-06-21 2022-04-01 深圳市儿童医院 一种用于检测室间隔缺损的生物标记物及其应用
KR20240023635A (ko) * 2021-06-21 2024-02-22 상하이 준스 바이오사이언스 컴퍼니 리미티드 ANGPTL3 유전자 발현을 억제하는 siRNA 및 이의 용도
IL309334A (en) 2021-06-23 2024-02-01 Univ Massachusetts Anti-FLT1 optimized oligonucleotide compounds for the treatment of preeclampsia and other angiogenic disorders
US20240287521A1 (en) * 2021-06-25 2024-08-29 Stichting Radboud Universitair Medisch Centrum Allele-specific silencing therapy for DFNA21 using antisense oligonucleotides
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US20230135763A1 (en) 2021-07-17 2023-05-04 Sirnaomics, Inc. Products and compositions
CA3227852A1 (en) 2021-08-03 2023-02-09 Alnylam Pharmaceuticals, Inc. Transthyretin (ttr) irna compositions and methods of use thereof
MX2024001573A (es) * 2021-08-13 2024-02-14 Alnylam Pharmaceuticals Inc Composiciones de acido ribonucleico de interferencia (arni) contra el factor xii (f12) y sus metodos de uso.
EP4392407A1 (de) 2021-08-26 2024-07-03 Volastra Therapeutics, Inc. Spiroindolinhemmer von kif18a
JP2024538859A (ja) * 2021-08-31 2024-10-24 アルナイラム ファーマシューティカルズ， インコーポレイテッド 細胞死誘導ＤＦＦＡ様エフェクターＢ（ＣＩＤＥＢ）ｉＲＮＡ組成物およびその使用方法
EP4396352A4 (de) 2021-09-01 2025-10-01 Ionis Pharmaceuticals Inc Verbindungen und verfahren zur reduzierung der dmpk-expression
CN118265544A (zh) 2021-09-16 2024-06-28 艾维迪提生物科学公司 治疗面肩肱型肌营养不良的组合物和方法
US12043832B2 (en) * 2021-09-16 2024-07-23 Washington University Methods and compositions for reducing pathogenic isoforms
CN118541392A (zh) 2021-09-28 2024-08-23 准星生物医药有限公司 多种形式的分子复合物
IL311518A (en) 2021-10-01 2024-05-01 Adarx Pharmaceuticals Inc Preparations that modulate perkalkerine and methods of using them
JP2024541974A (ja) * 2021-10-29 2024-11-13 アルナイラム ファーマシューティカルズ， インコーポレイテッド ハンチンチン（ＨＴＴ）ｉＲＮＡ剤組成物およびその使用方法
CA3234636A1 (en) 2021-10-29 2023-05-04 Alnylam Pharmaceuticals, Inc. Complement factor b (cfb) irna compositions and methods of use thereof
MX2024005862A (es) 2021-11-16 2024-07-10 Shanghai Argo Biopharmaceutical Co Ltd Composiciones y metodos para inhibir la expresion de la proteina angiotensinogeno (agt).
US20230167447A1 (en) * 2021-11-30 2023-06-01 Genetic Intelligence, Inc Compositions for FNIP1/FNIP2 Gene Modulation and Methods Thereof
EP4444885A2 (de) * 2021-12-07 2024-10-16 Alnylam Pharmaceuticals, Inc. Irna-zusammensetzungen und verfahren zum silencing von mylip
WO2023122805A1 (en) 2021-12-20 2023-06-29 Vestaron Corporation Sorbitol driven selection pressure method
MX2024007790A (es) 2021-12-22 2024-09-06 Camp4 Therapeutics Corp Modulación de la transcripción génica utilizando oligonucleótidos antisentido dirigidos a arn reguladores.
US20250075209A1 (en) * 2021-12-27 2025-03-06 Apellis Pharmaceuticals, Inc. Rnas for complement inhibition
JP2025507447A (ja) * 2022-02-01 2025-03-18 ４ディー・パス・インコーポレイテッド 画像に基づく疾患特性評価のためのシステム及び方法
US12090064B2 (en) 2022-03-01 2024-09-17 Medos International Sarl Stabilization members for expandable intervertebral implants, and related systems and methods
US11879125B2 (en) 2022-03-16 2024-01-23 Empirico Inc. GalNAc compositions for improving siRNA bioavailability
AU2023245603A1 (en) 2022-03-28 2024-11-07 Empirico Inc. Modified oligonucleotides
US12071621B2 (en) 2022-04-05 2024-08-27 Avidity Biosciences, Inc. Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
US20240035027A1 (en) * 2022-05-04 2024-02-01 University Of Massachusetts Oligonucleotides for pms2 modulation
WO2023220566A1 (en) * 2022-05-09 2023-11-16 The Regents Of The University Of California Crispr-cas effector polypeptides and methods of use thereof
CN119451683A (zh) * 2022-05-10 2025-02-14 艾米利克斯制药公司 寡核苷酸组合物及其方法
WO2023250368A2 (en) * 2022-06-24 2023-12-28 Eli Lilly And Company Atxn2 rna interference agents
US20240084301A1 (en) * 2022-07-25 2024-03-14 Amgen Inc. Rnai constructs and methods for inhibiting fam13a expression
CN116042822A (zh) * 2022-09-16 2023-05-02 湖南灵康医疗科技有限公司 Znf32调控ccnd1基因的表达在抗结直肠癌化疗耐药中的应用
US12152052B2 (en) 2022-09-23 2024-11-26 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing MECP2 expression
CN116004543B (zh) * 2022-09-26 2025-03-11 南通大学 Traf6抑制剂在制备人恶性黑色素瘤治疗药物中的应用
CN115844919B (zh) * 2022-09-28 2025-09-09 李永 一种抑制黑色素瘤生长的双核酸序列及应用
JP2025533864A (ja) * 2022-10-03 2025-10-09 システィック フィブロシス ファウンデーション Ｃｆｔｒの調節のための組成物および方法
WO2024104663A1 (en) 2022-11-16 2024-05-23 Unilever Ip Holdings B.V. Method of reducing malodour
CA3276325A1 (en) * 2022-12-07 2024-06-13 The Regents Of The University Of California Nucleic acid inhibitors and their methods of use
KR20250135915A (ko) 2022-12-15 2025-09-15 엠피리코 인크. Mst1 관련 질환 및 장애의 치료
EP4642911A2 (de) * 2022-12-29 2025-11-05 Voyager Therapeutics, Inc. Zusammensetzungen und verfahren zur regulierung von mapt
WO2024159113A1 (en) * 2023-01-27 2024-08-02 The Methodist Hospital Modulators of alternative polyadenylation and methods of use thereof
WO2024175586A2 (en) * 2023-02-21 2024-08-29 Vib Vzw Inhibitors of synaptogyrin-3 expression
EP4677090A2 (de) * 2023-03-09 2026-01-14 Leal Therapeutics, Inc. Zusammensetzungen und verfahren zur modulierung von c3
KR20260016905A (ko) * 2023-03-22 2026-02-04 오스페달레 산 라파엘 에스.알.엘. 유전자 치료
EP4695397A1 (de) * 2023-04-14 2026-02-18 Avicenna Biotech Research, Llc Rna-basierte zusammensetzungen und verfahren zur behandlung von brustkrebs
AU2024267619A1 (en) * 2023-05-05 2025-11-20 Children's Medical Research Institute Methods of treating alt-dependent cancers
WO2024233966A2 (en) * 2023-05-10 2024-11-14 The General Hospital Corporation Modulating stromal and immune cells in atrial disease
WO2024245930A2 (en) * 2023-05-26 2024-12-05 E-Therapeutics Plc Inhibitors of expression and/or function
CN118272371B (zh) * 2023-05-30 2026-02-06 北京大学 靶向plin2基因的小干扰核酸、短反义寡核苷酸及其用途
CN119698475A (zh) 2023-06-13 2025-03-25 昂拓生物医药有限公司 血管紧张素原的高效rna靶向(arnatar)
CN116794325B (zh) * 2023-06-15 2024-05-10 中山大学 敲低或抑制slc35f6的试剂在制备激活ampk的药物中的应用
WO2025006639A2 (en) 2023-06-27 2025-01-02 Avidity Biosciences, Inc. Compositions and methods of using prkag2-targeting antibody-oligonucleotide conjugates abstract
US12409230B2 (en) 2023-06-30 2025-09-09 Avidity Biosciences, Inc. Compositions comprising PLN-targeting anti-transferrin receptor antibody-polynucleotides and methods of use thereof to treat cardiomyopathy
CN116898975A (zh) * 2023-08-21 2023-10-20 中国福利会国际和平妇幼保健院 Ythdc1抑制剂在制备防治早产的药物中的应用
CN117323435A (zh) * 2023-09-15 2024-01-02 湖北工业大学 Styk1在制备预测、诊断或治疗胰腺癌产品中的应用
TW202530408A (zh) * 2023-09-29 2025-08-01 美商英西特羅公司 用於治療非酒精性脂肪肝病的組合物與方法
CN117070583B (zh) * 2023-10-16 2024-05-14 吉林凯莱英制药有限公司 抑制PCSK9基因表达的siRNA的制备方法
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
WO2025107242A1 (zh) * 2023-11-23 2025-05-30 成都福实生物科技有限公司 机械力响应型巨噬细胞亚群在胰腺癌诊断或预后评估中的应用
CN117959445B (zh) * 2024-02-04 2025-06-27 北京大学 Rna结合蛋白抑制剂在用于制备抑制慢性乙型肝炎病毒复制的药物中的用途
EP4603586A1 (de) * 2024-02-16 2025-08-20 Universität zu Lübeck Inhibitorische oligonukleotide gegen adamts7
US12553050B2 (en) * 2024-03-22 2026-02-17 Takeda Pharmaceutical Company Limited Compositions and methods for inhibiting cytochrome P450 family 7 subfamily a member 1 (CYP7A1) expression
WO2025212467A1 (en) 2024-03-31 2025-10-09 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of microtubule associated protein tau (mapt), compositions thereof, and methods of use
WO2025226343A1 (en) * 2024-04-26 2025-10-30 Research Institute At Nationwide Children's Hospital Products and methods to inhibit expression of dynamin-1 variants and replace dynamin-1
WO2025231449A1 (en) * 2024-05-02 2025-11-06 Institute For Myeloma & Bone Cancer Research Prediction, diagnosis, and treatment of multiple myeloma
CN118624918B (zh) * 2024-08-08 2024-11-15 中国医学科学院医药生物技术研究所 宿主细胞cxcr6基因作为抗黄病毒靶点在制备抗黄病毒药物中的应用
WO2026037289A1 (zh) * 2024-08-12 2026-02-19 广州必贝特医药股份有限公司 用于抑制尿酸盐转运体1基因表达的siRNA、药物及其应用
CN120775978A (zh) * 2025-03-14 2025-10-14 浙江省肿瘤医院 乳头状甲状腺癌早期预测标志物的筛选方法及应用
CN120241773B (zh) * 2025-04-07 2026-01-30 深圳市华元生物技术股份有限公司 一种抑制人PPP1R3B基因表达的siRNA试剂、组合物及其应用
CN120290720B (zh) * 2025-04-11 2025-12-23 新疆医科大学第三附属医院 靶向RPS4X基因的siRNA、LAMB3-PI3K-AKT信号通路抑制剂、卵巢癌药物及应用
CN120514724B (zh) * 2025-07-24 2025-10-10 济南瑞隆安生物技术有限公司 一种siRNA在制备餐后高血糖治疗制剂中的应用

Family Cites Families (342)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US647526A (en) * 1899-06-26 1900-04-17 William Allen Runyan Freight-car door.
US1541453A (en) * 1922-12-20 1925-06-09 Watkins Clayton Stuart Demountable rim and wheell for automobiles and other vehicles
US3260656A (en) * 1962-09-27 1966-07-12 Corning Glass Works Method and apparatus for electrolytically determining a species in a fluid
EG10142A (en) * 1968-01-29 1976-06-30 Bayer Ag N-tritylimidazolium salts
US3653841A (en) * 1969-12-19 1972-04-04 Hoffmann La Roche Methods and compositions for determining glucose in blood
US3719564A (en) * 1971-05-10 1973-03-06 Philip Morris Inc Method of determining a reducible gas concentration and sensor therefor
US3837339A (en) * 1972-02-03 1974-09-24 Whittaker Corp Blood glucose level monitoring-alarm system and method therefor
US4184429A (en) * 1972-02-09 1980-01-22 Max Datwyler & Co. Constant bevel doctor blade and method and apparatus using same
US3811449A (en) * 1972-03-08 1974-05-21 Becton Dickinson Co Dilating apparatus and method
US3908657A (en) * 1973-01-15 1975-09-30 Univ Johns Hopkins System for continuous withdrawal of blood
US4100048A (en) * 1973-09-20 1978-07-11 U.S. Philips Corporation Polarographic cell
US3911901A (en) * 1974-07-24 1975-10-14 Gen Electric In vivo hydrogen ion sensor
US3972320A (en) * 1974-08-12 1976-08-03 Gabor Ujhelyi Kalman Patient monitoring system
US3979274A (en) * 1975-09-24 1976-09-07 The Yellow Springs Instrument Company, Inc. Membrane for enzyme electrodes
US4016866A (en) * 1975-12-18 1977-04-12 General Electric Company Implantable electrochemical sensor
US4055175A (en) * 1976-05-07 1977-10-25 Miles Laboratories, Inc. Blood glucose control apparatus
DE2625834B2 (de) * 1976-06-09 1978-10-12 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur Bestimmung von Substraten oder Enzymaktivitäten
US4076596A (en) * 1976-10-07 1978-02-28 Leeds & Northrup Company Apparatus for electrolytically determining a species in a fluid and method of use
FR2387659A1 (fr) * 1977-04-21 1978-11-17 Armines Dispositif de controle et regulation de la glycemie
US4098574A (en) * 1977-08-01 1978-07-04 Eastman Kodak Company Glucose detection system free from fluoride-ion interference
JPS5912135B2 (ja) * 1977-09-28 1984-03-21 松下電器産業株式会社 酵素電極
US4151845A (en) * 1977-11-25 1979-05-01 Miles Laboratories, Inc. Blood glucose control apparatus
DK151000C (da) * 1978-02-17 1988-06-13 Radiometer As Fremgangsmaade og apparat til bestemmelse af en patients in vivo plasma-ph-vaerdi
US4172770A (en) * 1978-03-27 1979-10-30 Technicon Instruments Corporation Flow-through electrochemical system analytical method
HU177369B (en) * 1978-09-08 1981-09-28 Radelkis Electrokemiai Industrial molecule-selective sensing device and method for producing same
US4247297A (en) * 1979-02-23 1981-01-27 Miles Laboratories, Inc. Test means and method for interference resistant determination of oxidizing substances
US4573994A (en) * 1979-04-27 1986-03-04 The Johns Hopkins University Refillable medication infusion apparatus
US4458686A (en) * 1979-08-02 1984-07-10 Children's Hospital Medical Center Cutaneous methods of measuring body substances
US4401122A (en) * 1979-08-02 1983-08-30 Children's Hospital Medical Center Cutaneous methods of measuring body substances
US4450842A (en) * 1980-04-25 1984-05-29 Cordis Corporation Solid state reference electrode
US4340458A (en) * 1980-06-02 1982-07-20 Joslin Diabetes Center, Inc. Glucose sensor
US4401433A (en) * 1980-06-13 1983-08-30 Luther Ronald B Apparatus for advancing oversized catheter through cannula, and the like
DE3025785C2 (de) * 1980-07-08 1984-08-16 Storz, Karl, 7200 Tuttlingen Dilatator, Verfahren zu seiner Verwendung und Vorrichtung zur Durchführung des Verfahrens
US4404066A (en) * 1980-08-25 1983-09-13 The Yellow Springs Instrument Company Method for quantitatively determining a particular substrate catalyzed by a multisubstrate enzyme
US4356074A (en) * 1980-08-25 1982-10-26 The Yellow Springs Instrument Company, Inc. Substrate specific galactose oxidase enzyme electrodes
US4352960A (en) * 1980-09-30 1982-10-05 Baptist Medical Center Of Oklahoma, Inc. Magnetic transcutaneous mount for external device of an associated implant
US4390621A (en) * 1980-12-15 1983-06-28 Miles Laboratories, Inc. Method and device for detecting glucose concentration
US4369790A (en) * 1981-03-05 1983-01-25 Mccarthy John M Catheter
US4436094A (en) * 1981-03-09 1984-03-13 Evreka, Inc. Monitor for continuous in vivo measurement of glucose concentration
US4350151A (en) * 1981-03-12 1982-09-21 Lone Star Medical Products, Inc. Expanding dilator
DE3117802A1 (de) * 1981-05-06 1982-11-25 Max Dr. 8520 Erlangen Hubmann Katheterbesteck
AT369254B (de) * 1981-05-07 1982-12-27 Otto Dipl Ing Dr Tech Prohaska Medizinische sonde
FR2508305B1 (fr) * 1981-06-25 1986-04-11 Slama Gerard Dispositif pour provoquer une petite piqure en vue de recueillir une goutte de sang
US4440175A (en) * 1981-08-10 1984-04-03 University Patents, Inc. Membrane electrode for non-ionic species
DE3278334D1 (en) * 1981-10-23 1988-05-19 Genetics Int Inc Sensor for components of a liquid mixture
US4431004A (en) * 1981-10-27 1984-02-14 Bessman Samuel P Implantable glucose sensor
JPS58153154A (ja) * 1982-03-09 1983-09-12 Ajinomoto Co Inc 修飾電極
US4581336A (en) * 1982-04-26 1986-04-08 Uop Inc. Surface-modified electrodes
DE3221339A1 (de) * 1982-06-05 1983-12-08 Basf Ag, 6700 Ludwigshafen Verfahren zur elektrochemischen hydrierung von nicotinamidadenin-dinucleotid
US4427770A (en) * 1982-06-14 1984-01-24 Miles Laboratories, Inc. High glucose-determining analytical element
DE3228551A1 (de) * 1982-07-30 1984-02-02 Siemens AG, 1000 Berlin und 8000 München Verfahren zur bestimmung der zuckerkonzentration
US4534356A (en) * 1982-07-30 1985-08-13 Diamond Shamrock Chemicals Company Solid state transcutaneous blood gas sensors
US4571292A (en) * 1982-08-12 1986-02-18 Case Western Reserve University Apparatus for electrochemical measurements
US4461691A (en) * 1983-02-10 1984-07-24 The United States Of America As Represented By The United States Department Of Energy Organic conductive films for semiconductor electrodes
US4679562A (en) * 1983-02-16 1987-07-14 Cardiac Pacemakers, Inc. Glucose sensor
IT1170375B (it) * 1983-04-19 1987-06-03 Giuseppe Bombardieri Apparecchio che infonde insulina o glucosio nel soggetto diabetico sulla base di determinazioni di concentrazioni di glucosio ottenute senza bisogno di prelievi del sangue del paziente
CA1218704A (en) * 1983-05-05 1987-03-03 Graham Davis Assay systems using more than one enzyme
US4650547A (en) * 1983-05-19 1987-03-17 The Regents Of The University Of California Method and membrane applicable to implantable sensor
US4524114A (en) * 1983-07-05 1985-06-18 Allied Corporation Bifunctional air electrode
US4538616A (en) * 1983-07-25 1985-09-03 Robert Rogoff Blood sugar level sensing and monitoring transducer
US4543955A (en) * 1983-08-01 1985-10-01 Cordis Corporation System for controlling body implantable action device
US4655880A (en) * 1983-08-01 1987-04-07 Case Western Reserve University Apparatus and method for sensing species, substances and substrates using oxidase
US4601710B1 (en) * 1983-08-24 1998-05-05 United States Surgical Corp Trocar assembly
US4573448A (en) * 1983-10-05 1986-03-04 Pilling Co. Method for decompressing herniated intervertebral discs
US4522690A (en) * 1983-12-01 1985-06-11 Honeywell Inc. Electrochemical sensing of carbon monoxide
DE3479522D1 (en) * 1983-12-16 1989-09-28 Medisense Inc Assay for nucleic acids
JPS60135756A (ja) * 1983-12-24 1985-07-19 Ngk Insulators Ltd 電気化学的セルの製造方法
DE8407894U1 (de) * 1984-03-15 1984-09-06 Richard Wolf Gmbh, 7134 Knittlingen Dilatator zum aufweiten von einstichkanaelen der niere
EP0179823B1 (de) * 1984-04-30 1989-07-12 Stiftung, R. E. Verfahren zur sensibilisierung eines oxydo-reduktionsphotokatalysators und so erhaltener photokatalysator
DK8601218A (de) * 1984-07-18 1986-03-17
US4820399A (en) * 1984-08-31 1989-04-11 Shimadzu Corporation Enzyme electrodes
CA1254091A (en) * 1984-09-28 1989-05-16 Vladimir Feingold Implantable medication infusion system
US4721601A (en) * 1984-11-23 1988-01-26 Massachusetts Institute Of Technology Molecule-based microelectronic devices
US4717673A (en) * 1984-11-23 1988-01-05 Massachusetts Institute Of Technology Microelectrochemical devices
JPH0617889B2 (ja) * 1984-11-27 1994-03-09 株式会社日立製作所 生物化学センサ
GB8500729D0 (en) * 1985-01-11 1985-02-13 Hill H A O Surface-modified electrode
US4627445A (en) * 1985-04-08 1986-12-09 Garid, Inc. Glucose medical monitoring system
US4671288A (en) * 1985-06-13 1987-06-09 The Regents Of The University Of California Electrochemical cell sensor for continuous short-term use in tissues and blood
EP0230472B2 (de) * 1985-06-21 2000-12-13 Matsushita Electric Industrial Co., Ltd. Biosensor und dessen herstellung
US4796634A (en) * 1985-08-09 1989-01-10 Lawrence Medical Systems, Inc. Methods and apparatus for monitoring cardiac output
US4805624A (en) * 1985-09-09 1989-02-21 The Montefiore Hospital Association Of Western Pa Low-potential electrochemical redox sensors
US4680268A (en) * 1985-09-18 1987-07-14 Children's Hospital Medical Center Implantable gas-containing biosensor and method for measuring an analyte such as glucose
US4890620A (en) * 1985-09-20 1990-01-02 The Regents Of The University Of California Two-dimensional diffusion glucose substrate sensing electrode
CA1254616A (en) * 1985-11-11 1989-05-23 Calum J. Mcneil Electrochemical enzymic assay procedures
GB8529300D0 (en) * 1985-11-28 1986-01-02 Ici Plc Membrane
US4776944A (en) * 1986-03-20 1988-10-11 Jiri Janata Chemical selective sensors utilizing admittance modulated membranes
US4685463A (en) * 1986-04-03 1987-08-11 Williams R Bruce Device for continuous in vivo measurement of blood glucose concentrations
US4726378A (en) * 1986-04-11 1988-02-23 Minnesota Mining And Manufacturing Company Adjustable magnetic supercutaneous device and transcutaneous coupling apparatus
US4757022A (en) * 1986-04-15 1988-07-12 Markwell Medical Institute, Inc. Biological fluid measuring device
US4909908A (en) * 1986-04-24 1990-03-20 Pepi Ross Electrochemical cncentration detector method
US4795542A (en) * 1986-04-24 1989-01-03 St. Jude Medical, Inc. Electrochemical concentration detector device
DE3614821A1 (de) * 1986-05-02 1987-11-05 Siemens Ag Implantierbare, eichbare messvorrichtung fuer eine koerpersubstanz sowie eichverfahren
AU598820B2 (en) * 1986-06-20 1990-07-05 Molecular Devices Corporation Zero volume electrochemical cell
US4764416A (en) * 1986-07-01 1988-08-16 Mitsubishi Denki Kabushiki Kaisha Electric element circuit using oxidation-reduction substances
US4917800A (en) * 1986-07-07 1990-04-17 Bend Research, Inc. Functional, photochemically active, and chemically asymmetric membranes by interfacial polymerization of derivatized multifunctional prepolymers
US4726716A (en) * 1986-07-21 1988-02-23 Mcguire Thomas V Fastener for catheter
US4894137A (en) * 1986-09-12 1990-01-16 Omron Tateisi Electronics Co. Enzyme electrode
US4802479A (en) * 1986-10-31 1989-02-07 C. R. Bard, Inc. Hand-held instrument for implanting, dispensing, and inflating an inflatable membrane
DE3700119A1 (de) * 1987-01-03 1988-07-14 Inst Diabetestechnologie Gemei Implantierbarer elektrochemischer sensor
US4848351A (en) * 1987-03-04 1989-07-18 Sentry Medical Products, Inc. Medical electrode assembly
US4759828A (en) * 1987-04-09 1988-07-26 Nova Biomedical Corporation Glucose electrode and method of determining glucose
US4822337A (en) * 1987-06-22 1989-04-18 Stanley Newhouse Insulin delivery method and apparatus
JPH07122624B2 (ja) * 1987-07-06 1995-12-25 ダイキン工業株式会社 バイオセンサ
US4874500A (en) * 1987-07-15 1989-10-17 Sri International Microelectrochemical sensor and sensor array
GB8718430D0 (en) * 1987-08-04 1987-09-09 Ici Plc Sensor
JPS6431701U (de) * 1987-08-20 1989-02-27
US4815469A (en) * 1987-10-08 1989-03-28 Siemens-Pacesetter, Inc. Implantable blood oxygen sensor and method of use
US4813424A (en) * 1987-12-23 1989-03-21 University Of New Mexico Long-life membrane electrode for non-ionic species
US4862891A (en) * 1988-03-14 1989-09-05 Canyon Medical Products Device for sequential percutaneous dilation
US4923442A (en) * 1988-05-02 1990-05-08 Cryomedical Sciences Inc. Blood substitute
US4994027A (en) * 1988-06-08 1991-02-19 Farrell Edward M Percutaneous femoral bypass system
US5224952A (en) * 1988-07-06 1993-07-06 Ethicon, Inc. Safety trocar
US5514091A (en) * 1988-07-22 1996-05-07 Yoon; Inbae Expandable multifunctional manipulating instruments for various medical procedures
US5613950A (en) * 1988-07-22 1997-03-25 Yoon; Inbae Multifunctional manipulating instrument for various surgical procedures
US5831066A (en) 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US5002557A (en) * 1989-04-06 1991-03-26 Hasson Harrith M Laparoscopic cannula
US5176697A (en) * 1989-04-06 1993-01-05 Hasson Harrith M Laparoscopic cannula
WO1991004753A1 (en) * 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
US5114407A (en) * 1990-08-30 1992-05-19 Ethicon, Inc. Safety mechanism for trocar
US5188118A (en) * 1990-11-07 1993-02-23 Terwilliger Richard A Automatic biopsy instrument with independently actuated stylet and cannula
US5324261A (en) * 1991-01-04 1994-06-28 Medtronic, Inc. Drug delivery balloon catheter with line of weakness
AU648135B2 (en) * 1991-01-15 1994-04-14 Ethicon Inc. Knife for surgical trocar
US5176651A (en) * 1991-04-01 1993-01-05 Dexide, Inc. Combination surgical trocar housing and selective reducer sleeve assembly
US5295993A (en) * 1991-04-30 1994-03-22 United States Surgical Corporation Safety trocar
US5241972A (en) * 1991-05-03 1993-09-07 Meditron Devices, Inc. Method for debulking tissue to remove pressure on a nerve
US5183464A (en) * 1991-05-17 1993-02-02 Interventional Thermodynamics, Inc. Radially expandable dilator
CA2069060C (en) * 1991-06-26 2003-07-29 Daniel Shichman Powered trocar
US5195506A (en) * 1991-10-18 1993-03-23 Life Medical Products, Inc. Surgical retractor for puncture operation
GB9123947D0 (en) * 1991-11-12 1992-01-02 Imp Cancer Res Tech Therapeutic compounds
US5267554A (en) * 1991-11-15 1993-12-07 Wilk Peter J Spreadable laparoscopic retractor and associated method of use
AU671266B2 (en) * 1991-11-27 1996-08-22 Inbae Yoon Retractable safety penetrating instrument for portal sleeve introduction
US5713870A (en) * 1991-11-27 1998-02-03 Yoon; Inbae Retractable safety penetrating instrument with laterally extendable spring strip
US5171279A (en) * 1992-03-17 1992-12-15 Danek Medical Method for subcutaneous suprafascial pedicular internal fixation
US5290243A (en) * 1992-07-16 1994-03-01 Technalytics, Inc. Trocar system
WO1994002595A1 (en) * 1992-07-17 1994-02-03 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of animal diseases
US5312417A (en) * 1992-07-29 1994-05-17 Wilk Peter J Laparoscopic cannula assembly and associated method
US7060077B2 (en) * 1992-09-04 2006-06-13 Boston Scientific Scimed, Inc. Suturing instruments and methods of use
US6001992A (en) 1999-01-07 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of novel anti-apoptotic bcl-2-related proteins
US20040204380A1 (en) 1999-01-07 2004-10-14 Ackermann Elizabeth J Antisense modulation of novel anti-apoptotic bcl-2-related proteins
US20020086321A1 (en) 1993-02-02 2002-07-04 Craig Ruth W. Myeloid cell leukemia associated gene MCL-1
US5814073A (en) * 1996-12-13 1998-09-29 Bonutti; Peter M. Method and apparatus for positioning a suture anchor
FR2706309B1 (fr) * 1993-06-17 1995-10-06 Sofamor Instrument de traitement chirurgical d'un disque intervertébral par voie antérieure.
US5641756A (en) * 1993-07-27 1997-06-24 Hybridon, Inc. Modified VEGF oligonucleotides
US5731294A (en) * 1993-07-27 1998-03-24 Hybridon, Inc. Inhibition of neovasularization using VEGF-specific oligonucleotides
US6410322B1 (en) * 1993-07-27 2002-06-25 Hybridon Inc Antisense oligonucleotide inhibition of vascular endothelial growth factor expression
EP0745124B1 (de) 1994-02-14 1998-06-17 Amgen Inc. Zellzyklusprotein in Säugetieren
US5407430A (en) * 1994-03-21 1995-04-18 Peters; Michael J. Intravenous catheter
US5512037A (en) * 1994-05-12 1996-04-30 United States Surgical Corporation Percutaneous surgical retractor
WO1996000286A1 (en) 1994-06-27 1996-01-04 Toagosei Co., Ltd. Antisense nucleic acid compound
US5505710A (en) * 1994-08-22 1996-04-09 C. R. Bard, Inc. Telescoping probe
US5647857A (en) * 1995-03-16 1997-07-15 Endotex Interventional Systems, Inc. Protective intraluminal sheath
US5624447A (en) * 1995-03-20 1997-04-29 Othy, Inc. Surgical tool guide and entry hole positioner
US6206922B1 (en) * 1995-03-27 2001-03-27 Sdgi Holdings, Inc. Methods and instruments for interbody fusion
US5776156A (en) * 1995-09-05 1998-07-07 United States Surgical Corporation Endoscopic cutting instrument
US5817034A (en) * 1995-09-08 1998-10-06 United States Surgical Corporation Apparatus and method for removing tissue
US5830879A (en) * 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
US5772678A (en) * 1995-10-20 1998-06-30 Inlet Medical, Inc. Retractable disposable tip reusable trocar obturator
US6346398B1 (en) 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
WO2002096927A2 (en) * 2001-05-29 2002-12-05 Ribozyme Pharmaceuticals, Incorporated Ribozyme based treatment of female reproductive diseases
US5743881A (en) * 1995-11-03 1998-04-28 Aptec Medical Corporation Laparoscopic surgical instrument and method of using same
US5707359A (en) * 1995-11-14 1998-01-13 Bufalini; Bruno Expanding trocar assembly
AU1279397A (en) * 1995-12-08 1997-07-03 Hybridon, Inc. Modified vegf antisense oligonucleotides
AU1686997A (en) * 1995-12-08 1997-06-27 Hybridon, Inc. Modified vegf antisense oligonucleotides for treatment of skin disorders
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US6048309A (en) * 1996-03-04 2000-04-11 Heartport, Inc. Soft tissue retractor and delivery device therefor
US5810721A (en) * 1996-03-04 1998-09-22 Heartport, Inc. Soft tissue retractor and method for providing surgical access
US5792044A (en) * 1996-03-22 1998-08-11 Danek Medical, Inc. Devices and methods for percutaneous surgery
WO1997034536A2 (en) * 1996-03-22 1997-09-25 Sdgi Holdings, Inc. Devices and methods for percutaneous surgery
US6679833B2 (en) * 1996-03-22 2004-01-20 Sdgi Holdings, Inc. Devices and methods for percutaneous surgery
EP0910634A2 (de) * 1996-04-17 1999-04-28 Hoechst Marion Roussel Deutschland GmbH Antisens-inhibitoren der expression des vaskulären epithel-wachstumsfaktors (vegf/vpf)
US20050261485A1 (en) 1996-05-23 2005-11-24 Toagosei Co., Ltd., A Japan Corporation Method of producing antisense oligonucleotide
AU3249897A (en) 1996-07-01 1998-01-21 Jim A. Wright Oligonucleotides from the untranslated regions of housekeeping genes and methods of using same to modulate cell growth
US6264676B1 (en) * 1996-11-08 2001-07-24 Scimed Life Systems, Inc. Protective sheath for transvaginal anchor implantation devices
US6053935A (en) * 1996-11-08 2000-04-25 Boston Scientific Corporation Transvaginal anchor implantation device
US5893850A (en) * 1996-11-12 1999-04-13 Cachia; Victor V. Bone fixation device
DE69737208T2 (de) * 1996-11-15 2007-11-08 Cook Inc., Bloomington Stentanbringungsvorrichtung mit einer auftrennbaren hülle
AU6237198A (en) * 1996-12-19 1998-07-15 Isis Pharmaceuticals, Inc. Large-scale purification of full length oligonucleotides by solid-liquid affinity extraction
US6228058B1 (en) * 1997-04-03 2001-05-08 Core Dynamics, Inc. Sleeve trocar with penetration indicator
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
JPH1142091A (ja) * 1997-07-25 1999-02-16 Toagosei Co Ltd アンチセンス核酸化合物
US6293952B1 (en) * 1997-07-31 2001-09-25 Circon Corporation Medical instrument system for piercing through tissue
DE69835524T2 (de) * 1997-08-26 2007-04-05 Amgen Fremont Inc. Ein verfahren zur inhibierung der komplementaktivierung über einen alternativen weg
IL135360A (en) * 1997-10-01 2005-07-25 Boston Scient Ltd Body track dilation systems and related methods
US6030364A (en) * 1997-10-03 2000-02-29 Boston Scientific Corporation Apparatus and method for percutaneous placement of gastro-intestinal tubes
US6046319A (en) * 1997-10-22 2000-04-04 University Technologies International, Inc. Antisense oligodeoxynucleotides regulating expression of TNF-α
US6206826B1 (en) * 1997-12-18 2001-03-27 Sdgi Holdings, Inc. Devices and methods for percutaneous surgery
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
WO1999038965A1 (en) 1998-01-29 1999-08-05 The Trustees Of Columbia University In The City Of New York Human hairless gene, protein and uses thereof
US6111086A (en) 1998-02-27 2000-08-29 Scaringe; Stephen A. Orthoester protecting groups
AU765129B2 (en) * 1998-04-03 2003-09-11 Wisconsin Alumni Research Foundation Mammalian tolloid-like gene and protein
US6428541B1 (en) * 1998-04-09 2002-08-06 Sdgi Holdings, Inc. Method and instrumentation for vertebral interbody fusion
US20030228597A1 (en) 1998-04-13 2003-12-11 Cowsert Lex M. Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
US6447527B1 (en) * 1998-04-23 2002-09-10 Ronald J. Thompson Apparatus and methods for the penetration of tissue
CA2334960C (en) * 1998-06-10 2012-01-03 Biognostik Gesellschaft Fur Biomolekulare Diagnostik Mbh Combination of tgf-.beta. inhibition and immune stimulation to treat hyperproliferative diseases
US6007995A (en) * 1998-06-26 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of TNFR1 expression
US20030096775A1 (en) * 2001-10-23 2003-05-22 Isis Pharmaceuticals Inc. Antisense modulation of complement component C3 expression
JP2000010376A (ja) * 1998-06-26 2000-01-14 Fujitsu Ltd 画像形成装置
EP1093373A4 (de) 1998-07-02 2005-04-13 Univ Columbia OLIGONUKLEOTIDE INHIBITOREN DES bcl-xl
US5916145A (en) * 1998-08-07 1999-06-29 Scimed Life Systems, Inc. Device and method of using a surgical assembly with mesh sheath
US6093173A (en) * 1998-09-09 2000-07-25 Embol-X, Inc. Introducer/dilator with balloon protection and methods of use
US6117174A (en) * 1998-09-16 2000-09-12 Nolan; Wesley A. Spinal implant device
US5957902A (en) * 1998-09-28 1999-09-28 Teves; Leonides Y. Surgical tool for enlarging puncture opening made by trocar
US6228642B1 (en) * 1998-10-05 2001-05-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression
US6172216B1 (en) 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
AU1705100A (en) 1998-10-09 2000-05-01 Musc Foundation For Research Development Blocking factor b to treat complement-mediated immune disease
US6365577B1 (en) * 1998-10-26 2002-04-02 Avi Biopharma, Inc. p53 antisense agent and method
HUP0104302A3 (en) * 1998-11-06 2002-11-28 Abbott Gmbh & Co Kg Inhibition of the formation of vascular hyperpermeability
US5958773A (en) 1998-12-17 1999-09-28 Isis Pharmaceuticals Inc. Antisense modulation of AKT-1 expression
DE50008326D1 (de) * 1999-02-12 2004-11-25 Storz Karl Gmbh & Co Vorrichtung zum einführen eines intubationstubus in die trachea
DK1154991T3 (da) * 1999-02-18 2004-11-22 Univ California Salicylamid-lanthanidkomplekser til anvendelse som luminescerende markörer
EP1171617B1 (de) * 1999-04-08 2008-02-13 Novartis Vaccines and Diagnostics, Inc. Verbesserung der immunantwort als anwendung in impfstoff und gentherapie
US6607530B1 (en) * 1999-05-10 2003-08-19 Highgate Orthopedics, Inc. Systems and methods for spinal fixation
ATE324888T1 (de) 1999-06-14 2006-06-15 Cancer Rec Tech Ltd Krebstherapie
US6607547B1 (en) * 1999-08-25 2003-08-19 Origin Medsystems, Inc. Longitudinal dilator and method
US6200322B1 (en) * 1999-08-13 2001-03-13 Sdgi Holdings, Inc. Minimal exposure posterior spinal interbody instrumentation and technique
EP1757233A3 (de) * 1999-08-26 2007-05-23 Warsaw Orthopedic, Inc. Vorrichtung und Verfahren zur Implantation von Fusionskäfigen
US6770633B1 (en) * 1999-10-26 2004-08-03 Immusol, Inc. Ribozyme therapy for the treatment of proliferative skin and eye diseases
US6287313B1 (en) * 1999-11-23 2001-09-11 Sdgi Holdings, Inc. Screw delivery system and method
US7179796B2 (en) 2000-01-18 2007-02-20 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
US20070026394A1 (en) 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US6582441B1 (en) * 2000-02-24 2003-06-24 Advanced Bionics Corporation Surgical insertion tool
US6562049B1 (en) * 2000-03-01 2003-05-13 Cook Vascular Incorporated Medical introducer apparatus
PT1309726E (pt) 2000-03-30 2010-03-08 Whitehead Biomedical Inst Mediadores de interferência por rna específicos de sequência de rna
AU2001271427A1 (en) * 2000-06-26 2002-01-08 Sugen, Inc. Novel proteases
US6592553B2 (en) * 2000-07-05 2003-07-15 Cardiac Pacemakers, Inc. Introducer assembly and method therefor
EP1325121A2 (de) * 2000-10-13 2003-07-09 Institut de Cardiologie de Montreal Antisense oligonukleotid gerichtet gegen gene von vegf rezeptoren von säugetieren und deren verwendungen
AU2002243429A1 (en) * 2000-10-24 2002-06-24 Isis Pharmaceuticals, Inc. Antisense modulation of tnfr1 expression
MXPA03003856A (es) 2000-11-01 2004-04-20 Bki Holding Corp Eteres de celulosa y metodos para preparar los mismos.
KR100909681B1 (ko) * 2000-12-01 2009-07-29 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
WO2002047562A1 (fr) * 2000-12-12 2002-06-20 Olympus Optical Co., Ltd. Trocart et systeme de trocart
US20030143597A1 (en) 2000-12-28 2003-07-31 Finney Robert E. Methods for making polynucleotide libraries, polynucleotide arrays, and cell libraries for high-throughput genomics analysis
US20020150945A1 (en) * 2000-12-28 2002-10-17 Cell Therapeutics, Inc. Methods for making polynucleotide libraries, polynucleotide arrays, and cell libraries for high-throughput genomics analysis
EP1353676A4 (de) 2000-12-29 2006-05-31 Alteon Inc Methode zur behandlung von fibrosen oder anderen indikationen
US20020087152A1 (en) * 2001-01-04 2002-07-04 Endocare, Inc. Systems and methods for delivering a probe into tissue
WO2003035869A1 (de) 2001-10-26 2003-05-01 Ribopharma Ag Verwendung einer doppelsträngigen ribonukleinsäure zur gezielten hemmung der expression eines vorgegebenen zielgens
EP1372690A4 (de) * 2001-03-01 2005-08-24 Millennium Pharm Inc 93870, humaner g-protein-gekoppelter rezeptor und seine verwendungen
US6511481B2 (en) * 2001-03-30 2003-01-28 Triage Medical, Inc. Method and apparatus for fixation of proximal femoral fractures
US20030087259A1 (en) 2001-04-18 2003-05-08 Clancy Brian M. Methods and compositions for regulating bone and cartilage formation
WO2002085308A2 (en) * 2001-04-24 2002-10-31 Epigenesis Pharmaceuticals, Inc. Antisense and anti-inflammatory based compositions to treat respiratory disorders
AU2002305236A1 (en) * 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Composition, formulations and kits for treatment of respiratory and lung disease with anti-sense oligonucleotides and a bronchodilating agent
US20050239731A1 (en) 2001-05-18 2005-10-27 Sirna Therapeutics, Inc. RNA interference mediated inhibition of MAP kinase gene expression using short interfering nucleic acid (siNA)
US20040219671A1 (en) 2002-02-20 2004-11-04 Sirna Therapeutics, Inc. RNA interference mediated treatment of parkinson disease using short interfering nucleic acid (siNA)
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050176025A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
US20050227935A1 (en) 2001-05-18 2005-10-13 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA)
US20050130181A1 (en) 2001-05-18 2005-06-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of wingless gene expression using short interfering nucleic acid (siNA)
US20050048529A1 (en) 2002-02-20 2005-03-03 Sirna Therapeutics, Inc. RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
WO2003070910A2 (en) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP1390472A4 (de) 2001-05-29 2004-11-17 Sirna Therapeutics Inc Nukleinsäurebehandlung von krankheiten oder leiden im zusammenhang mit ras-, her2- und hiv-niveaus
US6746451B2 (en) * 2001-06-01 2004-06-08 Lance M. Middleton Tissue cavitation device and method
MXPA04000224A (es) 2001-07-10 2005-07-25 4Sc Ag Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos.
US6589240B2 (en) * 2001-08-28 2003-07-08 Rex Medical, L.P. Tissue biopsy apparatus with collapsible cutter
US6734017B2 (en) * 2001-09-28 2004-05-11 Isis Pharmaceuticals, Inc. Antisense modulation of vascular endothelial growth factor receptor-2 expression
JP4917225B2 (ja) 2001-09-28 2012-04-18 ローム株式会社 半導体装置
WO2003035870A1 (de) 2001-10-26 2003-05-01 Ribopharma Ag Medikament zur behandlung eines pankreaskarzinoms
US7008431B2 (en) * 2001-10-30 2006-03-07 Depuy Spine, Inc. Configured and sized cannula
US20040063654A1 (en) 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
AU2002368202B2 (en) 2001-11-02 2008-06-05 Insert Therapeutics, Inc Methods and compositions for therapeutic use of RNA interference
FR2832154B1 (fr) 2001-11-09 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
US6685706B2 (en) * 2001-11-19 2004-02-03 Triage Medical, Inc. Proximal anchors for bone fixation system
US20030186903A1 (en) 2001-11-23 2003-10-02 Isis Pharmaceuticals Inc. Antisense modulation of MyD88 expression
EP2014674B1 (de) 2001-11-26 2014-02-12 Laboratoire Biodim Protein-Protein-Wechselwirkungen beim menschlichen Immunschwächevirus
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
GB0130955D0 (en) * 2001-12-24 2002-02-13 Cancer Res Ventures Expression system
WO2003057272A2 (en) * 2001-12-26 2003-07-17 Yale University Vascular access device
KR100441894B1 (ko) * 2002-01-26 2004-07-27 한국전자통신연구원 마이크로 집적형 근접장 광기록 헤드 및 이를 이용한광기록 장치
WO2003064625A2 (en) * 2002-02-01 2003-08-07 Sequitur, Inc. Oligonucleotide compositions with enhanced efficiency
EP1478730A4 (de) * 2002-02-20 2006-01-25 Sirna Therapeutics Inc RNA-INTERFERENZ-VERMITTELTE HEMMUNG DER EXPRESSION DER GENE FÜR DIE TNF- UND TNF-REZEPTOR-SUPERFAMILIEN UNTER VERWENDUNG VON siNA (SHORT INTERFERING NUCLEIC ACID)
AU2003213119A1 (en) * 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF BCL2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
AU2003210895A1 (en) 2002-02-20 2003-09-09 Ribozyme Pharmaceuticals, Inc. Rna interference mediated inhibition of cyclin d1 gene expression using short interfering nucleic acid (sina)
AU2003207708A1 (en) * 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
WO2003079757A2 (en) 2002-03-20 2003-10-02 Massachusetts Institute Of Technology Hiv therapeutic
WO2003085090A2 (en) 2002-03-29 2003-10-16 Yun Yen A human ribonucleotide reductase m2 subunit
US20030224512A1 (en) 2002-05-31 2003-12-04 Isis Pharmaceuticals Inc. Antisense modulation of beta-site APP-cleaving enzyme expression
AU2003231886A1 (en) 2002-05-13 2003-11-11 Salviac Limited Retrieval catheter for an embolic filter
US20040101857A1 (en) 2002-11-23 2004-05-27 Isis Pharmaceuticals Inc. Modulation of cytokine-inducible kinase expression
AU2003239897A1 (en) 2002-05-23 2003-12-12 Ceptyr, Inc. Modulation of ptp1b signal transduction by rna interference
US20040102391A1 (en) 2002-11-21 2004-05-27 Isis Pharmaceuticals Inc. Modulation of Gankyrin expression
US20040101915A1 (en) 2002-06-18 2004-05-27 Irm Llc, A Delaware Limited Liability Company Diagnosis and treatment of chemoresistant tumors
US7993351B2 (en) * 2002-07-24 2011-08-09 Pressure Products Medical Supplies, Inc. Telescopic introducer with a compound curvature for inducing alignment and method of using the same
US7148342B2 (en) * 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
US6906186B1 (en) 2002-07-30 2005-06-14 Isis Pharmaceuticals, Inc. Antisense modulation of polo-like kinase expression
US20040029275A1 (en) 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
AU2003273336A1 (en) 2002-09-18 2004-04-08 Isis Pharmaceuticals, Inc. Efficient reduction of target rna's by single- and double-stranded oligomeric compounds
US7074226B2 (en) * 2002-09-19 2006-07-11 Sdgi Holdings, Inc. Oval dilator and retractor set and method
CA2500405A1 (en) 2002-09-30 2004-04-15 Oncotherapy Science, Inc. Genes and polypeptides relating to human myeloid leukemia
AU2003304386A1 (en) 2002-10-30 2005-02-25 The Center For Blood Research, Inc. Methods for treating and preventing apoptosis-related diseases using rna interfering agents
MXPA05004722A (es) 2002-11-01 2005-08-03 Univ Pennsylvania Composiciones y metodos para la inhibicion del factor inducible por hipoxia 1 alfa con acido ribonucleico corto de interferencia.
EP1567539B1 (de) 2002-11-04 2009-09-23 University of Massachusetts Allelspezifische rna-interferenz
US7635770B2 (en) 2002-11-14 2009-12-22 Dharmacon, Inc. siRNA targeting protein kinase N-3 (PKN-3)
US8090542B2 (en) 2002-11-14 2012-01-03 Dharmacon Inc. Functional and hyperfunctional siRNA
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US7582747B2 (en) 2002-11-14 2009-09-01 Dharmacon, Inc. siRNA targeting inner centromere protein antigens (INCENP)
US7592442B2 (en) 2002-11-14 2009-09-22 Dharmacon, Inc. siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
US7977471B2 (en) 2002-11-14 2011-07-12 Dharmacon, Inc. siRNA targeting TNFα
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US7951935B2 (en) 2002-11-14 2011-05-31 Dharmacon, Inc. siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
US7781575B2 (en) 2002-11-14 2010-08-24 Dharmacon, Inc. siRNA targeting tumor protein 53 (p53)
US7619081B2 (en) 2002-11-14 2009-11-17 Dharmacon, Inc. siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
US7612196B2 (en) 2002-11-14 2009-11-03 Dharmacon, Inc. siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
US7691998B2 (en) 2002-11-14 2010-04-06 Dharmacon, Inc. siRNA targeting nucleoporin 62kDa (Nup62)
US20040214198A1 (en) 2002-11-15 2004-10-28 University Of Massachusetts Allele-targeted RNA interference
US7217807B2 (en) 2002-11-26 2007-05-15 Rosetta Genomics Ltd Bioinformatically detectable group of novel HIV regulatory genes and uses thereof
WO2004052920A2 (en) 2002-12-12 2004-06-24 The Burnham Institute Conversion of apoptotic proteins
US20040248299A1 (en) * 2002-12-27 2004-12-09 Sumedha Jayasena RNA interference
US7166088B2 (en) * 2003-01-27 2007-01-23 Heuser Richard R Catheter introducer system
WO2004070062A2 (en) * 2003-02-04 2004-08-19 Wyeth Compositions and methods for diagnosing and treating cancers
FR2835837B1 (fr) * 2003-02-06 2007-03-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leurs utilisation pour reprimer specifiquement un gene codant pour un facteur de croissance
FR2835838B1 (fr) * 2003-02-06 2007-11-16 Centre Nat Rech Scient Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene codant pour un facteur de transcription
US7090680B2 (en) * 2003-02-12 2006-08-15 Bonati Alfred O Method for removing orthopaedic hardware
WO2004076639A2 (en) 2003-02-26 2004-09-10 Wyeth Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus
WO2004090105A2 (en) 2003-04-02 2004-10-21 Dharmacon, Inc. Modified polynucleotides for use in rna interference
AU2003224132A1 (en) 2003-04-24 2004-11-19 Galapagos Genomics N.V. Effective sirna knock-down constructs
US7399853B2 (en) 2003-04-28 2008-07-15 Isis Pharmaceuticals Modulation of glucagon receptor expression
KR20060013426A (ko) * 2003-05-30 2006-02-09 니뽄 신야쿠 가부시키가이샤 Ｂｃｌ-2의 발현을 억제하는 올리고 이중쇄 ＲＮＡ와그것을 함유하는 의약 조성물
KR20060063788A (ko) 2003-05-30 2006-06-12 니뽄 신야쿠 가부시키가이샤 올리고 핵산 담지 복합체, 이 복합체를 함유하는 의약조성물
US7459547B2 (en) 2003-06-02 2008-12-02 University Of Massachusetts Methods and compositions for controlling efficacy of RNA silencing
ATE485394T1 (de) 2003-06-02 2010-11-15 Univ Massachusetts Verfahren und zusammensetzungen zur verbesserung der wirksamkeit und spezifität von fnai
US7750144B2 (en) 2003-06-02 2010-07-06 University Of Massachusetts Methods and compositions for enhancing the efficacy and specificity of RNA silencing
EP1633770B1 (de) 2003-06-13 2015-04-29 Alnylam Europe AG Doppelsträngige ribonukleinsäure mit verbesserter wirksamkeit in einem organismus
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
DE10341333B4 (de) * 2003-09-08 2006-06-08 Siemens Ag Piezoaktor und Verfahren zum Herstellen eines Piezoaktors
KR100568246B1 (ko) * 2003-11-19 2006-04-05 삼성전자주식회사 컴퓨터 시스템 및 그 제어방법
US20050176045A1 (en) 2004-02-06 2005-08-11 Dharmacon, Inc. SNP discriminatory siRNA
WO2005089224A2 (en) 2004-03-12 2005-09-29 Alnylam Pharmaceuticals, Inc. iRNA AGENTS TARGETING VEGF
KR101147147B1 (ko) 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
EP1747022A4 (de) 2004-04-23 2010-03-31 Univ Columbia Hemmung von haarloser protein mrna
MXPA06012605A (es) 2004-05-04 2006-12-15 Nastech Pharm Co Composiciones y metodos para mejorar el suministro de acidos nucleicos en celulas y para modificar la expresion de genes objetivo en celulas.
AU2005248147A1 (en) 2004-05-11 2005-12-08 Alphagen Co., Ltd. Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same
US7605250B2 (en) 2004-05-12 2009-10-20 Dharmacon, Inc. siRNA targeting cAMP-specific phosphodiesterase 4D
JP2006013252A (ja) * 2004-06-28 2006-01-12 Hitachi Cable Ltd レーザダイオードの制御方法、制御回路、および光送信器
EP1799269B1 (de) 2004-09-28 2016-09-07 Quark Pharmaceuticals, Inc. Oligoribonukleotide und anwendungsverfahren dafür zur behandlung von alopezie, akuter niereninsuffizienz und anderen erkrankungen
US20060134189A1 (en) 2004-11-17 2006-06-22 Protiva Biotherapeutics, Inc siRNA silencing of apolipoprotein B
AU2006235489A1 (en) 2005-04-12 2006-10-19 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
US20060286575A1 (en) 2005-04-16 2006-12-21 Cylene Pharmaceuticals, Inc. MCL-1 quadruplex nucleic acids and uses thereof
US7825099B2 (en) 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
US7910566B2 (en) 2006-03-09 2011-03-22 Quark Pharmaceuticals Inc. Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
KR20120093306A (ko) 2006-05-19 2012-08-22 알콘 리서치, 리미티드 종양 괴사 인자 α-관련 증상의 ＲＮＡｉ-매개 억제
US8523707B2 (en) * 2006-05-31 2013-09-03 Bridgestone Sports Co., Ltd. Multi-piece solid golf ball
US8138160B2 (en) 2006-08-03 2012-03-20 Warsaw Orthopedic, Inc. Reagents, methods and systems to suppress pro-inflammatory cytokines
CN101640467B (zh) 2008-07-28 2012-05-30 鸿富锦精密工业（深圳）有限公司 弹片及音圈马达

Also Published As

Publication number Publication date
US7674896B2 (en) 2010-03-09
US7893247B2 (en) 2011-02-22
US20100267586A1 (en) 2010-10-21
EP2305812A3 (de) 2012-06-06
US20070093653A1 (en) 2007-04-26
US7820809B2 (en) 2010-10-26
US20110111983A1 (en) 2011-05-12
US7511132B2 (en) 2009-03-31
EP2284266A3 (de) 2012-01-25
US7576196B2 (en) 2009-08-18
US20080293593A1 (en) 2008-11-27
US20050256525A1 (en) 2005-11-17
US8093370B2 (en) 2012-01-10
US7745611B2 (en) 2010-06-29
US20100087335A1 (en) 2010-04-08
EP2278005A3 (de) 2012-05-23
US20080306015A1 (en) 2008-12-11
US20190345573A1 (en) 2019-11-14
US20100152064A1 (en) 2010-06-17
US7514550B2 (en) 2009-04-07
US20100029510A1 (en) 2010-02-04
US20050255487A1 (en) 2005-11-17
WO2004045543A3 (en) 2005-04-21
EP2284266A2 (de) 2011-02-16
US20070072823A1 (en) 2007-03-29
EP1560931B1 (de) 2011-07-27
US7807819B2 (en) 2010-10-05
US20070141611A1 (en) 2007-06-21
US20120052487A9 (en) 2012-03-01
EP2305813A3 (de) 2012-03-28
US20080293595A1 (en) 2008-11-27
EP2213738B1 (de) 2012-10-10
US20080091004A1 (en) 2008-04-17
US20080097090A1 (en) 2008-04-24
US20080300395A1 (en) 2008-12-04
US20070031844A1 (en) 2007-02-08
US8008474B2 (en) 2011-08-30
ES2440284T3 (es) 2014-01-28
US20070039072A1 (en) 2007-02-15
EP1560931A2 (de) 2005-08-10
US20090291497A1 (en) 2009-11-26
US7985854B2 (en) 2011-07-26
US20100291681A1 (en) 2010-11-18
US8000902B2 (en) 2011-08-16
US7595389B2 (en) 2009-09-29
US20120135892A1 (en) 2012-05-31
EP2213738A3 (de) 2010-11-17
US20090088563A1 (en) 2009-04-02
JP2006507841A (ja) 2006-03-09
US20100331214A1 (en) 2010-12-30
US7579457B2 (en) 2009-08-25
US8090542B2 (en) 2012-01-03
US20100004142A1 (en) 2010-01-07
US7655788B2 (en) 2010-02-02
US20070088153A1 (en) 2007-04-19
US20080139798A1 (en) 2008-06-12
US7608707B2 (en) 2009-10-27
EP2284266B1 (de) 2013-11-06
EP2305813A2 (de) 2011-04-06
US20080108803A1 (en) 2008-05-08
AU2003295600A1 (en) 2004-06-15
EP2278005A2 (de) 2011-01-26
EP2314691A3 (de) 2012-01-18
US7642349B2 (en) 2010-01-05
US20050246794A1 (en) 2005-11-03
US20090149644A1 (en) 2009-06-11
US7691997B2 (en) 2010-04-06
US20070207974A1 (en) 2007-09-06
EP2213738A2 (de) 2010-08-04
US20090163702A1 (en) 2009-06-25
EP1560931A4 (de) 2006-08-02
US7696344B2 (en) 2010-04-13
US20100323922A1 (en) 2010-12-23
US20080188648A1 (en) 2008-08-07
US20090298176A1 (en) 2009-12-03
EP2305812A2 (de) 2011-04-06
US7645869B2 (en) 2010-01-12
US20080108802A1 (en) 2008-05-08
US20080091002A1 (en) 2008-04-17
US20100075869A1 (en) 2010-03-25
US20110319474A1 (en) 2011-12-29
US8030474B2 (en) 2011-10-04
US20080091003A1 (en) 2008-04-17
US20070088155A1 (en) 2007-04-19
US7576197B2 (en) 2009-08-18
US7795420B2 (en) 2010-09-14
US20070088152A1 (en) 2007-04-19
US20090203895A1 (en) 2009-08-13
US7592444B2 (en) 2009-09-22
US20080114162A1 (en) 2008-05-15
US20080188647A1 (en) 2008-08-07
DK2284266T3 (da) 2014-01-13
US20090082556A1 (en) 2009-03-26
US20050245475A1 (en) 2005-11-03
JP2010187668A (ja) 2010-09-02
US7834170B2 (en) 2010-11-16
US20090163701A1 (en) 2009-06-25
US20080091001A1 (en) 2008-04-17
US20070099862A1 (en) 2007-05-03
US7803933B2 (en) 2010-09-28
EP2314691A2 (de) 2011-04-27
US20070088154A1 (en) 2007-04-19
AU2003295600A8 (en) 2004-06-15
PT2284266E (pt) 2013-12-17
US20080221317A1 (en) 2008-09-11
US7507811B2 (en) 2009-03-24
WO2004045543A2 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
ATE517992T1 (de) Funktionelle und hyperfunktionelle sirna
WO2006006948A3 (en) METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
ATE539170T1 (de) Abschätzung und verringerung des risikos von graft-versus-host-reaktion
WO2004058940A3 (en) Sirna-mediated gene silencing
ATE544774T1 (de) Rnai-modulation von mll-af4 und verwendungen dafür
DE602005015994D1 (de) siRNA-VERMITTELTES GEN-SILENCING VON ALPHA-SYNUKLEIN
EP1474433A4 (de) DURCH RNA-INTERFERENZ VERMITTELTE TARGET-LOKALISIERUNG UND TARGET-VALIDIERUNG MIT KURZER INTERFERIERENDER NUKLEINSÄURE (siNA)
NO20054079D0 (no) Hydrokarbongassprosess.
ATE541857T1 (de) Optimierte fc-varianten und herstellungsverfahren dafür
WO2006083800A3 (en) Nucleic acid silencing of huntington's disease gene
WO2004065613A3 (en) Inducible small interfering rna (sirna) expression constructs for targeted gene silencing
DK1616012T3 (da) Lentivirale vektorer bærende syntetiske bidirektionelle promotorer og anvendelser deraf
CY1111151T1 (el) Αναστολεις φωσφολιπασης α2 του κυτταροδιαλυματος
DE602004021836D1 (de) Meg1-endospermspezifische promotoren und gene
ATE506436T1 (de) Auf trans-splicing basierende amplifikationsvectoren
ATE512228T1 (de) Induzierbare expressionssysteme
CY1111587T1 (el) Αναεροβιος καθαρισμος λυματων
DE602008006254D1 (de) Doppel-oligonukleotid-nukleinsäurenachweisverfahren
CY1116649T1 (el) Τεχνητη dna αλληλουχια με βελτιστοποιημενη λειτουργια οδηγου σε 5' (5-utr) για βελτιωμενη εκφραση ετερολογων πρωτεϊνων σε φυτα
ITMO20030081A1 (it) Bioreattore, particolarmente per organi bioartificiali.
ATE460667T1 (de) Mikroarray-vorrichtungen mit steuerbarem reaktionsvolumen
ATE428783T1 (de) Expressionssystem für sirna
BR0316224A (pt) Sequência de dna da região genÈmica tcd de photorhabdus luminescens
DE602006010187D1 (de) Einzelsequenzhybridisierungssonden
ATE443261T1 (de) Scintillation proximity assay

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties